<SEC-DOCUMENT>0001104659-25-039098.txt : 20250425
<SEC-HEADER>0001104659-25-039098.hdr.sgml : 20250425
<ACCEPTANCE-DATETIME>20250425092913
ACCESSION NUMBER:		0001104659-25-039098
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20250425
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250425
DATE AS OF CHANGE:		20250425

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Verastem, Inc.
		CENTRAL INDEX KEY:			0001526119
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				273269467
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35403
		FILM NUMBER:		25870512

	BUSINESS ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 500
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
		BUSINESS PHONE:		(781) 292-4200

	MAIL ADDRESS:	
		STREET 1:		117 KENDRICK STREET
		STREET 2:		SUITE 500
		CITY:			NEEDHAM
		STATE:			MA
		ZIP:			02494
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm2513177d1_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:vstm="http://verastem.com/20250425">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_036_vstm_verastem.com_20250425 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20250425_20250425 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_050_edei%2D%2DEntityCentralIndexKey_0001526119 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 5pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000004" name="dei:EntityCentralIndexKey">0001526119</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="vstm-20250425.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-04-25">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001526119</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-04-25</xbrli:startDate>
        <xbrli:endDate>2025-04-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<div style="display: none">

</div>


<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin: 0; font-size: 10pt">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20250425__20250425_z1vUvohzWfwa"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b><span id="xdx_902_edei--DocumentPeriodEndDate_c20250425__20250425_zrnGECsIgopk"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">April 25, 2025</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span id="xdx_900_edei--EntityRegistrantName_c20250425__20250425_z5tJqoNnRPb3"><b><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000011" name="dei:EntityRegistrantName">Verastem,
Inc.</ix:nonNumeric></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in
Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="padding: 0.25pt; vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20250425__20250425_zssJcKJRM2L6"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityFileNumber_c20250425__20250425_ztOJ08Jwy1Ac"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000013" name="dei:EntityFileNumber">001-35403</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0.25pt; text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20250425__20250425_zfCkheUlzRFk"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000014" name="dei:EntityTaxIdentificationNumber">27-3269467</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="padding: 0.25pt; text-align: center; vertical-align: top">(State or Other Jurisdiction <br/>
of Incorporation)</td>
    <td style="padding: 0.25pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission<br/> File Number)</span></td>
    <td style="padding: 0.25pt; text-align: center; vertical-align: bottom">&#160;</td>
    <td style="padding: 0.25pt; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS Employer<br/> Identification No.)</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 49%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250425__20250425_z5AlmxZB7aDd"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000015" name="dei:EntityAddressAddressLine1">117 Kendrick Street</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20250425__20250425_zncoj0Aov7je"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 500</ix:nonNumeric></span>, <span id="xdx_904_edei--EntityAddressCityOrTown_c20250425__20250425_zQDUbPfxory5"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000017" name="dei:EntityAddressCityOrTown">Needham</ix:nonNumeric></span>, <span id="xdx_905_edei--EntityAddressStateOrProvince_c20250425__20250425_zJG9DmZ6KMRb"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000018" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></span></b></span></td>
    <td style="text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; width: 49%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityAddressPostalZipCode_c20250425__20250425_zJc356bpXwrf"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000019" name="dei:EntityAddressPostalZipCode">02494</ix:nonNumeric></span></b></span></td></tr>

<tr>
    <td style="vertical-align: top; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif">(Address of Principal Executive Offices)</span></td>
    <td style="text-align: center; vertical-align: bottom; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif">(Zip Code)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code: <b>(<span id="xdx_90C_edei--CityAreaCode_c20250425__20250425_zZuYFU8J5MCg"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000020" name="dei:CityAreaCode">781</ix:nonNumeric></span>) <span id="xdx_90F_edei--LocalPhoneNumber_c20250425__20250425_zfnbv7iw905c"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000021" name="dei:LocalPhoneNumber">292-4200</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former Name or Former Address, if Changed
Since Last Report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span style="font-family: Wingdings"><span id="xdx_905_edei--WrittenCommunications_c20250425__20250425_zW3atlumTAbk"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Written communications pursuant to Rule&#160;425&#160;under
the&#160;Securities Act&#160;(17 CFR 230.425)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_908_edei--SolicitingMaterial_c20250425__20250425_zzSQl3vesPll"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Soliciting material pursuant to Rule&#160;14a-12&#160;under
the&#160;Exchange Act&#160;(17 CFR 240.14a-12)</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_906_edei--PreCommencementTenderOffer_c20250425__20250425_z3fQoK9H9CF5"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under
the&#160;Exchange Act&#160;(17 CFR 240.14d-2(b))</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left"><span style="font-family: Wingdings"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20250425__20250425_zKXHxNwvdq61"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under
the&#160;Exchange Act&#160;(17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #221e1f">Securities registered pursuant to Section 12(b)
of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading<br/>Symbol(s)</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: center; width: 32%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--Security12bTitle_c20250425__20250425_zQMvoOQDzFx9"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000026" name="dei:Security12bTitle">Common stock, $0.0001 par value per share</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--TradingSymbol_c20250425__20250425_zc64K4VnjgB8"><ix:nonNumeric contextRef="AsOf2025-04-25" id="Fact000027" name="dei:TradingSymbol">VSTM</ix:nonNumeric></span></span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">The <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--SecurityExchangeName_c20250425__20250425_zRjrJjsZARm7"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif">Emerging
growth company </span><span style="font-family: Wingdings"><span style="font-family: Wingdings"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20250425__20250425_zn51KswzAc94"><ix:nonNumeric contextRef="AsOf2025-04-25" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement. </b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Securities Purchase Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">On April 25,
2025, Verastem, Inc. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration: underline">Purchase Agreement</span>&#8221;)
with certain institutional accredited investors named therein&#160;(each, an &#8220;<span style="text-decoration: underline">Investor</span>&#8221; and collectively, the &#8220;<span style="text-decoration: underline">Investors</span>&#8221;),
pursuant to which the Company agreed to sell to the Investors, in a private placement (the &#8220;<span style="text-decoration: underline">Private Placement</span>&#8221;), 3,429,287
shares (the &#8220;<span style="text-decoration: underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration: underline">Common Stock</span>&#8221;),
at an offering price of $7.00 per Share and,</span> in lieu of Common Stock to certain Investors, pre-funded warrants to purchase 7,285,713
shares of Common Stock (the &#8220;<span style="text-decoration: underline">Pre-Funded Warrants</span>,&#8221; and together with the Shares, the &#8220;<span style="text-decoration: underline">Securities</span>&#8221;),
at an offering price of $6.9999 per Pre-Funded Warrant. The gross proceeds of the Private Placement are expected to be approximately $75
million, before deducting placement agent fees and other expenses.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The exercise price of each Pre-Funded Warrant will equal $0.0001 per
underlying share of Common Stock. <span style="background-color: white">The exercise price and the number of shares of Common Stock issuable
upon exercise of each Pre-Funded Warrant is subject to appropriate adjustment in the event of certain stock dividends, stock splits, stock
combinations, or similar events affecting the Common Stock. The Pre-Funded Warrants are exercisable in cash or by means of a cashless
exercise and will not expire u</span>ntil the date the Pre-Funded Warrants are fully exercised<span style="background-color: white">.</span>
The Pre-Funded Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof
(together with its affiliates) immediately following such exercise would exceed a specified beneficial ownership limitation; provided,
however, that a holder may increase or decrease the beneficial ownership limitation by giving 61 days&#8217; notice to the Company, but
not to any percentage in excess of 19.99%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Private Placement is expected to close on April 28, 2025, subject
to the satisfaction of customary closing conditions. The Company intends to use the net proceeds from the Private Placement to fund the
potential launch of avutometinib and defactinib in low-grade serous ovarian cancer, continued clinical research and development of product
candidates, and for working capital and other general corporate purposes.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities, LLC, BTIG, LLC, Mizuho Securities USA LLC, B. Riley Securities, Inc.&#8239;and RBC Capital Markets, LLC
are acting as placement agents (the &#8220;<span style="text-decoration: underline">Placement Agents</span>&#8221;) for the Private Placement. The Company has agreed to pay customary
placement fees and reimburse certain expenses of the Placement Agents.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Purchase Agreement contains customary representations,
warranties and agreements by the Company, customary conditions to closing, indemnification obligations of the Company, other
obligations of the parties and termination provisions. Pursuant to the Purchase Agreement, the Company has agreed to certain
restrictions on the issuance and sale of shares of the Company&#8217;s securities for a period beginning on the date of the Purchase
Agreement until the earlier of (i) the close of trading on the sixtieth (60<sup>th</sup>) day following the date of the Purchase
Agreement and (ii) the business day immediately following the date the resale registration statement filed pursuant to the
Registration Rights Agreement (as defined below) becomes effective, subject to certain exceptions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Securities to be issued pursuant to the Purchase Agreement have
not been registered under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), or any state securities laws
and will be issued pursuant to the exemption from registration provided for under Section&#160;4(a)(2) of the Securities Act. The Company
relied on this exemption from registration based in part on representations made by the Investors. The Securities may not be offered or
sold in the United States absent registration or an applicable exemption from registration requirements. Neither this Current Report on
Form&#160;8-K,&#160;nor any exhibit attached hereto, is an offer to sell or the solicitation of an offer to buy the Securities described
herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Registration Rights Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the Private Placement, the Company and the Investors
entered into a Registration Rights Agreement, dated April 25, 2025 (the &#8220;<span style="text-decoration: underline">Registration Rights Agreement</span>&#8221;), providing
for the registration for resale of the Shares and the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants that are
not then registered on an effective registration statement, pursuant to a registration statement (the &#8220;<span style="text-decoration: underline">Registration Statement</span>&#8221;)
to be filed with the Securities and Exchange Commission (the &#8220;<span style="text-decoration: underline">SEC</span>&#8221;) no later than May 28, 2025. The Company has agreed
to use reasonable best efforts to cause the Registration Statement to be declared effective as soon as practicable, but in no event later
July 27, 2025, and to keep the Registration Statement continuously effective from the date on which the SEC declares the Registration
Statement to be effective until (i) the date on which the Investors shall have resold all the Registrable Securities (as such term is
defined in the Registration Rights Agreement) covered thereby, and (ii) the date on which the Registrable Securities may be resold by
the Investors without registration and without regard to any volume or manner-of-sale limitations by reason of Rule 144 as promulgated
by the SEC under the Securities Act (&#8220;<span style="text-decoration: underline">Rule 144</span>&#8221;), without the requirement for the Company to be in compliance with
the current public information requirement under Rule 144 under the Securities Act or any other rule of similar effect.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company has granted the Investors customary indemnification rights
in connection with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in
connection with the Registration Rights Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Purchase Agreement, Registration Rights
Agreement and the Pre-Funded Warrant is not complete and is qualified in its entirety by reference to the full text of the Purchase Agreement,
Registration Rights Agreement and form of Pre-Funded Warrant, which are filed as Exhibits 10.1, 10.2 and 10.3, respectively, to this Current
Report on Form&#160;8-K&#160;and are incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information contained in Item 1.01 of this Current Report on Form
8-K is incorporated by reference into this Item 3.02.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="background-color: white">Neither this Current Report on
Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy any securities of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 7.01 Regulation FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 25, 2025, the Company issued a press release announcing the
Private Placement. The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01
by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The information in this Item 7.01, including Exhibit 99.1 attached
hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise
subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of
1933, as amended, except as expressly set forth by specific reference in such filing.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Note Regarding Forward-Looking Statements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">This
Current Report on Form 8-K includes forward-looking statements. These forward-looking statements generally can be identified by the use
of words such as &#8220;anticipate,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;will,&#8221;
&#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;project,&#8221; and other words of similar
meaning. These forward-looking statements address various matters including the expected closing date of the Private Placement and the
expected use of proceeds from the Private Placement. Each forward-looking statement contained in this Current Report on Form 8-K is subject
to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable
risks and uncertainties include, among others, the risk that the conditions to closing of the Private Placement are not satisfied; that
the development and commercialization of our product candidates</span> may take longer or cost more than planned, including as a result
of conducting additional studies or our decisions regarding execution of such commercialization; that raising additional capital may cause
dilution to our stockholders; that our product candidates may not receive regulatory approval, become commercially successful products,
or result in new treatment options being offered to patients; and the risks identified under the heading &#8220;Risk Factors&#8221; in
our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and filed with the Securities and Exchange Commission, as
well as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements
contained in this presentation. You are encouraged to read our filings with the SEC for a discussion of these and other risks and uncertainties.
The forward-looking statements in this Current Report on Form 8-K speak only as of the date hereof, and we undertake no obligation to
update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above.
Investors, potential investors, and others should give careful consideration to these risks and uncertainties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>Item 9.01 Financial Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit&#160;No.</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 88%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2513177d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span>*</a></td>
    <td>&#160;</td>
    <td><a href="tm2513177d1_ex10-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities Purchase Agreement, dated April 25, 2025, by and among Verastem, Inc. and the investors party thereto</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2513177d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2513177d1_ex10-2.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated April 25, 2025, by and among Verastem, Inc. and the investors party thereto</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2513177d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2513177d1_ex10-3.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Pre-Funded Warrant</span></a></td></tr>
  <tr style="vertical-align: top">
    <td><a href="tm2513177d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></a></td>
    <td>&#160;</td>
    <td><a href="tm2513177d1_ex99-1.htm" style="-sec-extract: exhibit"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press release issued by Verastem, Inc. on April 25, 2025, related to the Private Placement</span></a></td></tr>
  <tr>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; background-color: white"><i>*&#8239;Certain schedules, exhibits and similar
attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The Company will provide a copy of such omitted materials
to the Securities and Exchange Commission or its staff upon request.</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VERASTEM, INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 47%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated: April 25, 2025</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/</span><span style="font-size: 10pt">s/ Daniel W. Paterson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Daniel W. Paterson</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>President and Chief Executive Officer</i></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 6; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZF02jbrrTokWsIkXEbbSjBNtMmcS/I3lLY4s4DAzDe997QsQip4WpkeEwKwvYYdPW2iOUeEZGe8LgyJarFMIt8WKcZ2199/7AjAKDgZkMlDoGobPejcMqBTkZqtFQjUGOUilhuhbRV8/Ink2F1htdg7YVbJlaNug1v/qEnX6SpebVVe2RnSGbQjKQvfwGJRMFG7rrB/HVQVFkIoq7iUTOdGuDa/70aL8kzGtsQp3r6f9GH/o+Snc= -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>tm2513177d1_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT><B><I>Execution
Version</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES PURCHASE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This <B>SECURITIES PURCHASE
AGREEMENT</B> (this &ldquo;<B>Agreement</B>&rdquo;) is dated as of April&nbsp;25, 2025, by and among Verastem,&nbsp;Inc., a Delaware corporation
(the &ldquo;<B>Company</B>&rdquo;), and each of the entities listed on <U>Exhibit&nbsp;A</U> attached to this Agreement (each, an &ldquo;<B>Investor</B>&rdquo;
and together, the &ldquo;<B>Investors</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section&nbsp;4(a)(2)&nbsp;of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
the Company desires to sell to the Investors, and each Investor desires to purchase from the Company, severally and not jointly, upon
the terms and subject to the conditions stated in this Agreement, (A)&nbsp;shares (the &ldquo;<B>Shares</B>&rdquo;) of the Company&rsquo;s
common stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), and/or (B)&nbsp;pre-funded warrants to purchase shares
of Common Stock substantially in the form attached hereto as <U>Exhibit&nbsp;B</U> (the &ldquo;<B>Warrants</B>&rdquo; and together with
the Shares, the &ldquo;<B>Securities</B>&rdquo;); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WHEREAS</B></FONT>,
contemporaneously with the sale of the Shares and the Warrants, the parties hereto will execute and deliver a Registration Rights Agreement,
substantially in the form attached hereto as <U>Exhibit&nbsp;C</U>, pursuant to which the Company will agree to provide certain registration
rights in respect of the Shares and the Warrant Shares (as defined below) under the Securities Act and applicable state securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOW
THEREFORE</B></FONT>, in consideration of the mutual agreements, representations, warranties and covenants herein contained, the Company
and each Investor, severally and not jointly, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Definitions</U>.
As used in this Agreement, the following terms shall have the following respective meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Affiliate</B>&rdquo;
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls, is controlled
by or is under common control with such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Agreement</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Amended and Restated
Bylaws</B>&rdquo; means the Bylaws of the Company, as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Certificate of Incorporation</B>&rdquo;
means the Restated Certificate of Incorporation of the Company, as amended and as currently in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Benefit Plan</B>&rdquo;
or &ldquo;<B>Benefit Plans</B>&rdquo; means employee benefit plans as defined in Section&nbsp;3(3)&nbsp;of ERISA and all other employee
benefit practices or arrangements, including, without limitation, any such practices or arrangements providing severance pay, sick leave,
vacation pay, salary continuation for disability, retirement benefits, deferred compensation, bonus pay, incentive pay, stock options
or other stock-based compensation, hospitalization insurance, medical insurance, life insurance, scholarships or tuition reimbursements,
maintained by the Company or to which the Company or any of its subsidiaries is obligated to contribute for employees or former employees
of the Company and its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Board of Directors</B>&rdquo;
means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Business Day</B>&rdquo;
means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on which banking
institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Closing Date</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;2.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Code</B>&rdquo;
means the U.S. Internal Revenue Code of 1986, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Common Stock Equivalents</B>&rdquo;
means any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or
otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Company</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Confidential Data</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.30</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Disclosure Document</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Drug Regulatory
Agency</B>&rdquo; means the U.S. Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;) or other foreign, state, local or comparable
governmental authority responsible for regulation of the research, development, testing, manufacturing, processing, storage, labeling,
sale, marketing, advertising, distribution and importation or exportation of drug or biological products and drug or biological product
candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Environmental Laws</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.15</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>ERISA</B>&rdquo;
means the U.S. Employee Retirement Income Security Act of 1974, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Exchange Act</B>&rdquo;
means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Financial Statements</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.8(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Fundamental Representations&rdquo;
</B>means the representations and warranties made by the Company in <U>Sections 3.1 (Organization and Power)</U>, <U>3.2 (Capitalization)</U>,
<U>3.4 (Authorization)</U>, <U>3.5 (Valid Issuance)</U>, <U>3.6 (No Conflict)</U>, <U>3.7 (Consents)</U>, <U>3.8 (SEC Filings; Financial
Statements)</U>, <U>3.18 (Nasdaq Stock Market)</U>, <U>3.19 (Sarbanes-Oxley Act)</U>, <U>3.23 (Price Stabilization of Common Stock)</U>,
<U>3.24 (Investment Company Act)</U>, <U>3.25 (General Solicitation; No Integration or Aggregation)</U>, <U>3.26 (Brokers and Finders)</U>,
<U>3.27 (Reliance by the Investors)</U> and <U>3.28 (No Additional Agreements)</U><B>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>GAAP</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.8(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>GDPR</B>&rdquo;</FONT>
has the meaning set forth in <U>Section&nbsp;3.31</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Governmental Authorizations</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Health Care Laws</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.21</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>HIPAA</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.30</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Indemnified Person&rdquo;
</B>has the meaning set forth in <U>Section&nbsp;5.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Intellectual Property</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.12</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Investor</B>&rdquo;
and &ldquo;<B>Investors</B>&rdquo; have the meanings set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>IT Systems</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.30</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Material Adverse
Effect</B>&rdquo; means any change, event, circumstance, development, condition, occurrence or effect that, individually or in the aggregate,
(a)&nbsp;was, is, or would reasonably be expected to be, materially adverse to the business, financial condition, properties, assets,
liabilities, stockholders&rsquo; equity or results of operations of the Company and its subsidiaries, taken as a whole, or (b)&nbsp;materially
delays or materially impairs the ability of the Company to comply, or prevents the Company from complying, with its obligations under
this Agreement, the other Transaction Agreements, or with respect to the Closing, or would reasonably be expected to do so.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Nasdaq</B>&rdquo;
means the Nasdaq Capital Market LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>National Exchange</B>&rdquo;
means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date in question, together
with any successor thereto: the NYSE American, The New York Stock Exchange, the Nasdaq Global Market, the Nasdaq Global Select Market
and the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or any other entity or organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Personal Data</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.30</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Placement Agents</B>&rdquo;
means Guggenheim Securities, LLC, RBC Capital Markets, LLC and BTIG, LLC, Mizuho Securities USA LLC and B. Riley Securities,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Privacy
Laws</B>&rdquo;</FONT> has the meaning set forth in <U>Section&nbsp;3.31</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Privacy
Statements</B>&rdquo; </FONT>has the meaning set forth in <U>Section&nbsp;3.31</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Process</B>&rdquo;
or &ldquo;<B>Processing</B>&rdquo; </FONT>has the meaning set forth in <U>Section&nbsp;3.31</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Registration Rights
Agreement</B>&rdquo; has the meaning set forth in <U>Section&nbsp;6.1(j)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Regulatory Agencies</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.20</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Rule&nbsp;144</B>&rdquo;
means Rule&nbsp;144 promulgated by the SEC pursuant to the Securities Act, as such Rule&nbsp;may be amended from time to time, or any
similar rule&nbsp;or regulation hereafter adopted by the SEC having substantially the same effect as such Rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>SEC</B>&rdquo; means
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&ldquo;SEC
Reports</B></FONT>&rdquo; means (a)&nbsp;the Company&rsquo;s most recently filed Annual Report on Form&nbsp;10-K and (b)&nbsp;all Quarterly
Reports on Form&nbsp;10-Q or Current Reports on Form&nbsp;8-K filed or furnished (as applicable) by the Company following the end of the
most recent fiscal year for which an Annual Report on Form&nbsp;10-K has been filed and prior to the execution of this Agreement, together
in each case with any documents incorporated by reference therein or exhibits thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Securities Act</B>&rdquo;
means the U.S. Securities Act of 1933, as amended, and all of the rules&nbsp;and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Shares</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Short Sales</B>&rdquo;
include, without limitation, (a)&nbsp;all &ldquo;short sales&rdquo; as defined in Rule&nbsp;200 promulgated under Regulation SHO under
the Exchange Act, whether or not against the box, and all types of direct and indirect stock pledges, forward sale contracts, options,
puts, calls, short sales, swaps, &ldquo;put equivalent positions&rdquo; (as defined in Rule&nbsp;16a-1(h)&nbsp;under the Exchange Act)
and similar arrangements (including on a total return basis), and (b)&nbsp;sales and other transactions through non-U.S. broker dealers
or non-U.S. regulated brokers (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Studies</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.20.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax Returns</B>&rdquo;
means returns, reports, information statements and other documentation (including any additional or supporting material) filed or maintained,
or required to be filed or maintained, in connection with the calculation, determination, assessment or collection of any Tax and shall
include any amended returns required as a result of examination adjustments made by the Internal Revenue Service or other Tax authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Tax</B>&rdquo; or
 &ldquo;<B>Taxes</B>&rdquo; means any and all federal, state, local, foreign and other taxes, levies, fees, imposts, duties and charges
of whatever kind (including any interest, penalties or additions to the tax imposed in connection therewith or with respect thereto),
whether or not imposed on the Company, including, without limitation, taxes imposed on, or measured by, income, franchise, profits or
gross receipts, and also ad valorem, value added, sales, use, service, real or personal property, capital stock, license, payroll, withholding,
employment, social security, workers&rsquo; compensation, unemployment compensation, utility, severance, production, excise, stamp, occupation,
premium, windfall profits, transfer and gains taxes and customs duties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transaction Agreements</B>&rdquo;
means this Agreement, the Warrants, and the Registration Rights Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Transfer Agent</B>&rdquo;
means, with respect to the Common Stock, Computershare or such other financial institution that provides transfer agent services as the
Company may engage from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrants</B>&rdquo;
has the meaning set forth in the recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Warrant Shares</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;3.4</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
and Sale of Securities</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">2.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase
and Sale</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the
Investors, severally and not jointly, agree to purchase, the number and type of Securities, for the aggregate purchase price, set forth
opposite the Investor&rsquo;s name on <U>Exhibit&nbsp;A</U>. The price per Share is $7.00. The price per Warrant is $6.9999.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">2.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Closing</U>.
Subject to the satisfaction or waiver of the conditions set forth in <U>Section&nbsp;5.6</U> of this Agreement, the closing of the purchase
and sale of the Securities (the &ldquo;<B>Closing</B>&rdquo; and the date on which the Closing occurs, the &ldquo;<B>Closing Date</B>&rdquo;)
shall occur remotely via the exchange of documents and signatures at such time as agreed to by the Company and the Investors but (i)&nbsp;in
no event earlier than the first Business Day after the date of this Agreement and (ii)&nbsp;in no event later than the fifth Business
Day after the date of this Agreement. At the Closing, (a)&nbsp;the Shares shall be issued and registered in the name of the Investor,
or in such nominee name(s)&nbsp;as designated by such Investor, representing the number of Shares to be purchased by the Investor at such
Closing as set forth in <U>Exhibit&nbsp;A</U> and (b)&nbsp;the Company shall deliver to the Investor (or such Investor&rsquo;s designated
custodian per its delivery instructions), or in such nominee name(s)&nbsp;as designated by such Investor, a Warrant exercisable for a
number of shares of Common Stock as set forth in <U>Exhibit&nbsp;A</U> with respect to such Investor, in each case against payment to
the Company of the purchase price therefor in full, by wire transfer to the Company of immediately available funds, at or prior to the
Closing, in accordance with wire instructions provided by the Company to the Investors no less than one Business Day prior to the Closing.
On the Closing Date, the Company will cause the Transfer Agent to issue the Shares in book-entry form, free and clear of all restrictive
and other legends (except as expressly provided in <U>Section&nbsp;4.10</U>). In the event that the Closing has not occurred within one
Business Day after the expected Closing Date, unless otherwise agreed by the Company and the Investors, the Company shall promptly (but
no later than one Business Day thereafter) return the previously wired amounts to each respective Investor by wire transfer of United
States dollars in immediately available funds to the account specified by each Investor, and any book entries for the Securities shall
be deemed cancelled; provided that, unless this Agreement has been terminated pursuant to <U>Section&nbsp;7</U>, such return of funds
shall not terminate this Agreement or relieve such Investor of its obligation to purchase, or the Company of its obligation to issue and
sell, the Securities at the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties of the Company</U>. Except as set forth in the SEC Reports (other than as to the Fundamental Representations, which are
not so qualified), the Company hereby represents and warrants to each of the Investors and the Placement Agents that the statements contained
in this <U>Section&nbsp;3</U> are true and correct as of the date of this Agreement and as of the Closing Date (except for the representations
and warranties that speak as of a specific date, which shall be made as of such date).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization
and Power</U>. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware,
has the requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted and described
in the SEC Reports and is qualified to do business in each jurisdiction in which the character of its properties or the nature of its
business requires such qualification, except where such failure to be in good standing or to have such power and authority or to so qualify
would not reasonably be expected to have a Material Adverse Effect. Each of the Company&rsquo;s subsidiaries is (i)&nbsp;duly incorporated
and validly existing and in good standing under the laws of the jurisdiction of its incorporation and has the requisite power and authority
to carry on its business as now conducted and to own or lease its properties and (ii)&nbsp;qualified to do business as a foreign corporation
and in good standing in each jurisdiction in which such qualification is required, except in each case as would not cause a Material Adverse
Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Capitalization</U>.
The Company&rsquo;s disclosure of its authorized, issued and outstanding capital stock in the SEC Reports containing such disclosure was
accurate in all material respects as of the date indicated in such SEC Reports. All of the issued and outstanding shares of Common Stock
have been duly authorized and validly issued and are fully paid and non-assessable. None of the outstanding shares of capital stock of
the Company were issued in violation of any preemptive or other similar rights of any securityholder of the Company which have not been
waived, and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights
of third parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights</U>. Except as set forth in the Transaction Agreements or as disclosed in the SEC Reports, the Company is presently not under any
obligation, and has not granted any rights, to register under the Securities Act any of the Company&rsquo;s presently outstanding securities
or any of its securities that may hereafter be issued, other than such rights and obligations that have expired or been satisfied or waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization</U>.
The Company has all requisite corporate power and authority to enter into the Transaction Agreements and to carry out and perform its
obligations under the terms of the Transaction Agreements, including the issuance and sale of the Securities and the issuance of the shares
of Common Stock issuable upon exercise of the Warrants (the &ldquo;<B>Warrant Shares</B>&rdquo;). All corporate action on the part of
the Company, its officers, directors and stockholders necessary for the authorization of the Shares and the Warrant Shares, the authorization,
execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated herein, including
the issuance and sale of the Securities and the Warrant Shares, has been taken. This Agreement has been duly executed and delivered by
the Company and, assuming the due authorization, execution and delivery by each Investor and that this Agreement constitutes the legal,
valid and binding agreement of each Investor, this Agreement and each of the Warrants constitutes a legal, valid and binding obligation
of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium and similar laws relating to or affecting creditors generally or by general equity principles (regardless
of whether such enforceability is considered in a proceeding in equity or at law). Upon its execution by the Company and the other parties
thereto and assuming that it constitutes legal, valid and binding agreements of the other parties thereto, the Registration Rights Agreement
will constitute a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except
as such enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium and similar laws relating to or affecting
creditors generally or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity
or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Valid
Issuance</U>. The Shares being purchased by the Investors hereunder have been duly and validly authorized and, upon issuance pursuant
to the terms of this Agreement against full payment therefor in accordance with the terms of this Agreement, will be duly and validly
issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions (other than those as provided
in the Transaction Agreements or restrictions on transfer under applicable state and federal securities laws), and the holder of the Shares
shall be entitled to all rights accorded to a holder of Common Stock. The Warrant Shares have been duly and validly authorized and reserved
for issuance and, upon issuance pursuant to the terms of the Warrants against full payment therefor in accordance with the terms of the
Warrants, will be duly and validly issued, fully paid and non-assessable and will be issued free and clear of any liens or other restrictions
(other than those as provided in the Transaction Agreements or restrictions on transfer under applicable state and federal securities
laws), and the holder of the Warrant Shares shall be entitled to all rights accorded to a holder of Common Stock. Subject to the accuracy
of the representations and warranties made by the Investors in <U>Section&nbsp;4</U>, the offer and sale of the Securities to the Investors
is and will be in compliance with applicable exemptions from (i)&nbsp;the registration and prospectus delivery requirements of the Securities
Act and (ii)&nbsp;the registration and qualification requirements of applicable securities laws of the states of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflict</U>. The execution, delivery and performance of the Transaction Agreements by the Company, the issuance and sale of the Securities
and the consummation of the other transactions contemplated by the Transaction Agreements will not (i)&nbsp;violate any provision of the
Certificate of Incorporation or Amended and Restated Bylaws of the Company, (ii)&nbsp;conflict with or result in a violation of or default
(with or without notice or lapse of time, or both) under, or give rise to a right of termination, cancellation or acceleration of any
obligation, a change of control right or to a loss of a benefit under any agreement or instrument, credit facility, franchise, license,
judgment, order, statute, law, ordinance, rule&nbsp;or regulations, applicable to the Company or any of its subsidiaries or their respective
properties or assets,&nbsp;<FONT STYLE="background-color: white">or (iii)&nbsp;result in a violation of any law, rule, regulation, order,
judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any of its subsidiaries
is subject (including federal and state securities laws and regulations) and the rules&nbsp;and regulations of any self-regulatory organization
to which the Company or its securities are subject, or by which any property or asset of the Company or any of its subsidiaries is bound
or affected,&nbsp;</FONT>except, in the case of clauses (ii)&nbsp;and (iii), as would not, individually or in the aggregate, be reasonably
expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consents</U>.
Assuming the accuracy of the representations and warranties of the Investors in <U>Section&nbsp;4</U>, no consent, approval, authorization,
filing with or order of or registration with, any court or governmental agency or body is required in connection with the authorization,
execution or delivery by the Company of the Transaction Agreements, the issuance and sale of the Securities and the performance by the
Company of its other obligations under the Transaction Agreements, except such as (a)&nbsp;have been or will be obtained or made under
the Securities Act or the Exchange Act, (b)&nbsp;the filing of any requisite notices and/or application(s)&nbsp;to the National Exchange
for the issuance and sale of the Shares or the Warrant Shares and the listing of the Shares or the Warrant Shares for trading or quotation,
as the case may be, thereon in the time and manner required thereby, (c)&nbsp;customary post-closing filings with the SEC or pursuant
to state securities laws in connection with the offer and sale of the Shares or the Warrant Shares by the Company in the manner contemplated
herein, which will be filed on a timely basis, and (d)&nbsp;the filing of the registration statement required to be filed by the Registration
Rights Agreement, or (e)&nbsp;such that the failure of which to obtain would not have a Material Adverse Effect. All notices, consents,
authorizations, orders, filings and registrations which the Company is required to deliver or obtain prior to the Closing pursuant to
the preceding sentence have been obtained or made or will be delivered or obtained or effected, and shall remain in full force and effect,
on or prior to the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>SEC
Filings; Financial Statements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company has filed all forms, statements, certifications, reports and documents required to be filed by it with the SEC under Section&nbsp;13,
14(a)&nbsp;and 15(d)&nbsp;of the Exchange Act for the one year preceding the date of this Agreement and is in compliance with General
Instruction I.A.3 of Form&nbsp;S-3. As of the time it was filed with the SEC (or, if amended or superseded by a filing prior to the date
of this Agreement, then on the date of such filing), each of the filed SEC Reports complied in all material respects with the applicable
requirements of the Exchange Act, and, as of the time they were filed, none of the filed SEC Reports contained any untrue statement of
a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in light of the circumstances under which they were made, not misleading. There are no outstanding or unresolved comments from the SEC
staff with respect to the SEC Reports. To the Company&rsquo;s knowledge, none of the SEC Reports are the subject of an ongoing SEC review.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
financial statements of the Company included in the SEC Reports (collectively, the &ldquo;<B>Financial Statements</B>&rdquo;) comply in
all material respects with applicable accounting requirements and the rules&nbsp;and regulations of the SEC with respect thereto as in
effect at the time of filing (or to the extent corrected by a subsequent restatement) and fairly present in all material respects the
consolidated financial position of the Company as of the dates indicated, and the results of its operations and cash flows for the periods
therein specified, all in accordance with United States generally accepted accounting principles (&ldquo;<B>GAAP</B>&rdquo;) (except as
otherwise noted therein, and in the case of unaudited financial statements, as permitted by Form&nbsp;10-Q of the SEC, and except that
the unaudited financial statements may not contain footnotes and are subject to normal and recurring year-end adjustments) applied on
a consistent basis throughout the periods therein specified (unless otherwise noted therein). Except as set forth in the Financial Statements
filed prior to the date of this Agreement, the Company has not incurred any liabilities, contingent or otherwise, except (i)&nbsp;those
incurred in the ordinary course of business, consistent with past practices since the date of such financial statements or (ii)&nbsp;liabilities
not required under GAAP to be reflected in the Financial Statements, in either case, none of which, individually or in the aggregate,
have had or would reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Changes</U>. Between December&nbsp;31, 2024 and the date of this Agreement, (a)&nbsp;the Company has conducted its business only in
the ordinary course of business and there have been no material transactions entered into by the Company (except for the execution and
performance of this Agreement and the discussions, negotiations and transactions related thereto); (b)&nbsp;no material change to any
material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject has been entered
into; and (c)&nbsp;there has not been any other event or condition of any character that has had or would reasonably be expected to have
a Material Adverse Effect; provided, however, that none of the following will be deemed in themselves, either alone or in combination,
to constitute, and that none of the following will be taken into account in determining whether there has been or will be, a Material
Adverse Effect under this <U>Section&nbsp;3.9</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
change generally affecting the economy, financial markets or political, economic or regulatory conditions in the United States or any
other geographic region in which the Company conducts business, provided that the Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;general
financial, credit or capital market conditions, including interest rates or exchange rates, or any changes therein, provided that the
Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;any
change that generally affects industries in which the Company and its subsidiaries conduct business, provided that the Company is not
disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;earthquakes,
hurricanes, tsunamis, tornadoes, floods, mudslides, fires or other natural disasters, weather conditions, global pandemics, including
the COVID-19 pandemic and related strains, epidemic or similar health emergency, and other force majeure events in the United States or
any other location, provided that the Company is not disproportionately affected thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;national
or international political or social conditions (or changes in such conditions), whether or not pursuant to the declaration of a national
emergency or war, or the occurrence of any military or terrorist attack, provided that the Company is not disproportionately affected
thereby;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;material
changes in laws after the date of this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;in
and of itself, any material failure by the Company to meet any published or internally prepared estimates of revenues, expenses, earnings
or other economic performance for any period ending on or after the date of this Agreement (it being understood that the facts and circumstances
giving rise to such failure may be deemed to constitute, and may be taken into account in determining whether there has been, a Material
Adverse Effect to the extent that such facts and circumstances are not otherwise described in clauses (i)-(v)&nbsp;of this definition).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Absence
of Litigation</U>. There is no action, suit, proceeding, arbitration, claim, investigation, charge, complaint or inquiry pending or, to
the Company&rsquo;s knowledge, threatened against the Company or any of its subsidiaries which, individually or in the aggregate, has
had or would reasonably be expected to have a Material Adverse Effect, nor are there any orders, writs, injunctions, judgments or decrees
outstanding of any court or government agency or instrumentality and binding upon the Company or any of its subsidiaries that have had
or would reasonably be expected to have a Material Adverse Effect. <FONT STYLE="background-color: white">Neither the Company nor any subsidiary,
nor to the knowledge of the Company, any director or officer of the Company or any subsidiary, is, or within the last ten years has been,
the subject of any action involving a claim of violation of or liability under federal or state securities laws relating to the Company
or such subsidiary or a claim of breach of fiduciary duty relating to the Company or such subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Law; Permits</U>. Neither the Company nor any of its subsidiaries is in violation of, or has received any notices of violations with
respect to, any laws, statutes, ordinances, rules&nbsp;or regulations of any governmental body, court or government agency or instrumentality,
except for violations which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse
Effect. The Company and its subsidiaries have all required licenses, permits, certificates and other authorizations (collectively, &ldquo;<B>Governmental
Authorizations</B>&rdquo;) from such federal, state or local government or governmental agency, department or body that are currently
necessary for the operation of the business of the Company and its subsidiaries as currently conducted, except where the failure to possess
currently such Governmental Authorizations has not had and is not reasonably expected to have a Material Adverse Effect. Neither the Company
nor any subsidiary has received any written (or, to the Company&rsquo;s knowledge, oral) notice regarding any revocation or material modification
of any such Governmental Authorization, which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or
finding, has or would reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intellectual
Property</U>. To the Company&rsquo;s knowledge, the Company and its subsidiaries own, or have rights to use, all material inventions,
patent applications, patents, trademarks, trade names, service names, service marks, copyrights, trade secrets, know how (including unpatented
and/or unpatentable proprietary of confidential information, systems or procedures) and other intellectual property as described in the
SEC Reports necessary for, or used in the conduct of their respective businesses (including as described in the SEC Reports) (collectively,
 &ldquo;<B>Intellectual Property</B>&rdquo;), except where any failure to own, possess or acquire such Intellectual Property has not had,
and would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The Intellectual Property of
the Company and its subsidiaries has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or
in part. To the Company&rsquo;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, including
no liens, security interests, or other encumbrances; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property,
except, in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse
Effect. No action, suit, or other proceeding is pending, or, to the Company&rsquo;s knowledge, is threatened: (A)&nbsp;challenging the
Company&rsquo;s or its subsidiaries&rsquo; rights in or to any Intellectual Property; (B)&nbsp;challenging the validity, enforceability
or scope of any Intellectual Property; or (C)&nbsp;alleging that the Company or any of its subsidiaries infringes, misappropriates, or
otherwise violates any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others, except,
in each case, which, individually or in the aggregate, have not had and would not reasonably be expected to have a Material Adverse Effect.
The Company and its subsidiaries have complied in all material respects with the terms of each agreement pursuant to which Intellectual
Property has been licensed to the Company or any of its subsidiaries in all material respects, and to the Company&rsquo;s knowledge all
such agreements are in full force and effect. To the Company&rsquo;s knowledge, there are no material defects in any of the patents or
patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect,
maintain and safeguard their Intellectual Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Employee
Benefits</U>. Except as would not be reasonably likely to result in a Material Adverse Effect, each Benefit Plan has been established
and administered in accordance with its terms and in compliance with the applicable provisions of ERISA, the Code, the Patient Protection
and Affordable Care Act of 2010, as amended, and other applicable laws, rules&nbsp;and regulations. The Company and its subsidiaries are
in compliance with all applicable federal, state and local laws, rules&nbsp;and regulations regarding employment, except for any failures
to comply that are not reasonably likely, individually or in the aggregate, to have a Material Adverse Effect. There is no labor dispute,
strike or work stoppage&nbsp;against the Company or its subsidiaries pending or, to the knowledge of the Company, threatened which may
interfere with the business activities of the Company, except where such dispute, strike or work stoppage&nbsp;is not reasonably likely,
individually or in the aggregate, to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Taxes</U>.
The Company and its subsidiaries have filed all federal, state and foreign income Tax Returns and other Tax Returns required to have been
filed under applicable law (or extensions have been duly obtained) and have paid all Taxes required to have been paid by them, except
for those which are being contested in good faith and except where failure to file such Tax Returns or pay such Taxes would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. No assessment in connection with United States federal
tax returns has been made against the Company. The charges, accruals and reserves on the books of the Company in respect of any income
and corporation tax liability for any years not finally determined are adequate to meet any assessments or reassessments for additional
income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect.
No audits, examinations, or other proceedings with respect to any material amounts of Taxes of the Company and its subsidiaries are presently
in progress or have been asserted or proposed in writing without subsequently being paid, settled or withdrawn. There are no liens on
any of the assets of the Company. At all times since inception, the Company has been and continues to be classified as a corporation for
U.S. federal income tax purposes. Neither the Company nor any of its subsidiaries has been a United States real property holding corporation
within the meaning of Code Section&nbsp;897(c)-2 during the period specified in Code Section&nbsp;897(c)(1)(A)(ii).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Environmental
Laws</U>. The Company and its subsidiaries (i)&nbsp;are in compliance with any and all applicable foreign, federal, state and local laws
and regulations relating to the protection of human health and safety, the environment or hazardous or toxic substances or wastes, pollutants
or contaminants (&ldquo;<B>Environmental Laws</B>&rdquo;), (ii)&nbsp;have received all permits and other Governmental Authorizations required
under applicable Environmental Laws to conduct their business and (iii)&nbsp;are in compliance with all terms and conditions of any such
permit, license or approval, except where such noncompliance with Environmental Laws, failure to receive required permits, licenses or
other approvals or failure to comply with the terms and conditions of such permits, licenses or approvals would not, individually or in
the aggregate, reasonably be expected to have a Material Adverse Effect. None of the Company nor any of its subsidiaries has received
since January&nbsp;1, 2024, any written notice or other communication (in writing or otherwise), whether from a governmental authority
or other Person, that alleges that the Company or any subsidiary is not in compliance with any Environmental Law and, to the knowledge
of the Company, there are no circumstances that may prevent or interfere with the Company&rsquo;s or any subsidiary&rsquo;s compliance
with any Environmental Law in the future, except where such failure to comply would not reasonably be expected to have a Material Adverse
Effect. To the knowledge of the Company: (i)&nbsp;no current or (during the time a prior property was leased or controlled by the Company)
prior property leased or controlled by the Company or any subsidiary has received since January&nbsp;1, 2024, any written notice or other
communication relating to property owned or leased at any time by the Company, whether from a governmental authority, or other Person,
that alleges that such current or prior owner or the Company or any subsidiary is not in compliance with or violated any Environmental
Law relating to such property and (ii)&nbsp;the Company has no material liability under any Environmental Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Title</U>.
Each of the Company and its subsidiaries has good and marketable title to all personal property owned by it that is material to the business
of the Company, free and clear of all liens, encumbrances and defects except such as do not materially affect the value of such property
and do not interfere with the use made and proposed to be made of such property by the Company or its subsidiaries, as the case may be.
Any real property and buildings held under lease by the Company or its subsidiaries is held under valid, subsisting and enforceable leases
with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings
by the Company or its subsidiaries, as the case may be. The Company does not own any real property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Insurance</U>.
The Company carries or is entitled to the benefits of insurance in such amounts and covering such risks that is customary for comparably
situated companies and is adequate for the conduct of its business and the value of its real and personal properties (owned or leased)
and tangible assets, and each of such insurance policies is in full force and effect and the Company is in compliance in all material
respects with the terms of such insurance policies. Other than customary end-of-policy notifications from insurance carriers, since January&nbsp;1,
2024, the Company has not received any notice or other communication regarding any actual or possible: (i)&nbsp;cancellation or invalidation
of any material insurance policy or (ii)&nbsp;refusal or denial of any coverage, reservation of rights or rejection of any material claim
under any insurance policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Nasdaq
Stock Market</U>. The issued and outstanding shares of Common Stock are registered pursuant to Section&nbsp;12(b)&nbsp;of the Exchange
Act and are listed for trading on the Nasdaq Capital Market under the symbol &ldquo;VSTM&rdquo;. The Company is in compliance with all
listing requirements of Nasdaq applicable to the Company. There is no suit, action, proceeding or investigation pending or, to the knowledge
of the Company, threatened against the Company by Nasdaq or the SEC, respectively, to prohibit or terminate the listing of the Common
Stock on the Nasdaq Capital Market or to deregister the Common Stock under the Exchange Act. The Company has taken no action that is designed
to terminate the registration of the Common Stock under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.19&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Sarbanes-Oxley
Act</U>. The Company is, and since January&nbsp;1, 2024 has been, in compliance in all material respects with all applicable requirements
of the Sarbanes-Oxley Act of 2002 and applicable rules&nbsp;and regulations promulgated by the SEC thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.20&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Clinical
Data and Regulatory Compliance</U>. Except as would not reasonably be expected to result in a Material Adverse Effect: (i)&nbsp;the preclinical
tests and clinical trials and other studies used to support regulatory approval (collectively, &ldquo;<B>Studies</B>&rdquo;) being conducted
by the Company that are described in, or the results of which are referred to in, the SEC Reports were (and, if still pending, are being)
conducted in all material respects in accordance with the protocols, procedures and controls designed and approved for such Studies and
with standard medical and scientific research procedures; (ii)&nbsp;each description of the results of such Studies is accurate and complete
in all material respects and fairly presents the data derived from such Studies, and the Company and its subsidiaries have no knowledge
of any other studies the results of which are inconsistent with, or otherwise call into question, the results described or referred to
in the SEC Reports; (iii)&nbsp;the Company and its subsidiaries have made all such filings and obtained all such approvals as may be required
by the FDA or from any other U.S. federal, state or local government or foreign government or Drug Regulatory Agency, or Institutional
Review Board, each having jurisdiction over biopharmaceutical products (collectively, the &ldquo;<B>Regulatory Agencies</B>&rdquo;) for
the conduct of its business as described in the SEC Reports; (iv)&nbsp;neither the Company nor any of its subsidiaries has received any
notice of, or correspondence from, any of the Regulatory Agencies requiring the termination or suspension of or imposing any clinical
hold on any clinical trials that are described or referred to in the SEC Reports; and (v)&nbsp;the Company and its subsidiaries have each
operated and currently are in compliance in all material respects with all applicable rules, regulations and policies of the Regulatory
Agencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.21&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Health Care Laws</U>. The Company and its subsidiaries are in compliance in all material respects with all Health Care Laws to the
extent applicable to the Company&rsquo;s current business and research use only products. For purposes of this Agreement, &ldquo;<B>Health
Care Laws</B>&rdquo; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section&nbsp;301 et seq.), and the regulations
promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without
limitation, the Anti-Kickback Statute (42 U.S.C. Section&nbsp;1320a-7b(b)); (iii)&nbsp;HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv)&nbsp;the Patient Protection and Affordable Care Act
of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v)&nbsp;the European Union (&ldquo;<B>EU</B>&rdquo;)
Clinical Trials Regulation (Regulation (EU) No.&nbsp;536/2014); (vi)&nbsp;the EU Regulation regarding community procedures for authorization
and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Regulation (EC) No.&nbsp;726/2004);
(vii)&nbsp;licensure, quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory
bodies; (viii)&nbsp;all other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company
or its subsidiaries, and (ix)&nbsp;the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof.
Neither the Company nor any of its subsidiaries has received written or, to the Company&rsquo;s knowledge, oral notice of any claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory
authority or third party alleging that any product operation or activity is in material violation of any Health Care Laws nor, to the
Company&rsquo;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action
threatened. The Company and its subsidiaries have filed, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on the date filed in all
material respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries is a
party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or
imposed by any governmental or regulatory authority. Additionally, neither the Company nor any of its subsidiaries nor any of their respective
employees, officers, directors, or, to the knowledge of the Company, agents has been excluded, suspended or debarred from participation
in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,
investigation, proceeding, or other similar action that would reasonably be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.22&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Accounting
Controls and Disclosure Controls and Procedures</U>. The Company maintains a system of internal control over financial reporting (as defined
in Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)&nbsp;of the Exchange Act) that is designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP, including policies and
procedures sufficient to provide reasonable assurance (i)&nbsp;that the Company maintains records that in reasonable detail accurately
and fairly reflect the Company&rsquo;s transactions and dispositions of assets, (ii)&nbsp;that transactions are recorded as necessary
to permit preparation of financial statements in accordance with GAAP, (iii)&nbsp;that receipts and expenditures are made only in accordance
with authorizations of management and the Board of Directors and (iv)&nbsp;regarding prevention or timely detection of the unauthorized
acquisition, use or disposition of the Company&rsquo;s assets that could have a material effect on the Company&rsquo;s financial statements.
Except as disclosed in the Company&rsquo;s SEC Reports filed prior to the date of this Agreement, the Company has not identified any material
weaknesses in the design or operation of the Company&rsquo;s internal control over financial reporting. The Company&rsquo;s &ldquo;disclosure
controls and procedures&rdquo; (as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;of the Exchange Act) are designed to provide
reasonable assurance that all information (both financial and non-financial) required to be disclosed by the Company in the reports that
it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules&nbsp;and
forms of the SEC, and that all such information is accumulated and communicated to the Company&rsquo;s management as appropriate to allow
timely decisions regarding required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.23&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Price
Stabilization of Common Stock</U>. The Company has not taken, nor will it take, directly or indirectly, any action designed to stabilize
or manipulate the price of the Common Stock to facilitate the sale or resale of the Shares or the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.24&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Company Act</U>. The Company is not, and immediately after receipt of payment for the Securities will not be, an &ldquo;investment company&rdquo;
within the meaning of the U.S. Investment Company Act of 1940, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.25&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>General
Solicitation; No Integration or Aggregation</U>. Neither the Company nor any other person or entity authorized by the Company to act on
its behalf has engaged in a general solicitation or general advertising (within the meaning of Regulation D of the Securities Act) of
investors with respect to offers or sales of Securities pursuant to this Agreement. The Company has not, directly or indirectly, sold,
offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act) which,
to its knowledge, is or will be (i)&nbsp;integrated with the Securities sold pursuant to this Agreement for purposes of the Securities
Act <FONT STYLE="background-color: white">or (ii)&nbsp;aggregated with prior offerings by the Company for the purposes of the rules&nbsp;and
regulations of the Nasdaq Capital Market</FONT>. Assuming the accuracy of the representations and warranties of the Investors set forth
in <U>Section&nbsp;4</U>, neither the Company nor any of its Affiliates, its subsidiaries nor any Person acting on their behalf has, directly
or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances
that would adversely affect reliance by the Company on Section&nbsp;4(a)(2)&nbsp;for the exemption from registration for the transactions
contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.26&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Brokers
and Finders</U>. Other than the Placement Agents, neither the Company nor any other Person authorized by the Company to act on its behalf
has retained, utilized or been represented by any broker or finder in connection with the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.27&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
by the Investors</U>. The Company has a reasonable basis for making each of the representations set forth in this <U>Section&nbsp;3</U>.
The Company acknowledges that each of the Investors will rely upon the truth and accuracy of, and the Company&rsquo;s compliance with,
the representations, warranties, agreements, acknowledgements and understandings of the Company set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.28&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Additional Agreements</U>. There are no agreements or understandings between the Company and any Investor with respect to the transactions
contemplated by the Transaction Agreements other than (i)&nbsp;as specified in the Transaction Agreements and (ii)&nbsp;any side letter
agreements with any of the Investors, which side letters the Company has shared with all Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.29&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE=""><U>Anti-Bribery
and Anti-Money Laundering Laws</U></FONT>. Each of the Company, its subsidiaries and, to the knowledge of the Company, any of their respective
officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation
in the offering will not violate: (A)&nbsp;anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of
any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery
of Foreign Public Officials in International Business Transactions, signed December&nbsp;17, 1997, including the U.S. Foreign Corrupt
Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule&nbsp;or regulation of similar purposes and scope
or (B)&nbsp;anti-money laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws,
regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and
1957, the Patriot Act, the Bank Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental
group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which
designation the United States representative to the group or organization continues to concur, all as amended, and any executive order,
directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.30&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE=""><U>Cybersecurity</U></FONT>.
The Company and its subsidiaries&rsquo; information technology assets and equipment, computers, systems, networks, hardware, software,
websites, applications, and databases (collectively, &ldquo;<B>IT Systems</B>&rdquo;) are adequate for, and operate and perform in all
material respects as required in connection with the operation of the business of the Company and its subsidiaries as currently conducted,
and, to the knowledge of the Company, are free and clear of all material Trojan horses, time bombs, malware and other malicious code.
The Company and its subsidiaries have implemented and maintained commercially reasonable physical, technical and administrative controls
designed to maintain and protect the confidentiality, integrity, availability, privacy and security of all sensitive, confidential or
regulated data (&ldquo;<B>Confidential Data</B>&rdquo;) used or maintained in connection with their businesses and Personal Data (defined
below), and the integrity, availability continuous operation, redundancy and security of all IT Systems. &ldquo;<B>Personal Data</B>&rdquo;
means the following data used in connection with the Company&rsquo;s and its subsidiaries&rsquo; businesses and in their possession or
control: (i)&nbsp;a natural person&rsquo;s name, street address, telephone number, e-mail address, photograph, social security number
or other tax identification number, driver&rsquo;s license number, passport number, credit card number or bank information; (ii)&nbsp;information
that identifies or may reasonably be used to identify an individual; (iii)&nbsp;any information that would qualify as &ldquo;protected
health information&rdquo; under the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information
Technology for Economic and Clinical Health Act (collectively, &ldquo;<B>HIPAA</B>&rdquo;); and (iv)&nbsp;any information that would qualify
as &ldquo;personal data,&rdquo; &ldquo;personal information&rdquo; (or similar term) under the Privacy Laws. To the Company&rsquo;s knowledge,
there have been no breaches, outages or unauthorized uses of or accesses to the Company&rsquo;s IT Systems, Confidential Data, or Personal
Data that would require notification under Privacy Laws (as defined below).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.31&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
with Data Privacy Laws</U>. The Company and its subsidiaries are, and at all prior times were, in material compliance with all applicable
state, federal and foreign data privacy and security laws and regulations regarding the collection, use, storage, retention, disclosure,
transfer, disposal, or any other processing (collectively &ldquo;<B>Process</B>&rdquo; or &ldquo;<B>Processing</B>&rdquo;) of Personal
Data, including without limitation HIPAA, the EU General Data Protection Regulation (&ldquo;<B>GDPR</B>&rdquo;) (Regulation (EU) No.&nbsp;2016/679),
all other local, state, federal, national, supranational and foreign laws relating to the regulation of the Company or its subsidiaries,
and the regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof (collectively, the &ldquo;<B>Privacy
Laws</B>&rdquo;). To ensure material compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and
take all appropriate steps necessary to ensure compliance in all material respects with their policies and procedures relating to data
privacy and security, and the Processing of Personal Data and Confidential Data (the &ldquo;<B>Privacy Statements</B>&rdquo;). The Company
and its subsidiaries have, except as would not reasonably be expected, individually or in the aggregate, to result in a Material Adverse
Effect, at all times since inception provided accurate notice of their Privacy Statements then in effect to its customers, employees,
third party vendors and representatives. None of such disclosures made or contained in any Privacy Statements have been materially inaccurate,
misleading, incomplete, or in material violation of any Privacy Laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">3.32&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE=""><U>Transactions
with Affiliates and Employees</U></FONT>. No relationship, direct or indirect, exists between or among the Company, on the one hand, and
the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the
SEC Reports that is not so described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties of Each Investor</U>. Each Investor, severally for itself and not jointly with any other Investor, represents and warrants
to the Company and the Placement Agents that the statements contained in this <U>Section&nbsp;4</U> are true and correct as of the date
of this Agreement and the Closing Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Organization</U>.
The Investor is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization and has the
requisite power and authority to own, lease and operate its properties and to carry on its business as now conducted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Authorization</U>.
The Investor has all requisite corporate or similar power and authority to enter into this Agreement and the other Transaction Agreements
to which it will be a party and to carry out and perform its obligations hereunder and thereunder. All corporate, member or partnership
action on the part of such Investor or its stockholders, members or partners necessary for the authorization, execution, delivery and
performance of this Agreement and the other Transaction Agreements to which it will be a party and the consummation of the other transactions
contemplated in this Agreement has been taken. The execution, delivery and performance by such Investor of the Transaction Agreements
to which such Investor is a party has been duly authorized and each has been duly executed. Assuming this Agreement constitutes the legal
and binding agreement of the Company, this Agreement constitutes a legal, valid and binding obligation of such Investor, enforceable against
such Investor in accordance with its respective terms, except as such enforceability may be limited or otherwise affected by bankruptcy,
insolvency, fraudulent conveyance, reorganization, moratorium and/or similar laws relating to or affecting the rights of creditors generally
or by general equity principles (regardless of whether such enforceability is considered in a proceeding in equity or at law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflicts</U>. The execution, delivery and performance of the Transaction Agreements by the Investor, the purchase of the Securities in
accordance with their terms and the consummation by the Investor of the other transactions contemplated hereby will not conflict with
or result in any violation of, breach or default by such Investor (with or without notice or lapse of time, or both) under, conflict with,
or give rise to a right of termination, cancellation or acceleration of any obligation, a change of control right or to a loss of a material
benefit under (i)&nbsp;any provision of the organizational documents of the Investor, including, without limitation, its incorporation
or formation papers, bylaws, indenture of trust or partnership or operating agreement, as may be applicable or (ii)&nbsp;any agreement
or instrument, undertaking, credit facility, franchise, license, judgment, order, ruling, statute, law, ordinance, rule&nbsp;or regulations,
applicable to such Investor or its respective properties or assets, except, in the case of clause (ii), as would not, individually or
in the aggregate, be reasonably expected to materially delay or hinder the ability of the Investor to perform its obligations under the
Transaction Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Residency</U>.
The Investor&rsquo;s residence (if an individual) or offices in which its investment decision with respect to the Securities was made
(if an entity) are located at the address immediately below the Investor&rsquo;s name on <U>Exhibit&nbsp;A</U>, except as otherwise communicated
by the Investor to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Brokers
and Finders</U>. The Investor has not retained, utilized or been represented by any broker or finder in connection with the transactions
contemplated by this Agreement whose fees the Company would be required to pay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Representations and Warranties</U>. The Investor hereby represents and warrants that, it (i)&nbsp;as of the date of this Agreement is,
if an entity, a &ldquo;qualified institutional buyer&rdquo; (as defined in Rule&nbsp;144A under the Securities Act) or an institutional
 &ldquo;accredited investor&rdquo; as that term is defined in Rule&nbsp;501(a)&nbsp;under Regulation D promulgated pursuant to the Securities
Act; or (ii)&nbsp;if an individual, is an &ldquo;accredited investor&rdquo; as that term is defined in Rule&nbsp;501(a)&nbsp;of Regulation
D of the Securities Act and has such knowledge and experience in financial and business matters as to be able to protect its own interests
in connection with an investment in the Securities. The Investor further represents and warrants that (x)&nbsp;it is capable of evaluating
the merits and risk of such investment, and (y)&nbsp;that it has not been organized for the purpose of acquiring the Securities and is
an &ldquo;institutional account&rdquo; as defined by FINRA Rule&nbsp;4512(c). The Investor understands and agrees that the offering and
sale of the Securities has not been registered under the Securities Act or any applicable state securities laws and is being made in reliance
upon federal and state exemptions for transactions not involving a public offering which depend upon, among other things, the bona fide
nature of the investment intent and the accuracy of the Investor&rsquo;s representations as expressed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Intent</U>.
The Investor is purchasing the Securities solely for the Investor&rsquo;s own account and not for the account of others, and not with
a view to the resale or distribution of any part thereof in violation of the Securities Act, and the Investor has no present intention
of selling, granting any participation in, or otherwise distributing the same in violation of the Securities Act without prejudice, however,
to the Investor&rsquo;s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance with applicable
federal and state securities laws. Notwithstanding the foregoing, if the Investor is purchasing the Securities as a fiduciary or agent
for one or more investor accounts, the Investor has full investment discretion with respect to each such account, and the full power and
authority to make the acknowledgements, representations and agreements herein on behalf of each owner of each such account. The Investor
has no present arrangement to sell the Securities to or through any person or entity. The Investor understands that the Securities must
be held indefinitely unless such Securities are resold pursuant to a registration statement under the Securities Act or an exemption from
registration is available. Nothing contained herein shall be deemed a representation or warranty by the Investor to hold the Securities
for any period of time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Investment
Experience; Ability to Protect Its Own Interests and Bear Economic Risks</U>. The Investor acknowledges that it can bear the economic
risk and complete loss of its investment in the Securities and has knowledge and experience in finance, securities, taxation, investments
and other business matters as to be capable of evaluating the merits and risks of investments of the kind described in this Agreement
and contemplated hereby, and the Investor has had an opportunity to seek, and has sought, such accounting, legal, business and tax advice
as the Investor has considered necessary to make an informed investment decision. The Investor acknowledges that the Investor (i)&nbsp;is
a sophisticated investor, experienced in investing in private placements of equity securities and capable of evaluating investment risks
independently, both in general and with regard to all transactions and investment strategies involving a security or securities and (ii)&nbsp;has
exercised independent judgment in evaluating its participation in the purchase of the Securities. The Investor acknowledges that the Investor
is aware that there are substantial risks incident to the purchase and ownership of the Securities, including those set forth in the Company&rsquo;s
filings with the SEC. Alone, or together with any professional advisor(s), the Investor has adequately analyzed and fully considered the
risks of an investment in the Securities and determined that the Securities are a suitable investment for the Investor. The Investor is,
at this time and in the foreseeable future, able to afford the loss of the Investor&rsquo;s entire investment in the Securities and the
Investor acknowledges specifically that a possibility of total loss exists.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Independent
Investment Decision</U>. The Investor understands that nothing in the Transaction Agreements or any other materials presented by or on
behalf of the Company to the Investor in connection with the purchase of the Securities constitutes legal, tax or investment advice. The
Investor has consulted such legal, tax and investment advisors as it, in such Investor&rsquo;s sole discretion, has deemed necessary or
appropriate in connection with its purchase of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Securities
Not Registered; Legends</U>. The Investor acknowledges and agrees that the Securities are being offered in a transaction not involving
any public offering within the meaning of the Securities Act, and the Investor understands that the Securities have not been registered
under the Securities Act, by reason of their issuance by the Company in a transaction exempt from the registration requirements of the
Securities Act, and that the Securities must continue to be held and may not be offered, resold, transferred, pledged or otherwise disposed
of by the Investor unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration
and in each case in accordance with any applicable securities laws of any state of the United States. The Investor understands that the
exemptions from registration afforded by Rule&nbsp;144 (the provisions of which are known to it) promulgated under the Securities Act
depend on the satisfaction of various conditions including, but not limited to, the time and manner of sale, the holding period and on
requirements relating to the Company which are outside of the Investor&rsquo;s control and which the Company may not be able to satisfy,
and that, if applicable, Rule&nbsp;144 may afford the basis for sales only in limited amounts. The Investor acknowledges and agrees that
it has been advised to consult legal counsel prior to making any offer, resale, transfer, pledge or disposition of any of the Securities.
The Investor acknowledges that no federal or state agency has passed upon or endorsed the merits of the offering of the Securities or
made any findings or determination as to the fairness of this investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Investor understands that
any certificates or book entry notations evidencing the Securities may bear one or more legends in substantially the following form and
substance:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&ldquo;THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR THE SECURITIES LAWS OF ANY
STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY&nbsp;NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS
(I)&nbsp;SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (II)&nbsp;SUCH SECURITIES MAY&nbsp;BE SOLD PURSUANT
TO RULE 144, (III)&nbsp;THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY&nbsp;LAWFULLY
BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV)&nbsp;THE SECURITIES ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE
OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the Securities
may contain a legend regarding affiliate status of the Investor, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
General Solicitation</U>. The Investor acknowledges and agrees that the Investor is purchasing the Securities directly from the Company.
Investor became aware of this offering of the Securities solely by means of direct contact from the Placement Agents or directly from
the Company as a result of a pre-existing, substantive relationship with the Company or the Placement Agents, and/or their respective
advisors (including, without limitation, attorneys, accountants, bankers, consultants and financial advisors), agents, control persons,
representatives, affiliates, directors, officers, managers, members, and/or employees, and/or the representatives of such persons. The
Securities were offered to Investor solely by direct contact between Investor and the Company, the Placement Agents and/or their respective
representatives. Investor did not become aware of this offering of the Securities, nor were the Securities offered to Investor, by any
other means, and none of the Company, the Placement Agents or their respective representatives acted as investment advisor, broker or
dealer to Investor. The Investor is not purchasing the Securities as a result of any general or public solicitation or general advertising,
or publicly disseminated advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine
or similar media or broadcast over television, radio or the internet or presented at any seminar or any other general solicitation or
general advertisement, including any of the methods described in Section&nbsp;502(c)&nbsp;of Regulation D under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Access
to Information</U>. The Investor acknowledges and agrees that the Investor and the Investor&rsquo;s professional advisor(s), if any, have
had the opportunity to ask such questions, receive such answers and obtain such information from the Company regarding the Company, its
business and the terms and conditions of the offering of the Securities as the Investor and the Investor&rsquo;s professional advisor(s),
if any, have deemed necessary to make an investment decision with respect to the Securities and that the Investor has independently made
its own analysis and decision to invest in the Company. Neither such inquiries nor any other due diligence investigation conducted by
the Investor shall modify, limit or otherwise affect the Investor&rsquo;s right to rely on the Company&rsquo;s representations and warranties
contained in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">4.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Certain
Trading Activities</U>. Other than consummating the transaction contemplated hereby, the Investor has not, nor has any Person acting on
behalf of or pursuant to any understanding with the Investor, directly or indirectly executed any purchases or sales, including Short
Sales, of the securities of the Company during the period commencing as of the time that the Investor was first contacted by the Company
or any other Person regarding the transaction contemplated hereby and ending immediately prior to the date of this Agreement. Notwithstanding
the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate
portions of such Investor&rsquo;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio
managers managing other portions of such Investor&rsquo;s assets, the representation set forth above shall only apply with respect to
the portion of the assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement. Other than to other Persons party to this Agreement and to its advisors and agents who had a need to know such information,
the Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow
in order to effect Short Sales or similar transactions in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Further
Assurances</U>. Prior to and at Closing, each party agrees to cooperate with each other and their respective officers, employees, attorneys,
accountants and other agents, and, generally, do such other reasonable acts and things in good faith as may be necessary to effectuate
the intents and purposes of this Agreement, subject to the terms and conditions of this Agreement and compliance with applicable law,
including taking reasonable action to facilitate the filing of any document or the taking of reasonable action to assist the other parties
hereto in complying with the terms of this Agreement. The Investor acknowledges that the Company and the Placement Agents will rely on
the acknowledgments, understandings, agreements, representations and warranties contained in this Agreement. Prior to the Closing, the
Investor agrees to promptly notify the Company if any of the acknowledgments, understandings, agreements, representations and warranties
set forth in <U>Section&nbsp;4</U> of this Agreement are no longer accurate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing</U>.
The Company shall use commercially reasonable efforts to maintain the listing and trading of its Common Stock on the Nasdaq Capital Market
and, in accordance therewith, will use reasonable best efforts to comply in all material respects with the Company&rsquo;s reporting,
filing and other obligations under the rules&nbsp;and regulations of Nasdaq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Disclosure
of Transactions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company shall, by 9:00 a.m., New York City time, on the first (1st) Business Day immediately following the date of this Agreement (or,
if the Agreement is executed on a Business Day prior to 8:00 a.m., New York City Time on the date of this Agreement, by 9:00 a.m., New
York City time, on the date of this Agreement) file with the SEC a Current Report on Form&nbsp;8-K (including all exhibits thereto, the
 &ldquo;<B>Disclosure Document</B>&rdquo;) disclosing all material terms of the transactions contemplated hereby and by the other Transaction
Agreements and attaching this Agreement and the other Transaction Agreements as exhibits to such Disclosure Document. Following the filing
of the Disclosure Document, other than any Investor who agreed to receive certain clinical data of the Company that the Company expects
to present at, or disclose in connection with, the American Society of Clinical Oncology (ASCO) Annual Meeting or certain regulatory updates,
each at the option of such Investor (collectively the &ldquo;<B>Additional Non-Public Information</B>&rdquo;), no Investor shall be in
possession of any material non-public information concerning the Company disclosed to the Investors by the Company or its representatives.
The Company understands and confirms that the Investors will rely on the foregoing representation in effecting securities transactions.
Notwithstanding anything in this Agreement to the contrary, the Company shall not publicly disclose the name of any Investor or any of
its Affiliates or advisers, or include the name of any Investor or any of its Affiliates or advisers in any press release, public announcement
or filing with the SEC (other than any registration statement contemplated by the Registration Rights Agreement) or any regulatory agency,
without the prior written consent of the Investor, except (i)&nbsp;as required by the federal securities law in connection with (A)&nbsp;any
registration statement contemplated by the Registration Rights Agreement and (B)&nbsp;the filing of final Transaction Agreements with
the SEC or pursuant to other routine proceedings of regulatory authorities, or (ii)&nbsp;to the extent such disclosure is required by
law, at the request of the staff of the SEC or regulatory agency or under the regulations of the Nasdaq Capital Market, in which case
the Company shall allow the Investor, to the extent reasonably practicable in the circumstances, reasonable time to comment on such release,
announcement or filing in advance of such issuance or filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>No
later than June&nbsp;3, 2025, the Company shall issue a press release and/or a Current Report on Form&nbsp;8-K (the actual date of such
press release and/or Current Report on Form&nbsp;8-K, the &ldquo;<B>Disclosure Date</B>&rdquo;) disclosing the Additional Non-Public Information.
Consequently, following the Disclosure Date, no Investor shall be in possession of any material non-public information concerning the
Company disclosed to the Investors by the Company or its representatives. The Company understands and confirms that the Investors will
rely on the foregoing representation in effecting securities transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Integration</U>.
The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer
for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section&nbsp;2 of the Securities Act)
that will be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities
Act of the sale of the Securities to the Investors, or that will be integrated with the offer or sale of the Securities for purposes of
the rules&nbsp;and regulations of any National Exchange such that it would require stockholder approval prior to the closing of such other
transaction unless stockholder approval is obtained before the closing of such subsequent transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Removal
of Legends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In
connection with any sale, assignment, transfer or other disposition of the Shares or Warrant Shares by an Investor pursuant to Rule&nbsp;144
or pursuant to any other exemption under the Securities Act such that the purchaser acquires freely tradable shares and upon compliance
by the Investor with the requirements of this Agreement, if requested by the Investor by notice to the Company, the Company shall request
the Transfer Agent to remove any restrictive legends related to the book entry account holding such shares and make a new, unlegended
entry for such book entry shares sold or disposed of without restrictive legends as soon as reasonably practicable following any such
request therefor from the Investor, provided that the Company has timely received from the Investor customary representations and other
documentation reasonably acceptable to the Company in connection therewith. The Company shall be responsible for the fees of its Transfer
Agent and its legal counsel associated with such legend removal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Subject
to receipt from the Investor by the Company and the Transfer Agent of customary representations and other documentation reasonably acceptable
to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares or Warrant Shares (i)&nbsp;have
been registered under the Securities Act pursuant to an effective registration statement; (ii)&nbsp;have been sold pursuant to Rule&nbsp;144,
or (iii)&nbsp;are eligible for resale under Rule&nbsp;144(b)(1)&nbsp;without the requirement for the Company to be in compliance with
the current public information requirements under Rule&nbsp;144(c)(1)&nbsp;(or any successor provision), the Company shall, in accordance
with the provisions of this <U>Section&nbsp;5.5(b)</U>&nbsp;and as soon as reasonably practicable following any request therefor from
an Investor accompanied by such customary and reasonably acceptable documentation referred to above, (A)&nbsp;deliver to the Transfer
Agent irrevocable instructions (in a form that the Company has, prior to the Closing Date, agreed with the Transfer Agent) that the Transfer
Agent shall make a new, unlegended entry for such book entry shares, and (B)&nbsp;cause its counsel to deliver to the Transfer Agent one
or more opinions to the effect that the removal of such legends in such circumstances may be effected under the Securities Act if required
by the Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Withholding
Taxes</U>. Each Investor agrees to furnish the Company with any information, representations and forms as shall reasonably be requested
by the Company from time to time to assist the Company in complying with any applicable tax law (including any withholding obligations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fees
and Commissions</U>. The Company shall be solely responsible for the payment of any placement agents&rsquo; fees, financial advisory fees,
or broker&rsquo;s commissions (other than for Persons engaged by an Investor) relating to or arising out of the transactions contemplated
hereby, including, without limitation, any fees or commissions payable to the Placement Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Conflicting Agreements</U>. The Company will not take any action, enter into any agreement or make any commitment that would conflict
or interfere in any material respect with the Company&rsquo;s obligations to the Investors under the Transaction Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Indemnification.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees to indemnify and hold harmless each Investor and its Affiliates, and their respective directors, officers, trustees, members,
managers, employees, investment advisers and agents (collectively, the &ldquo;<B>Indemnified Persons</B>&rdquo;), from and against any
and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements
and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim
or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any
breach of representation, warranty, covenant or agreement made by or to be performed on the part of the Company under the Transaction
Agreements, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts
have been finally judicially determined not to <FONT STYLE="background-color: white">have resulted from such Person&rsquo;s fraud or willful
misconduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Any
person entitled to indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with respect
to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel reasonably
satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate
counsel and to participate in the defense of such claim, but the fees and expenses of such counsel shall be at the expense of such person
unless (a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&nbsp;the indemnifying party shall have
failed to assume the defense of such claim and employ counsel reasonably satisfactory to such person or (c)&nbsp;in the reasonable judgment
of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party
with respect to such claims (in which case, if the person notifies the indemnifying party in writing that such person elects to employ
separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such
claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein
shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give notice shall materially
adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall
not, in connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys
at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent
shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement unless such
judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving
of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the indemnified
party in respect of such claim or litigation in favor of, and (iii)&nbsp;does not include any admission of fault, culpability, wrongdoing,
or wrongdoing or malfeasance by or on behalf of, the indemnified party. No indemnified party will, except with the consent of the indemnifying
party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Subsequent
Equity Sales</U>. From the date of this Agreement until the earlier of (a)&nbsp;sixty (60) days after the Closing Date and (b)&nbsp;the
Business Day immediately following the effective date of the registration statement filed pursuant to the Registration Rights Agreement
(the &ldquo;<B>Restricted Period</B>&rdquo;), the Company shall not (A)&nbsp;issue shares of Common Stock or Common Stock Equivalents,
(B)&nbsp;effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the outstanding
Common Stock or (C)&nbsp;file with the SEC a registration statement under the Securities Act relating to any shares of Common Stock or
Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement or as set forth in the following sentence.
Notwithstanding the foregoing, the provisions of this <U>Section&nbsp;5.10</U> shall not apply to (i)&nbsp;the issuance of the Securities
hereunder, (ii)&nbsp;the issuance of Common Stock or Common Stock Equivalents upon the conversion, exercise or vesting of any securities
of the Company outstanding on the date of this Agreement or outstanding pursuant to clause (iii)&nbsp;below, (iii)&nbsp;the issuance of
any Common Stock or Common Stock Equivalents pursuant to any Company stock-based compensation plans or in accordance with Nasdaq Stock
Market Rule&nbsp;5635(c)(4), (iv)&nbsp;the filing of a registration statement on Form&nbsp;S-8 under the Securities Act to register the
offer and sale of securities on an equity incentive plan or employee stock purchase plan, or (v)&nbsp;the filing of a registration statement
on Form&nbsp;S-3 under the Securities Act inclusive of an at-the-market program, provided however that no sales pursuant to such S-3 Registration
Statement shall be permitted during the Restricted Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">5.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reservation
of Common Stock</U>. As of the date of this Agreement, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Warrant Shares that are issuable upon the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
of Closing</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">6.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to the Obligation of the Investors</U>. The several obligations of each Investor to consummate the transactions to be consummated at the
Closing, and to purchase and pay for the Securities being purchased by it at the Closing pursuant to this Agreement, are subject to the
satisfaction or waiver in writing of the following conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties</U>. The representations and warranties of the Company contained herein shall be true and correct in all material respects,
except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in
all respects, as of the date of this Agreement and as of the Closing Date, as though made on and as of such date, except to the extent
any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true
and correct in all material respects as of such earlier date, except for those representations and warranties qualified by materiality
or Material Adverse Effect, which shall be true and correct in all respects as of such earlier date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance</U>.
The Company shall have performed in all material respects the obligations and conditions herein required to be performed or observed by
the Company on or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Injunction</U>. The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental
or court order or regulation and no such prohibition shall have been threatened in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consents</U>.
The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of
the purchase and sale of the Securities, all of which shall be in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Transfer
Agent</U>. The Company shall have furnished all required materials to the Transfer Agent to reflect the issuance of the Shares at the
Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Adverse
Changes</U>. Since the date of this Agreement, no event or series of events shall have occurred that has had or would reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Opinion
of Company Counsel</U>. The Company shall have delivered to the Investors and the Placement Agents the opinion of Ropes&nbsp;&amp; Gray
LLP, dated as of the Closing Date, in customary form and substance to be reasonably agreed upon with the Investors and addressing such
legal matters as the Investors and the Company reasonably agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Compliance
Certificate</U>. An authorized officer of the Company shall have delivered to the Investors at the Closing Date a certificate certifying
that the conditions specified in <U>Sections 6.1(a)&nbsp;(Representations and Warranties)</U>, <U>6.1(b)&nbsp;(Performance)</U>, <U>6.1(c)&nbsp;(No
Injunction)</U>, <U>6.1(d)&nbsp;(Consents)</U>, <U>6.1(e)&nbsp;(Transfer Agent)</U>, <U>6.1(f)&nbsp;(Adverse Changes)</U>, <U>6.1(k)&nbsp;(Listing
Requirements)</U> and <U>6.1(l)&nbsp;(No Injunction)</U> of this Agreement have been fulfilled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Secretary&rsquo;s
Certificate</U>. The Secretary of the Company shall have delivered to the Investors at the Closing Date a certificate certifying (i)&nbsp;the
Certificate of Incorporation; (ii)&nbsp;the Amended and Restated Bylaws; and (iii)&nbsp;resolutions of the Company&rsquo;s Board of Directors
(or an authorized committee thereof) approving this Agreement, the other Transaction Agreements, the transactions contemplated by this
Agreement and the issuance of the Securities and the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights Agreement</U>. The Company shall have executed and delivered the Registration Rights Agreement in the form attached hereto as <U>Exhibit&nbsp;B</U>
(the &ldquo;<B>Registration Rights Agreement</B>&rdquo;) to the Investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Listing
Requirements</U>. No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock. The Common Stock shall be listed on a National Exchange and shall not have been
suspended, as of the Closing Date, by the SEC or the National Exchange from trading thereon nor shall suspension by the SEC or the National
Exchange have been threatened, as of the Closing Date, in writing by the SEC or the National Exchange; and the Company shall have filed
with Nasdaq a Notification Form: Listing of Additional Shares for the listing of the Shares and the Warrant Shares and Nasdaq shall have
raised no objection to such notice and the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No
Injunction</U>. No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any
bankruptcy court or judge, or any order of or by any Governmental Entity, shall have been issued, and no action or proceeding shall have
been instituted by any Governmental Entity, enjoining or preventing the consummation of the transactions contemplated hereby or in the
other Transaction Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="background-color: white"><U>Payment</U>.
The Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for
the number of </FONT>Securities <FONT STYLE="background-color: white">being purchased by each Investor at the Closing as set forth in
<U>Exhibit&nbsp;A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Lock-Up
Agreements</U>. The Company shall have delivered to the Investors reasonable and customary lock-up agreements, dated as of the date of
this Agreement, duly executed by the directors and executive officers of the Company and restricting the directors and executive officers
from offering for sale, issuing, selling, contracting to sell, pledging or otherwise disposing of any of the Company&rsquo;s Common Stock
or securities convertible into the Company&rsquo;s Common Stock without the prior written consent of Guggenheim Securities, LLC for ninety
(90) days after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">6.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Conditions
to the Obligation of the Company</U>. The obligation of the Company to consummate the transactions to be consummated at the Closing, and
to issue and sell to each Investor the Securities to be purchased by it at the Closing pursuant to this Agreement, is subject to the satisfaction
or waiver in writing of the following conditions precedent:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Representations
and Warranties</U>. The representations and warranties of each Investor in <U>Section&nbsp;4</U> hereto shall be true and correct on and
as of the Closing Date, with the same force and effect as though made on and as of the Closing Date and consummation of the Closing shall
constitute a reaffirmation by the Investor of each of the representations, warranties, covenants and agreements of the Investor contained
in this Agreement as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Performance</U>.
Each Investor shall have performed or complied with in all material respects all obligations and conditions herein required to be performed
or observed by such Investor on or prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Injunction</U>.
The purchase of and payment for the Securities by each Investor shall not be prohibited or enjoined by any law or governmental or court
order or regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Registration
Rights Agreement</U>. Each Investor shall have executed and delivered the Registration Rights Agreement to the Company in the form attached
as <U>Exhibit&nbsp;B</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><FONT STYLE="background-color: white"><U>Payment</U>.
The Company shall have received payment, by wire transfer of immediately available funds, in the full amount of the purchase price for
the number of </FONT>Securities <FONT STYLE="background-color: white">being purchased by each Investor at the Closing as set forth in
<U>Exhibit&nbsp;A</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">7.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Termination</U>.
The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the mutual written consent of the Company and the Investors that agreed to purchase a majority of the Securities prior to the Closing;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
the Company if any of the conditions set forth in <U>Section&nbsp;6.2</U> shall have become incapable of fulfillment, and shall not have
been waived by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
an Investor (with respect to itself only) if any of the conditions set forth in <U>Section&nbsp;6.1</U> shall have become incapable of
fulfillment, and shall not have been waived by such Investor; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;By
either the Company or an Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth Business Day
following the date of this Agreement; provided, however, that, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, the party seeking
to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or
agreements contained in the Transaction Agreements if such breach has resulted in the circumstances giving rise to such party&rsquo;s
seeking to terminate its obligation to effect the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">7.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice</U>.
In the event of termination by the Company or the Investor of its obligations to effect the Closing pursuant to <U>Section&nbsp;7.1</U>,
written notice thereof shall be given to the other Investors by the Company. Nothing in this <U>Section&nbsp;7</U> shall be deemed to
release any party from any liability for any breach by such party of the other terms and provisions of the Transaction Agreements or to
impair the right of any party to compel specific performance by any other party of its other obligations under the Transaction Agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Miscellaneous
Provisions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.1&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Public
Statements or Releases</U>. Except as set forth in <U>Section&nbsp;5.3</U>, neither the Company nor any Investor shall make any public
announcement with respect to the existence or terms of this Agreement or the transactions provided for herein without the prior consent
of the other party (which consent shall not be unreasonably withheld). Notwithstanding the foregoing, and subject to compliance with <U>Section&nbsp;5.3</U>,
nothing in this <U>Section&nbsp;8.1</U> shall prevent any party from making any public announcement it considers necessary in order to
satisfy its obligations under the law, including applicable securities laws, or under the rules&nbsp;of any national securities exchange
or securities market, in which case the Company shall allow the Investors reasonable time to comment on such release or announcement in
advance of such issuance, and the Company will consider in good faith any Investor comments. The Company shall not include the name of
the Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any filing with the SEC)
without the prior written consent of the Investors, except as otherwise required by law or the applicable rules&nbsp;or regulations of
any securities exchange or securities market, in which case the Company shall allow the Investors, to the extent reasonably practicable
in the circumstances, reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding anything
to the contrary in this <U>Section&nbsp;8.1</U>,&nbsp;Investor review shall not be required for Company disclosures that are substantially
consistent with prior Company disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.2&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notices</U>.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when
delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient&rsquo;s next Business Day, (c)&nbsp;three
(3)&nbsp;days after having been sent by certified or registered mail, return-receipt requested and postage prepaid, or (d)&nbsp;one (1)&nbsp;Business
Day after deposit with a nationally recognized overnight courier, freight prepaid, specifying next business day delivery, with written
verification of receipt:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
to the Company, addressed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Verastem,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">117 Kendrick Street, Suite&nbsp;500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Needham, MA 02494</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attention: Daniel Calkins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: dcalkins@verastem.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">with a copy (which shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Ropes&nbsp;&amp; Gray LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Prudential Tower, 800 Boylston Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Boston, MA 02199-3600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attention: Thomas Danielski</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: Thomas.Danielski@ropesgray.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>If
to any Investor, at its address or e-mail address set forth on <U>Exhibit&nbsp;A</U>, or such address as subsequently modified by written
notice given in accordance with this <U>Section&nbsp;8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any Person may change the
address to which notices and communications to it are to be addressed by notification as provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.3&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Consent
to Electronic Notice</U>. Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation
Law (the &ldquo;<B>DGCL</B>&rdquo;), as amended or superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the
DGCL (or any successor thereto) at the e-mail address set forth below the Investor&rsquo;s name on the signature page&nbsp;or Exhibit&nbsp;A,
as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or
undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been
provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify
the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.4&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.5&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing
Law; Submission to Jurisdiction; Venue; Waiver of Trial by Jury</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This
Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to choice of laws or
conflicts of laws provisions thereof that would require the application of the laws of any other jurisdiction, except to the extent that
mandatory principles of Delaware law may apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company and each of the Investors hereby irrevocably and unconditionally:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;submits
for itself and its property in any legal action or proceeding relating solely to this Agreement or the transactions contemplated hereby,
to the general jurisdiction of the any state court or United States Federal court sitting in the Borough of Manhattan, City of New York
in the State of New York;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(ii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;consents
that any such action or proceeding may be brought in such courts, and waives any objection that it may now or hereafter have to the venue
of any such action or proceeding in any such court or that such action or proceeding was brought in an inconvenient court and agrees not
to plead or claim the same to the extent permitted by applicable law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;agrees
that service of process in any such action or proceeding may be effected by mailing a copy thereof by registered or certified mail (or
any substantially similar form of mail), postage prepaid, to the party, as the case may be, at its address set forth in <U>Section&nbsp;8.2</U>
or at such other address of which the other party shall have been notified pursuant thereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(iv)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;agrees
that nothing herein shall affect the right to effect service of process in any other manner permitted by law or shall limit the right
to sue in any other jurisdiction for recognition and enforcement of any judgment or if jurisdiction in the courts referenced in the foregoing
clause (i)&nbsp;are not available despite the intentions of the parties hereto;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(v)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;agrees
that final judgment in any such suit, action or proceeding brought in such a court may be enforced in the courts of any jurisdiction to
which such party is subject by a suit upon such judgment, provided that service of process is effected upon such party in the manner specified
herein or as otherwise permitted by law;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vi)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;agrees
that to the extent that such party has or hereafter may acquire any immunity from jurisdiction of any court or from any legal process
with respect to itself or its property, such party hereby irrevocably waives such immunity in respect of its obligations under this Agreement,
to the extent permitted by law; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(vii)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;irrevocably
and unconditionally waives trial by jury in any legal action or proceeding in relation to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.6&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Waiver</U>.
No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall
be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other
term, provision or condition of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.7&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Expenses</U>.
Except as expressly set forth in the Transaction Agreements to the contrary, each party shall pay its own out-of-pocket fees and expenses,
including the fees and expenses of attorneys, accountants and consultants employed by such party, incurred in connection with the proposed
investment in the Securities and the consummation of the transactions contemplated thereby; provided, however, that the Company shall
pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing of any instruction letter delivered
by the Company), stamp taxes and other taxes (other than income taxes) and duties levied in connection with the delivery of any Securities
to the Investors. The Company shall pay all Placement Agent fees relating to or arising out of the transactions contemplated by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.8&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Assignment</U>.
None of the parties may assign its rights or obligations under this Agreement or designate another person (i)&nbsp;to perform all or part
of its obligations under this Agreement or (ii)&nbsp;to have all or part of its rights and benefits under this Agreement, in each case
without the prior written consent of (x)&nbsp;the Company, in the case of an Investor, and (y)&nbsp;the Investors, in the case of the
Company, provided that an Investor may, without the prior consent of the Company, assign its rights to purchase the Securities hereunder
to any of its Affiliates or to any other investment funds or accounts managed or advised by the investment manager who acts on behalf
of such Investor (provided each such assignee agrees to be bound by the terms of this Agreement and makes the same representations and
warranties set forth in <U>Section&nbsp;4</U> ). In the event of any assignment in accordance with the terms of this Agreement, the assignee
shall specifically assume and be bound by the provisions of this Agreement by executing a writing agreeing to be bound by and subject
to the provisions of this Agreement and shall deliver an executed counterpart signature page&nbsp;to this Agreement and, notwithstanding
such assumption or agreement to be bound hereby by an assignee, no such assignment shall relieve any party assigning any interest hereunder
from its obligations or liability pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.9&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Confidential
Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Investor covenants that until such time as the transactions contemplated by this Agreement and any material non-public information provided
to such Investor are publicly disclosed by the Company, such Investor will maintain the confidentiality of all disclosures made to it
in connection with this transaction (including the existence and terms of this transaction), other than to such Investor&rsquo;s outside
attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance
of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required
by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company may request from the Investors such reasonable and customary additional information as the Company may deem necessary to evaluate
the eligibility of the Investor to acquire the Securities, and the Investor shall promptly provide such information as may reasonably
be requested to the extent readily available; provided, that the Company agrees to keep any such information provided by the Investor
confidential, except (i)&nbsp;as required by the federal securities laws, rules&nbsp;or regulations and (ii)&nbsp;to the extent such disclosure
is required by other laws, rules&nbsp;or regulations, at the request of the staff of the SEC or regulatory agency or under the regulations
of Nasdaq. The Investor acknowledges that the Company may file a copy of this Agreement and the Registration Rights Agreement with the
SEC as exhibit to a periodic report or a registration statement of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.10&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Reliance
by and Exculpation of Placement Agents</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Each
Investor agrees for the express benefit of each of the Placement Agents and their respective affiliates and representatives that (i)&nbsp;the
Placement Agents or their respective affiliates and representatives have not made, and will not make any representations or warranties
with respect to the Company or the offer and sale of the Securities, and the Investor will not rely on any statements made by any of the
Placement Agents, orally or in writing, to the contrary, (ii)&nbsp;the Investor will be responsible for conducting its own due diligence
investigation with respect to the Company and the offer and sale of the Securities, (iii)&nbsp;the Investor will be purchasing Securities
based on the results of its own due diligence investigation of the Company and none of the Placement Agents or their respective directors,
officers, employees, representatives, and controlling persons have made independent investigation with respect to the Company, the Securities,
or the accuracy, completeness, or adequacy of any information supplied to the Investor by the Company, (iv)&nbsp;the Investor has negotiated
the offer and sale of the Securities directly with the Company, and the Placement Agents will not be responsible for the ultimate success
of any such investment and (v)&nbsp;the decision to invest in the Company will involve a significant degree of risk, including a risk
of total loss of such investment. Each Investor further represents and warrants to each Placement Agent that it, including any fund or
funds that it manages or advises that participates in the offer and sale of the Securities, is permitted under its constitutive documents
(including, without limitation, all limited partnership agreements, charters, bylaws, limited liability company agreements, all applicable
side letters with investors, and similar documents) to make investments of the type contemplated by this Agreement. This <U>Section&nbsp;8.10</U>
shall survive any termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees and acknowledges that the Placement Agents may rely on its representations, warranties, agreements and covenants contained
in this Agreement and each Investor agrees that the Placement Agents may rely on such Investor&rsquo;s representations and warranties
contained in this Agreement as if such representations and warranties, as applicable, were made directly to the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Neither
the Placement Agents nor any of their Affiliates or representatives (1)&nbsp;shall be liable for any improper payment made in accordance
with the information provided by the Company; (2)&nbsp;makes any representation or warranty, or has any responsibilities as to the validity,
accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to
the Transaction Agreements or in connection with any of the transactions contemplated therein; or (3)&nbsp;shall be liable (x)&nbsp;for
any action taken, suffered or omitted by any of them in good faith and reasonably believed to be authorized or within the discretion or
rights or powers conferred upon it by the Transaction Agreements or (y)&nbsp;for anything which any of them may do or refrain from doing
in connection with the Transaction Agreements, except in each case for such party&rsquo;s own gross negligence or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The
Company agrees that the Placement Agents and their respective affiliates and representatives shall be entitled to (1)&nbsp;rely on, and
shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them
by or on behalf of the Company, and (2)&nbsp;be indemnified by the Company for acting as the Placement Agents hereunder pursuant to the
indemnification provisions set forth in the applicable letter agreement between the Company and each of the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.11&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Third
Parties</U>. Nothing in this Agreement, express or implied, is intended to confer on any Person other than the parties to this Agreement
any rights, remedies, claims, benefits, obligations or liabilities under or by reason of this Agreement, and no Person that is not a party
to this Agreement (including, without limitation, any partner, member, shareholder, director, officer, employee or other beneficial owner
of any party to this Agreement, in its own capacity as such or in bringing a derivative action on behalf of a party to this Agreement)
shall have any standing as a third party beneficiary with respect to this Agreement or the transactions contemplated hereby. Notwithstanding
the foregoing, (i)&nbsp;the Placement Agents are an intended third-party beneficiaries of the representations and warranties of the Company
and of each Investor set forth in <U>Section&nbsp;3</U>, <U>Section&nbsp;4</U> and <U>Section&nbsp;6.1(h)</U>&nbsp;and <U>Section&nbsp;8.10</U>
respectively, of this Agreement and (ii)&nbsp;the Indemnified Persons are intended third-party beneficiaries of <U>Section&nbsp;5.9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.12&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Independent
Nature of Investors&rsquo; Obligations and Right.</U> The obligations of each Investor under this Agreement are several and not joint
with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance obligations of any other
Investor under this Agreement. Nothing contained herein, and no action taken by any Investor pursuant hereto, shall be deemed to constitute
the Investors as, and the Company acknowledges that the Investors do not so constitute, a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group, and the Company
will not assert any such claim with respect to such obligations or the transactions contemplated by this Agreement. The Company acknowledges
and each Investor confirms that it has independently participated in the negotiation of the transaction contemplated hereby with the advice
of its own counsel and advisors. Each Investor also acknowledges that Ropes&nbsp;&amp; Gray LLP has not rendered legal advice to such
Investor. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising
out of this Agreement, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for
such purpose. The Company has elected to provide all Investors with the same terms and Transaction Agreements for the convenience of the
Company and not because it was required or requested to do so by any Investor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.13&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.14&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Counterparts</U>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not
a facsimile or pdf (or other electronic reproduction of a) signature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.15&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Entire
Agreement; Amendments</U>. This Agreement and the other Transaction Agreements (including all schedules and exhibits hereto and thereto),
together with any side letter agreements with any of the Investors, constitute the entire agreement between the parties hereto respecting
the subject matter of this Agreement and supersedes all prior agreements, negotiations, understandings, representations and statements
respecting the subject matter of this Agreement, whether written or oral. No amendment, modification, alteration, or change in any of
the terms of this Agreement shall be valid or binding upon the parties hereto unless made in writing and duly executed by the Company
and the Investors of at least a majority in interest of the Securities then held by the Investors, provided that prior to the Closing
the consent of all Investors shall be required. Notwithstanding the foregoing, this Agreement may not be amended and the observance of
any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment
or waiver applies to all Investors in the same fashion. The Company, on the one hand, and each Investor, on the other hand, may by an
instrument signed in writing by such parties waive the performance, compliance or satisfaction by such Investor or the Company, respectively,
with any term or provision of this Agreement or any condition hereto to be performed, complied with or satisfied by such Investor or the
Company, respectively. Notwithstanding the foregoing or anything else herein to the contrary, no amendment, modification, alteration,
change or waiver of this <U>Section&nbsp;8.15</U> shall be valid without the prior written consent of the Placement Agents, which consent
may be granted or withheld in the sole discretion of the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.16&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Survival</U>.
The covenants, representations and warranties made by each party hereto contained in this Agreement shall survive the Closing and the
delivery of the Securities in accordance with their respective terms. Each Investor shall be responsible only for its own representations,
warranties, agreements and covenants hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.17&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Contract
Interpretation.</U> This Agreement is the joint product of each Investor and the Company and each provision of this Agreement has been
subject to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">8.18&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Arm&rsquo;s
Length Negotiations</U>. For the avoidance of doubt, the parties acknowledge and confirm that the terms and conditions of the Securities
were determined as a result of arm&rsquo;s-length negotiations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Remainder of Page&nbsp;Intentionally Left Blank.]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">COMPANY:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">VERASTEM,&nbsp;INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Daniel W. Paterson</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%">Daniel W. Paterson</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto have
executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">RTW MASTER FUND, LTD.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto have
executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">RTW INNOVATION MASTER FUND, LTD.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto
have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>RTW BIOTECH OPPORTUNITIES OPERATING
    LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    Roderick Wong, M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Roderick Wong,
    MD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Partner</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ATLAS PRIVATE HOLDINGS (CAYMAN) LTD.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Scott Schroeder</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Scott Schroeder</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Director</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ALYESKA MASTER FUND, LP</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Jason Bragg</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Jason Bragg</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CFO, Alyeska Investment Group, LP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">NCP RFM LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BLACKWELL PARTNERS LLC - SERIES A, solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED PRIVATE INVESTMENTS IX, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Capital GP IX LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Advisors LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its Managing Member</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED GENESIS MASTER FUND, L.P.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Genesis GP LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Advisors LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its Managing Member</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">CVI INVESTMENTS,&nbsp;INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Heights Capital Management,&nbsp;Inc.,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Martin Kobinger</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Martin Kobinger</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">President</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY ASSET MASTER, LTD</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY TAX EFFICIENT, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY TAX EFFICIENT III, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">STONEPINE CAPITAL, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Jon M. Plexico</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Jon M. Plexico</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Managing Member of the General Partner</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BIOTECHNOLOGY VALUE FUND II, L.P.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BIOTECHNOLOGY VALUE TRADING FUND OS LP</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value
Trading Fund OS LP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IN
WITNESS WHEREOF</B></FONT>, the parties hereto have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">OCTAGON INVESTMENTS MASTER FUND LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Ting Jia</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Ting Jia</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Managing Member</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INVESTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;OF PRE-FUNDED WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 54 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;C</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 55; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>tm2513177d1_ex10-2.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><FONT><B><I>Execution
Version</I></B></FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION RIGHTS AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>THIS
REGISTRATION RIGHTS AGREEMENT</B></FONT> (this &ldquo;<B>Agreement</B>&rdquo;), dated as of April&nbsp;25, 2025, is entered into by and
among Verastem,&nbsp;Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and the several investors signatory hereto (individually
as an &ldquo;<B>Investor</B>&rdquo; and collectively together with their respective permitted assigns, the &ldquo;<B>Investors</B>&rdquo;).&nbsp;Capitalized
terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Securities Purchase Agreement by
and among the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time,
the &ldquo;<B>Purchase Agreement</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>WHEREAS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;Upon
the terms and subject to the conditions of the Purchase Agreement, the Company has agreed to issue to the Investors, and the Investors
have agreed to purchase, severally and not jointly, an aggregate of&nbsp;up to $75,005,000 of (x)&nbsp;shares (the &ldquo;<B>Initial
Shares</B>&rdquo;) of the Company's common stock, par value $0.0001 per share (the &ldquo;<B>Common Stock</B>&rdquo;), and/or (y)&nbsp;pre-funded
warrants to purchase shares of Common Stock (the &ldquo;<B>Warrants</B>&rdquo;) to purchase shares of Common Stock, in each case, pursuant
to the Purchase Agreement. The Initial Shares and the shares of Common Stock issuable upon exercise of the Warrants, without giving effect
to any limitations on exercise of the pre-funded warrants, and assuming all of the pre-funded warrants are exercised for cash, are collectively
referred to herein as the &ldquo;<B>Shares</B>.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">B.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
induce the Investors to enter into the Purchase Agreement, the Company has agreed to provide certain registration rights under the U.S.
Securities Act of 1933, as amended, and the rules&nbsp;and regulations thereunder, or any similar successor statute (collectively, the
 &ldquo;<B>Securities Act</B>&rdquo;), and applicable state securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>NOW,
THEREFORE,</B></FONT> in consideration of the promises and the mutual covenants contained herein and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Investors hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1.</B></FONT></TD><TD><B>DEFINITIONS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">For
purposes of this Agreement,</FONT> the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Person</B>&rdquo;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or any other entity or organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Register</B>,&rdquo;
 &ldquo;<B>Registered</B>,&rdquo; and &ldquo;<B>Registration</B>&rdquo; refer to a registration effected by preparing and filing one or
more registration statements of the Company in compliance with the Securities Act and providing for offering securities on a continuous
basis, and the declaration or ordering of effectiveness of such registration statement(s)&nbsp;by the U.S. Securities and Exchange Commission
(the &ldquo;<B>SEC</B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Registrable
Securities</B>&rdquo; means the Shares and any Common Stock issued or issuable with respect to the Shares as a result of any stock split
or subdivision, stock dividend, recapitalization, exchange or similar event. Registrable Securities shall cease to be Registrable Securities
upon the date on which the Investors shall have resold all the Registrable Securities covered by the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Registration
Expenses</B>&rdquo; means all registration and filing fee expenses incurred by the Company in effecting any registration pursuant to this
Agreement, including (i)&nbsp;all registration, qualification, and filing fees, printing expenses, and any other fees and expenses associated
with filings required to be made with the SEC, FINRA or any other regulatory authority, (ii)&nbsp;all fees and expenses in connection
with compliance with or clearing the Registrable Securities for sale under any securities or &ldquo;Blue Sky&rdquo; laws, (iii)&nbsp;all
printing, duplicating, word processing, messenger, telephone, facsimile and delivery expenses, and (iv)&nbsp;all fees and disbursements
of counsel for the Company and of all independent certified public accountants of the Company (including the expenses of any special audit
and cold comfort letters required by or incident to such performance).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Registration
Statement</B>&rdquo; means any registration statement of the Company filed with, or to be filed with, the SEC under the Securities Act,
that Registers the Registrable Securities, including the related prospectus, amendments and supplements to such registration statement,
including any pre- and post-effective amendments, and all exhibits and all material incorporated by reference in such registration statement
as may be necessary to comply with applicable securities laws. &ldquo;Registration Statement&rdquo; shall also include a New Registration
Statement, as amended when each became effective, including all documents filed as part thereof or incorporated by reference therein,
and including any information contained in a prospectus subsequently filed with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">&ldquo;<B>Selling
Expenses</B>&rdquo; means all underwriting discounts and selling commissions applicable to the sale of Registrable Securities and all
similar fees and commissions relating to the Investors&rsquo; disposition of the Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2.</B></FONT></TD><TD><B>REGISTRATION.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Mandatory
Registration</U>.&nbsp;The Company shall, as promptly as reasonably practicable and in any event no later than 30 days after the Closing
Date (the &ldquo;<B>Filing Deadline</B>&rdquo;), prepare and file with the SEC an initial Registration Statement (the &ldquo;<B>Initial
Registration Statement</B>&rdquo;) to Register the resale of all Registrable Securities. Before filing the Registration Statement, the
Company shall furnish to the Investors a copy of the Registration Statement. The Investors and their counsel shall have at least three
Business Days prior to the anticipated filing date of a Registration Statement to review and comment upon such Registration Statement
and any amendment or supplement to such Registration Statement and any related prospectus, prior to its filing with the SEC. Subject to
any SEC comments, such Registration Statement shall include the plan of distribution substantially in the form attached hereto as <U>Exhibit&nbsp;A</U>.
The Company shall (a)&nbsp;use commercially reasonable efforts to address in each such document prior to being so filed with the SEC such
comments as the Investor or its counsel reasonably proposed by the Investor, and (b)&nbsp;not file any Registration Statement or related
prospectus or any amendment or supplement thereto containing information regarding the Investor to which Investor reasonably objects,
unless such information is required to comply with any applicable law or regulation. The Investors shall furnish all information reasonably
requested by the Company and as shall be reasonably required in connection with any registration referred to in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Effectiveness.</U>&nbsp;The
Company shall use its reasonable best efforts to have the Initial Registration Statement and any amendment declared effective by the SEC
at the earliest possible date, but in any event no later than the earlier of (i)&nbsp;the 60th calendar day following the initial filing
date of the Initial Registration Statement if the SEC notifies the Company that it will &ldquo;review&rdquo; the Initial Registration
Statement and (ii)&nbsp;the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by
the SEC that the Initial Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject to further review (the &ldquo;<B>Effectiveness
Deadline</B>&rdquo;). The Company shall notify the Investor by e-mail as promptly as practicable, and in any event, within 24 hours, after
the Registration Statement is declared effective or is supplemented and shall provide the Investor with copies of any related prospectus
to be used in connection with the sale or other disposition of the securities covered thereby. The Company shall use reasonable best efforts
to keep the Initial Registration Statement continuously effective pursuant to Rule&nbsp;415 promulgated under the Securities Act and available
for the resale by the Investors of all of the Registrable Securities covered thereby at all times until the earliest to occur of the following
events: (i)&nbsp;the date on which the Investors shall have resold all the Registrable Securities covered thereby; and (ii)&nbsp;the date
on which the Registrable Securities may be resold by the Investors without registration and without regard to any volume or manner-of-sale
limitations by reason of Rule&nbsp;144, without the requirement for the Company to be in compliance with the current public information
requirement under Rule&nbsp;144 under the Securities Act or any other rule&nbsp;of similar effect (the &ldquo;<B>Registration Period</B>&rdquo;).
The Initial Registration Statement (including any amendments or supplements thereto and prospectuses contained therein) shall not contain
any untrue statement of a material fact or omit to state a material fact required to be stated therein, or necessary to make the statements
therein, in light of the circumstances in which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Sufficient
Number of Shares Registered</U>.&nbsp;In the event the number of shares available under the Initial Registration Statement at any time
is insufficient to cover the Registrable Securities, the Company shall, to the extent necessary and permissible, amend the Initial Registration
Statement or file a new registration statement (together with any prospectuses or prospectus supplements thereunder, a &ldquo;<B>New Registration
Statement</B>&rdquo;), so as to cover all of such Registrable Securities as soon as reasonably practicable, but in any event not later
than ten Business Days after the necessity therefor arises (the &ldquo;<B>New Registration Filing Deadline</B>&rdquo;).&nbsp;The Company
shall use its reasonable best efforts to have such amendment and/or New Registration Statement become effective as soon as reasonably
practicable following the filing thereof but no later than the earlier of (i)&nbsp;the 60th calendar day following the initial filing
date of the New Registration Statement if the SEC notifies the Company that it will &ldquo;review&rdquo; the New Registration Statement
and (ii)&nbsp;the fifth Business Day after the date the Company is notified (orally or in writing, whichever is earlier) by the SEC that
the New Registration Statement will not be &ldquo;reviewed&rdquo; or will not be subject to further review (the earlier of such dates,
the &ldquo;<B>New Registration Effectiveness Deadline</B>&rdquo;). The provisions of <U>Section&nbsp;2(a)</U>&nbsp;and <U>(b)</U>&nbsp;shall
apply to the New Registration Statement, except as modified hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Allowable
Delays.</U>&nbsp;On no more than two occasions and for not more than 30 consecutive days or for a total of not more than 60 days in any
12 month period, the Company may delay the effectiveness of the Initial Registration Statement or any other Registration Statement, or
suspend the use of any prospectus included in any Registration Statement, in the event that the Company determines in good faith that
such delay or suspension is necessary to (A)&nbsp;delay the disclosure of material non-public information concerning the Company, the
disclosure of which at the time is not, in the good faith opinion of the Company, in the best interests of the Company or (B)&nbsp;amend
or supplement the affected Registration Statement or the related prospectus so that such Registration Statement or prospectus shall not
include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the
statements therein, in the case of the prospectus in light of the circumstances under which they were made, not misleading (an &ldquo;<B>Allowed
Delay</B>&rdquo;); provided, that the Company shall promptly (a)&nbsp;notify each Investor in writing of the commencement of an Allowed
Delay, but shall not (without the prior written consent of an Investor) disclose to such Investor any material non-public information
giving rise to an Allowed Delay, (b)&nbsp;advise the Investors in writing to cease all sales under the Registration Statement until the
end of the Allowed Delay and (c)&nbsp;use commercially reasonable efforts to terminate an Allowed Delay as promptly as practicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;415;
Cutback</U>. If at any time the SEC takes the position that the offering of some or all of the Registrable Securities in any Registration
Statement is not eligible to be made on a delayed or continuous basis under the provisions of Rule&nbsp;415 under the Securities Act (provided,
however, the Company shall be obligated to use reasonable best efforts to advocate with the SEC for the registration of all of the Registrable
Securities) or requires any Investor to be named as an &ldquo;underwriter,&rdquo; the Company shall (i)&nbsp;promptly notify each holder
of Registrable Securities thereof and (ii)&nbsp;make commercially reasonable efforts to persuade the SEC that the offering contemplated
by such Registration Statement is a valid secondary offering and not an offering &ldquo;by or on behalf of the issuer&rdquo; as defined
in Rule&nbsp;415 and that none of the Investors is an &ldquo;underwriter.&rdquo; Each Investor shall have the right, at such Investor&rsquo;s
expense, to have its legal counsel review and oversee any registration or matters pursuant to this <U>Section&nbsp;2(f)</U>, including
participation in any meetings or discussions with the SEC regarding the SEC&rsquo;s position and to comment on any written submission
made to the SEC with respect thereto. No such written submission with respect to this matter shall be made to the SEC to which any Investor&rsquo;s
counsel reasonably objects. In the event that, despite the Company&rsquo;s reasonable best efforts and compliance with the terms of this
<U>Section&nbsp;2(f)</U>, the SEC refuses to alter its position, the Company shall (i)&nbsp;remove from such Registration Statement such
portion of the Registrable Securities (the &ldquo;<B>Cut Back Shares</B>&rdquo;) and/or (ii)&nbsp;agree to such restrictions and limitations
on the registration and resale of the Registrable Securities as the SEC may require to assure the Company&rsquo;s compliance with the
requirements of Rule&nbsp;415 (collectively, the &ldquo;<B>SEC Restrictions</B>&rdquo;); provided, however, that the Company shall not
name any Investor as an &ldquo;underwriter&rdquo; in such Registration Statement without the prior written consent of such Investor (provided
that, in the event an Investor withholds such consent, the Company shall have no obligation hereunder to include any Registrable Securities
of such Investor in any Registration Statement covering the resale thereof until such time as the SEC no longer requires such Investor
to be named as an &ldquo;underwriter&rdquo; in such Registration Statement or such Investor otherwise consents in writing to being so
named). Any cut-back imposed on the Investors pursuant to this <U>Section&nbsp;2(f)</U>&nbsp;shall be allocated among the Investors on
a pro rata basis and shall be applied first to any of the Registrable Securities of such Investor as such Investor shall designate, unless
the SEC Restrictions otherwise require or provide or the Investors otherwise agree. No liquidated damages shall accrue as to any Cut Back
Shares until such date as the Company is able to effect the registration of such Cut Back Shares in accordance with any SEC Restrictions
applicable to such Cut Back Shares (such date, the &ldquo;<B>Restriction Termination Date</B>&rdquo;). From and after the Restriction
Termination Date applicable to any Cut Back Shares, all of the provisions of this <U>Section&nbsp;2</U> (including the Company&rsquo;s
obligations with respect to the filing of a Registration Statement and its obligations to use reasonable efforts to have such Registration
Statement declared effective within the time periods set forth herein and the liquidated damages provisions relating thereto) shall again
be applicable to such Cut Back Shares; provided, however, that&nbsp;the date by which the Company is required to file the Registration
Statement with respect to such Cut Back Shares shall be the tenth day following the Restriction Termination Date and the date by which
the Company is required to have the Registration Statement effective with respect to such Cut Back Shares shall be the 55<SUP>th</SUP>
day immediately after the Restriction Termination Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3.</B></FONT></TD><TD><B>RELATED COMPANY OBLIGATIONS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to the Registration
Statement and whenever any Registrable Securities are to be Registered pursuant to <U>Section&nbsp;2</U>, including on the Initial Registration
Statement or on any New Registration Statement, the Company shall use its reasonable best efforts to effect the registration of the Registrable
Securities in accordance with the intended method of disposition thereof and, pursuant thereto, the Company shall have the following obligations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notifications</U>.
The Company will promptly notify the Investors of the time when any subsequent amendment to the Initial Registration Statement or any
New Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or
where a receipt has been issued therefor or any subsequent supplement to a prospectus has been filed and of any request by the SEC for
any amendment or supplement to the Registration Statement, any New Registration Statement or any prospectus or for additional information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Amendments.</U>
The Company will prepare and file with the SEC any amendments, post-effective amendments or supplements to the Initial Registration Statement,
any New Registration Statement or any related prospectus, as applicable, (a)&nbsp;as may be necessary to keep such Registration Statement
effective for the Registration Period and to comply with the provisions of the Securities Act and the Securities Exchange Act of 1934,
as amended (the &ldquo;<B>Exchange Act</B>&rdquo;) with respect to the distribution of all of the Registrable Securities covered thereby,
or (b)&nbsp;in the reasonable opinion of the Investors and the Company, as may be necessary or advisable in connection with any acquisition
or sale of Registrable Securities by the Investors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investor
Review</U>. The Company will not file any amendment or supplement to the Registration Statement, any New Registration Statement or any
prospectus, other than documents incorporated by reference, relating to the Investors, the Registrable Securities or the transactions
contemplated hereby unless (A)&nbsp;the Investors and their counsel shall have been advised and afforded the opportunity to review and
comment thereon at least three (3)&nbsp;Business Days prior to filing with the SEC and (B)&nbsp;the Company shall have given reasonable
due consideration to any comments thereon received from the Investors or their counsel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Copies
Available</U>. The Company will furnish to any Investor whose Registrable Securities are included in any Registration Statement and its
counsel copies of the Initial Registration Statement, any prospectus thereunder (including all documents incorporated by reference therein),
any prospectus supplement thereunder, any New Registration Statement and all amendments to the Initial Registration Statement or any New
Registration Statement that are filed with the SEC during the Registration Period (including all documents filed with or furnished to
the SEC during such period that are deemed to be incorporated by reference therein), each letter written by or on behalf of the Company
to the SEC or the staff of the SEC, and each item of correspondence from the SEC or the staff of the SEC, in each case relating to such
Registration Statement (other than any portion thereof which contains information for which the Company has sought confidential treatment)
and <FONT STYLE="background-color: white">such other documents as Investor may reasonably request in order to facilitate the disposition
of the Registrable Securities owned by Investor that are covered by such Registration Statement</FONT>, in each case as soon as reasonably
practicable upon such Investor&rsquo;s request and in such quantities as such Investor may from time to time reasonably request; provided,
however, that the Company shall not be required to furnish any document to the Investor to the extent such document is available on EDGAR.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notification
of Stop Orders; Material Changes</U>. The Company shall use commercially reasonable efforts to (i)&nbsp;prevent the issuance of any stop
order or other suspension of effectiveness and, (ii)&nbsp;if such order is issued, obtain the withdrawal of any such order as soon as
practicable. The Company shall advise the Investors promptly (but in no event later than 12 hours) and shall confirm such advice in writing,
in each case: (i)&nbsp;of the Company&rsquo;s receipt of notice of any request by the SEC or any other federal or state governmental authority
for amendment of or a supplement to the Registration Statement or any prospectus or for any additional information; (ii)&nbsp;of the Company&rsquo;s
receipt of notice of the issuance by the SEC or any other federal or state governmental authority of any stop order suspending the effectiveness
of the Initial Registration Statement or prohibiting or suspending the use of any prospectus or prospectus supplement, or any New Registration
Statement, or of the Company&rsquo;s receipt of any notification of the suspension of qualification of the Registrable Securities for
offering or sale in any jurisdiction or the initiation or contemplated initiation of any proceeding for such purpose; and (iii)&nbsp;of
the Company becoming aware of the happening of any event, which makes any statement of a material fact made in any Registration Statement
or any prospectus untrue or which requires the making of any additions to or changes to the statements then made in any Registration Statement
or any prospectus in order to state a material fact required by the Securities Act to be stated therein or necessary in order to make
the statements then made therein (in the case of any prospectus, in light of the circumstances under which they were made) not misleading,
or of the necessity to amend any Registration Statement or any prospectus to comply with the Securities Act or any other law. The Company
shall not be required to disclose to the Investors the substance of specific reasons of any of the events set forth in clause (i)&nbsp;to
(iii)&nbsp;of the immediately preceding sentence (each, a &ldquo;<B>Suspension Event</B>&rdquo;), but rather, shall only be required to
disclose that the event has occurred. If at any time the SEC, or any other federal or state governmental authority shall issue any stop
order suspending the effectiveness of any Registration Statement or prohibiting or suspending the use of any prospectus or prospectus
supplement, the Company shall use its reasonable best efforts to obtain the withdrawal of such order at the earliest practicable time.
The Company shall furnish to the Investors, without charge, a copy of any correspondence from the SEC or the staff of the SEC, or any
other federal or state governmental authority to the Company or its representatives relating to the Initial Registration Statement, any
New Registration Statement or any prospectus, or prospectus supplement as the case may be. In the event of a Suspension Event set forth
in clause (iii)&nbsp;of the first sentence of this <U>Section&nbsp;3(e)</U>, the Company will use its commercially reasonable efforts
to publicly disclose such event as soon as reasonably practicable, or otherwise resolve the matter such that sales under Registration
Statements may resume; provided, for the avoidance of doubt, however, that the Company may avail itself of any Allowable Delay pursuant
to Section&nbsp;2(d).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Confirmation
of Effectiveness</U>. If reasonably requested by an Investor at any time in respect of any Registration Statement, the Company shall deliver
to such Investor a written confirmation from Company&rsquo;s counsel of whether or not the effectiveness of such Registration Statement
has lapsed at any time for any reason (including, without limitation, the issuance of a stop order) and whether or not such Registration
Statement is currently effective and available to the Company for sale of Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Listing</U>.
The Company shall use best efforts to cause all Registrable Securities covered by a Registration Statement to be listed on the Nasdaq
Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Compliance</U>.
The Company shall otherwise use best efforts to comply with all applicable rules&nbsp;and regulations of the SEC under the Securities
Act and the Exchange Act, including, without limitation, Rule&nbsp;172 under the Securities Act, file any final prospectus, including
any supplement or amendment thereof, with the SEC pursuant to Rule&nbsp;424 under the Securities Act, promptly inform the Investor in
writing if, at any time during the Registration Period, the Company does not satisfy the conditions specified in Rule&nbsp;172 and, as
a result thereof, the Investor is required to deliver a prospectus in connection with any disposition of Registrable Securities and take
such other actions as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder, and make available
to its security holders, as soon as reasonably practicable, but not later than the Availability Date (as defined below), an earnings statement
covering a period of at least 12 months, beginning after the effective date of each Registration Statement, which earnings statement shall
satisfy the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act, including Rule&nbsp;158 promulgated thereunder (for the purpose
of this <U>subsection 3(h)</U>, &ldquo;<B>Availability Date</B>&rdquo; means the 45<SUP>th</SUP> day following the end of the fourth fiscal
quarter that includes the effective date of such Registration Statement, except that, if such fourth fiscal quarter is the last quarter
of the Company&rsquo;s fiscal year, &ldquo;<B>Availability Date</B>&rdquo; means the 90<SUP>th</SUP> day after the end of such fourth
fiscal quarter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Blue-Sky</U>.
The Company shall register or qualify or cooperate with the Investor and their counsel in connection with the registration or qualification
of such Registrable Securities for the offer and sale under the securities or blue sky laws of such jurisdictions reasonably requested
by the Investor; provided, however, that the Company shall not be required in connection therewith or as a condition thereto to (i)&nbsp;qualify
to do business in any jurisdiction where it would not otherwise be required to qualify but for this <U>Section&nbsp;3(i)</U>, (ii)&nbsp;subject
itself to general taxation in any jurisdiction where it would not otherwise be so subject but for this <U>Section&nbsp;3(i)</U>, or (iii)&nbsp;file
a general consent to service of process in any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Rule&nbsp;144</U>.
With a view to making available to the Investors the benefits of Rule&nbsp;144 (or its successor rule) and any other rule&nbsp;or regulation
of the SEC that may at any time permit the Investors to sell shares of Common Stock to the public without registration, the Company covenants
and agrees to: (i)&nbsp;make and keep adequate current public information available, as those terms are understood and defined in Rule&nbsp;144,
until the earlier of (A)&nbsp;six months after such date as all of the Registrable Securities may be sold without restriction by the holders
thereof pursuant to Rule&nbsp;144 or any other rule&nbsp;of similar effect or (B)&nbsp;such date as there are no longer Registrable Securities;
(ii)&nbsp;file with the SEC in a timely manner all reports and other documents required of the Company under the Exchange Act; and (iii)&nbsp;furnish
electronically to each Investor upon request, as long as such Investor owns any Registrable Securities, (A)&nbsp;a written statement by
the Company that it has complied with the reporting requirements of the Exchange Act, (B)&nbsp;a copy of or electronic access to the Company&rsquo;s
most recent Annual Report on Form&nbsp;10-K or Quarterly Report on Form&nbsp;10-Q, and (C)&nbsp;such other information as may be reasonably
requested in order to avail such Investor of any rule&nbsp;or regulation of the SEC that permits the selling of any such Registrable Securities
without registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cooperation.</U>&nbsp;The
Company shall cooperate with the holders of the Registrable Securities to facilitate the timely preparation and delivery of certificates
or uncertificated shares representing the Registrable Securities to be sold pursuant to such Registration Statement or Rule&nbsp;144 free
of any restrictive legends and representing such number of shares of Common Stock and registered in such names as the holders of the Registrable
Securities may reasonably request to the extent permitted by such Registration Statement or Rule&nbsp;144 to effect sales of Registrable
Securities ; for the avoidance of doubt, the Company may satisfy its obligations hereunder without issuing physical stock certificates
through the use of The Depository Trust Company&rsquo;s Direct Registration System.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4.</B></FONT></TD><TD><B>OBLIGATIONS OF THE INVESTORS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investor
Information</U>. Each Investor shall provide a completed Investor Questionnaire in the form attached hereto as <U>Exhibit&nbsp;B</U> in
connection with the registration of the Registrable Securities. If the Company has not received such completed Questionnaire from an Investor
within three business days of the Company&rsquo;s request, the Company may file the Registration Statement without including such Investor&rsquo;s
Registrable Securities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Suspension
of Sales</U>. Each Investor, severally and not jointly with any other Investor, agrees that, upon receipt of any notice from the Company
of the existence of Suspension Event as set forth in <U>Section&nbsp;3(e)</U>, the Investor will immediately discontinue disposition of
Registrable Securities pursuant to any Registration Statement covering such Registrable Securities until the Investor's receipt of a notice
from the Company confirming the resolution of such Suspension Event and that such dispositions may again be made.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Investor
Cooperation</U>. Each Investor, severally and not jointly with any other Investor, agrees to cooperate with the Company as reasonably
requested by the Company in connection with the preparation and filing of any amendments and supplements to any Registration Statement
or New Registration Statement hereunder, unless such Investor has notified the Company in writing of its election to exclude all of its
Registrable Securities from such Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>5.</B></FONT></TD><TD><B>EXPENSES OF REGISTRATION.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">All Registration Expenses incurred
in connection with registrations pursuant to this Agreement shall be borne by the Company. All Selling Expenses relating to securities
registered on behalf of the Investors shall be borne by the Investors pro rata on the basis of the number of Registrable Securities so
registered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>6.</B></FONT></TD><TD><B>INDEMNIFICATION.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">To
the fullest extent permitted by law, the Company will, and hereby does, indemnify, hold harmless and defend each Investor, each Person,
if any, who controls any Investor, the members, the directors, officers, partners, employees, members, managers, agents, representatives
and advisors of each Investor and each Person, if any, who controls any Investor within the meaning of the Securities Act or the Exchange
Act (each, an &ldquo;<B>Indemnified Person</B>&rdquo;), against any losses, obligation, claims, damages, liabilities, contingencies, judgments,
fines, penalties, charges, costs (including, without limitation, court costs and costs of preparation), reasonable and documented attorneys&rsquo;
fees, amounts paid in settlement and reasonable and documented expenses (collectively, &ldquo;<B>Losses</B>&rdquo;)) reasonably incurred
in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation or appeal taken from the foregoing
by or before any court or governmental, administrative or other regulatory agency or body or the SEC (each, a &ldquo;<B>Claim</B>&rdquo;),
whether pending or threatened, whether or not an indemnified party is or may be a party thereto (&ldquo;<B>Indemnified Damages</B>&rdquo;),
to which any of them may become subject insofar as such Claims (or actions or proceedings, whether commenced or threatened, in respect
thereof) arise out of or are based upon: (i)&nbsp;any untrue statement or alleged untrue statement or omission or alleged omission of
any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus, or any amendment or supplement
thereof, or (ii)&nbsp;any violation or alleged violation by the Company or any of its subsidiaries of the Securities Act, Exchange Act
or any other state securities or other &ldquo;blue sky&rdquo; laws of any jurisdiction in which Registrable Securities are offered or
any rule&nbsp;or regulation promulgated thereunder applicable to the Company or its agents and relating to action or inaction required
of the Company in connection with such registration of the Registrable Securities (the matters in the foregoing clauses (i)&nbsp;and (ii)&nbsp;being,
collectively, &ldquo;<B>Violations</B>&rdquo;).&nbsp;The Company shall reimburse each Indemnified Person promptly as such Losses are incurred
and are due and payable as incurred by them in connection with investigating or defending any such Claim.&nbsp;Notwithstanding anything
to the contrary contained herein, the indemnification agreement contained in this <U>Section&nbsp;6(a)</U>: (A)&nbsp;shall not apply to
a Claim by an Indemnified Person arising out of or based upon a Violation which occurs in reliance upon and in conformity with information
furnished in writing to the Company by the relevant Investor or such relevant Indemnified Person specifically for use in such Registration
Statement or prospectus and was reviewed and approved in writing by such Investor or such Indemnified Person expressly for use in connection
with the preparation of any Registration Statement, any prospectus or any such amendment thereof or supplement thereto, if such in each
case if the foregoing was timely made available by the Company; (B)&nbsp;with respect to any superseded prospectus, shall not inure to
the benefit of any such Person from whom the Person asserting any such Claim purchased the Registrable Securities that are the subject
thereof (or to the benefit of any other Indemnified Person) if the untrue statement or omission of material fact contained in the superseded
prospectus was corrected in the revised prospectus, as then amended or supplemented, and the Indemnified Person was promptly advised in
writing not to use the outdated, defective or incorrect prospectus prior to the use giving rise to a violation; (C)&nbsp;shall not apply
to amounts paid in settlement of any Claim if such settlement is effected without the prior written consent of the Company, which consent
shall not be unreasonably withheld, conditioned or delayed.&nbsp;Such indemnity shall remain in full force and effect regardless of any
investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Registrable Securities by the Investor
pursuant to <U>Section&nbsp;8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">In
connection with the Initial Registration Statement, any New Registration Statement or any prospectus, each Investor, severally and not
jointly, agrees to indemnify, hold harmless and defend, the Company, each of its directors, each of its officers who signed the Initial
Registration Statement or signs any New Registration Statement, and each Person, if any, who controls the Company within the meaning of
the Securities Act or the Exchange Act (each, an &ldquo;<B>Indemnified Party</B>&rdquo;), against any losses, claims, damages, liabilities
and expense (including reasonable attorney fees) resulting from any untrue statement or alleged untrue statement or omission or alleged
omission of any material fact contained in any Registration Statement, any preliminary prospectus or final prospectus, or any amendment
or supplement thereof, but only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission of
any material fact was made in reliance upon and in conformity with information about the relevant Investor furnished in writing by such
Investor to the Company for use in such Registration Statement and reviewed and approved in writing by such Investor or such Indemnified
Person expressly for use in connection with the preparation of the Registration Statement, any New Registration Statement, any prospectus
or any such amendment thereof or supplement thereto. In no event shall the liability of any Investor be greater in amount than the dollar
amount of the proceeds (net of all expenses paid by such Investor in connection with any claim relating to this <U>Section&nbsp;6</U>
and the amount of any damages such Investor has otherwise been required to pay by reason of such untrue statement or omission) received
by such Investor upon the sale of the Registrable Securities included in such Registration Statement giving rise to such indemnification
obligation. Such indemnity shall remain in full force and effect regardless of any investigation made by or on behalf of such Indemnified
Party and shall survive the transfer of the Registrable Securities by any Investor pursuant to <U>Section&nbsp;8</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">Promptly
after receipt by an Indemnified Person or Indemnified Party under this <U>Section&nbsp;6</U> of notice of the commencement of any action
or proceeding (including any governmental action or proceeding) involving a Claim, such Indemnified Person or Indemnified Party shall,
if a Claim in respect thereof is to be made against any indemnifying party under this <U>Section&nbsp;6</U>, deliver to the indemnifying
party a written notice of the commencement thereof, and the indemnifying party shall have the right to participate in, and, to the extent
the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to assume control of the defense thereof
with counsel mutually satisfactory to the indemnifying party and the Indemnified Person or the Indemnified Party, as the case may be,
and upon such notice, the indemnifying party shall not be liable to the Indemnified Person or the Indemnified Party for any legal or other
expenses subsequently incurred by the Indemnified Person or the Indemnified Party in connection with the defense thereof; provided, however,
that an Indemnified Person or Indemnified Party (together with all other Indemnified Persons and Indemnified Parties that may be represented
without conflict by one counsel) shall have the right to retain its own counsel with the reasonable fees and expenses to be paid by the
indemnifying party, if, in the reasonable opinion of counsel retained by the indemnifying party, the representation by such counsel of
the Indemnified Person or Indemnified Party and the indemnifying party would be inappropriate due to actual or potential differing interests
between such Indemnified Person or Indemnified Party and any other party represented by such counsel in such proceeding. The Indemnified
Party or Indemnified Person shall cooperate with the indemnifying party in connection with any negotiation or defense of any such action
or claim by the indemnifying party and shall furnish to the indemnifying party all information reasonably available to the Indemnified
Party or Indemnified Person which relates to such action or claim.&nbsp;The indemnifying party shall keep the Indemnified Party or Indemnified
Person fully apprised as to the status of the defense or any settlement negotiations with respect thereto.&nbsp;No indemnifying party
shall be liable for any settlement of any action, claim or proceeding effected without its written consent, provided, however, that the
indemnifying party shall not unreasonably withhold, delay or condition its consent.&nbsp;No indemnifying party shall, without the consent
of the Indemnified Party or Indemnified Person, consent to entry of any judgment or enter into any settlement or other compromise unless
such judgment or settlement (i)&nbsp;imposes no liability or obligation on, (ii)&nbsp;includes as an unconditional term thereof the giving
of a complete, explicit and unconditional release from the party bringing such indemnified claims of all liability of the Indemnified
Party or Indemnified Person in respect to or arising out of such claim or litigation in favor of, and (iii)&nbsp;does not include any
admission of fault, culpability, wrongdoing, or wrongdoing or malfeasance by or on behalf of, the Indemnified Party or Indemnified Person.&nbsp;Following
indemnification as provided for hereunder, the indemnifying party shall be subrogated to all rights of the Indemnified Party or Indemnified
Person with respect to all third parties, firms or corporations relating to the matter for which indemnification has been made.&nbsp;The
failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall not
relieve such indemnifying party of any liability to the Indemnified Person or Indemnified Party under this <U>Section&nbsp;6</U>, except
to the extent that the indemnifying party is prejudiced in its ability to defend such action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
indemnification required by this <U>Section&nbsp;6</U> shall be made by periodic payments of the amount thereof during the course of the
investigation or defense, as and when bills are received or Indemnified Damages are incurred.&nbsp;Any Person receiving a payment pursuant
to this <U>Section&nbsp;6</U> which person is later determined to not be entitled to such payment shall return such payment (including
reimbursement of expenses) to the person making it.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">The
indemnity agreements contained herein shall be in addition to (i)&nbsp;any cause of action or similar right of the Indemnified Party or
Indemnified Person against the indemnifying party or others, and (ii)&nbsp;any liabilities the indemnifying party may be subject to pursuant
to the law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>7.</B></FONT></TD><TD><B>CONTRIBUTION.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">To the extent any indemnification
by an indemnifying party is prohibited or limited by law, the indemnifying party agrees to make the maximum contribution with respect
to any amounts for which it would otherwise be liable under <U>Section&nbsp;6</U> to the fullest extent permitted by law; provided, however,
that: (i)&nbsp;no seller of Registrable Securities guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of
the Securities Act) shall be entitled to contribution from any seller of Registrable Securities who was not guilty of fraudulent misrepresentation;
and (ii)&nbsp;contribution by any seller of Registrable Securities shall be limited in amount to the net amount of proceeds (net of all
expenses paid by such holder in connection with any claim relating to this <U>Section&nbsp;7</U> and the amount of any damages such holder
has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission) received by such
seller from the sale of such Registrable Securities giving rise to such contribution obligation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>8.</B></FONT></TD><TD><B>ASSIGNMENT OF REGISTRATION RIGHTS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; background-color: white">The
Company shall not assign this Agreement or any rights or obligations hereunder (whether by operation of law or otherwise) without the
prior written consent of the Investors holding a majority of the Registrable Securities then outstanding (determined as if all of the
Warrants then outstanding have been exercised without regard to any limitations on the exercise of such Warrants); provided, however,
that in any transaction, whether by merger, reorganization, restructuring, consolidation, financing or otherwise, whereby the Company
is a party and in which the Registrable Securities are converted into the equity securities of another Person, from and after the effective
time of such transaction, such Person shall, by virtue of such transaction, be deemed to have assumed the obligations of the Company hereunder,
the term &ldquo;Company&rdquo; shall be deemed to refer to such Person and the term &ldquo;Registrable Securities&rdquo; shall be deemed
to include the securities received by the Investor in connection with such transaction unless such securities are otherwise freely tradable
by the Investor after giving effect to such transaction, and the prior written consent of the Investors holding a majority of the Registrable
Securities then outstanding (determined as if all of the Warrants then outstanding have been exercised without regard to any limitations
on the exercise of such Warrants) shall not be required for such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; background-color: white; color: #222222">An
Investor may transfer or assign its rights hereunder, in whole or from time to time in part, to one or more Persons in connection with
the transfer of Registrable Securities (including Registrable Securities issuable upon exercise of Warrants) by such Investor to such
Person,&nbsp;provided&nbsp;that such Investor complies with all laws applicable thereto, and the provisions of the Purchase Agreement,
and provides written notice of assignment to the Company promptly after such assignment is effected, and such Person agrees in writing
to be bound by all of the provisions contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in; background-color: white">The
provisions of this Agreement shall be binding upon and inure to the benefit of the Investor and its successors and permitted assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>9.</B></FONT></TD><TD><B>AMENDMENTS AND WAIVERS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
provisions of this Agreement, including the provisions of this sentence, may be amended, modified or supplemented, or waived only by a
written instrument executed by (i)&nbsp;the Company and (ii)&nbsp;the holders of a majority of the then outstanding Registrable Securities
</FONT>(determined as if all of the Warrants then outstanding have been exercised without regard to any limitations on the exercise of
such Warrants), provided that (A)&nbsp;any party may give a waiver as to itself, and (B)&nbsp;any amendment, modification, supplement
or waiver that disproportionately and adversely affects the rights and obligations of any Investor relative to the comparable rights and
obligations of the other Investors shall require the prior written consent of such adversely affected Investor or each Investor, as applicable.
Notwithstanding the foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively
to the rights of one or more Investors and that does not adversely directly or indirectly affect the rights of other Investors may be
given by Investors holding all of the Registrable Securities to which such waiver or consent relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>10.</B></FONT></TD><TD><B>MISCELLANEOUS.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Notices</U>.
Any notices or other communications required or permitted to be given hereunder shall be in writing and shall be deemed to be given (a)&nbsp;when
delivered if personally delivered to the party for whom it is intended, (b)&nbsp;when delivered, if sent by electronic mail during normal
business hours of the recipient, and if not sent during normal business hours, then on the recipient&rsquo;s next business day (provided
no rejection or undeliverable notice is received), (c)&nbsp;three days after having been sent by certified or registered mail, return-receipt
requested and postage prepaid, or (d)&nbsp;one business day after deposit with a nationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
to the Company, addressed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Verastem,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">117 Kendrick Street, Suite&nbsp;500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Needham, MA 02494</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attention: Daniel Calkins</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: dcalkins@verastem.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">with a copy (which shall not constitute
notice):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Ropes&nbsp;&amp; Gray LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Prudential Tower, 800 Boylston Street</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Boston, MA 02199-3600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Attention: Thomas Danielski</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2.5in">Email: Thomas.Danielski@ropesgray.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ii.</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">If
to any Investor, at its e-mail address or address set forth on its signature page&nbsp;to the Purchase Agreement or to such e-mail address,
or address as subsequently modified by written notice given in accordance with this <U>Section&nbsp;10</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Any Person may change the address to which notices
and communications to it are to be addressed by notification as provided for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Consent
to Electronic Notice. </U>Each Investor consents to the delivery of any stockholder notice pursuant to the Delaware General Corporation
Law (the &ldquo;<B>DGCL</B>&rdquo;), as amended or superseded from time to time, by electronic mail pursuant to Section&nbsp;232 of the
DGCL (or any successor thereto) at the e-mail address set forth below the Investor&rsquo;s name on the signature page&nbsp;or Exhibit&nbsp;A,
as updated from time to time by notice to the Company. To the extent that any notice given by means of electronic mail is returned or
undeliverable for any reason, the foregoing consent shall be deemed to have been revoked until a new or corrected e-mail address has been
provided, and such attempted electronic notice shall be ineffective and deemed to not have been given. Each party agrees to promptly notify
the other parties of any change in its e-mail address, and that failure to do so shall not affect the foregoing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Waiver.</U>
No waiver of any term, provision or condition of this Agreement, whether by conduct or otherwise, in any one or more instances, shall
be deemed to be, or be construed as, a further or continuing waiver of any such term, provision or condition or as a waiver of any other
term, provision or condition of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Governing
Law</U>. The provisions of <U>Section&nbsp;8.5</U> of the Purchase Agreement are incorporated by reference herein <I>mutatis mutandis</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Headings</U>.
The titles, subtitles and headings in this Agreement are for convenience of reference and shall not form part of, or affect the interpretation
of, this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Counterparts</U>.
This Agreement may be executed in two or more identical counterparts, all of which shall be considered one and the same agreement and
shall become effective when counterparts have been signed by each party and delivered to the other party; provided that a facsimile or
pdf signature including any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com shall be considered
due execution and shall be binding upon the signatory thereto with the same force and effect as if the signature were an original, not
a facsimile or pdf (or other electronic reproduction) of a signature.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Further
Assurances</U>. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
and deliver all such other agreements, certificates, instruments and documents as the other party may reasonably request in order to carry
out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Contract
Interpretation</U>. This Agreement is the joint product of each Investor and the Company and each provision hereof has been subject to
the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>No
Third Party Beneficiaries</U>. Except as otherwise provided in Section&nbsp;6 and Section&nbsp;8, nothing in this Agreement, express or
implied, is intended to confer on any Person other than the parties to this Agreement any rights, remedies, claims, benefits, obligations
or liabilities under or by reason of this Agreement, and no Person that is not a party to this Agreement (including, without limitation,
any partner, member, shareholder, director, officer, employee or other beneficial owner of any party to this Agreement, in its own capacity
as such or in bringing a derivative action on behalf of a party to this Agreement) shall have any standing as a third party beneficiary
with respect to this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Severability</U>.
If any part or provision of this Agreement is held unenforceable or in conflict with the applicable laws or regulations of any jurisdiction,
the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes, to the extent possible, the original
business purpose of such part or provision in a valid and enforceable manner, and the remainder of this Agreement shall remain binding
upon the parties hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Non-Recourse</U>.
Notwithstanding anything that may be expressed or implied in this Agreement, the Company covenants, agrees and acknowledges that no recourse
under this Agreement or any documents or instruments delivered in connection with this Agreement shall be had against any current or future
director, officer, employee, stockholder, general or limited partner or member of the Investors or of any affiliates or assignees thereof,
whether by the enforcement of any assessment or by any legal or equitable proceeding, or by virtue of any statute, regulation or other
applicable law, it being expressly agreed and acknowledged that no personal liability whatsoever shall attach to, be imposed on or otherwise
be incurred by any current or future director, officer, employee, stockholder, general or limited partner or member of the Investors or
of any affiliates or assignees thereof, as such for any obligation of the Investors under this Agreement or any documents or instruments
delivered in connection with this Agreement for any claim based on, in respect of or by reason of such obligations or their creation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Specific
Performance.</U> In addition to any and all other remedies that may be available at law in the event of any breach of this Agreement,
each Investor shall be entitled to specific performance of the agreements and obligations of the Company hereunder and to such other injunction
or other equitable relief as may be granted by a court of competent jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt"><U>Cumulative
Remedies</U>. The remedies provided herein are cumulative and not exclusive of any remedies provided by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page&nbsp;Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">COMPANY:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: bold 10pt Times New Roman, Times, Serif">VERASTEM,&nbsp;INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Daniel W. Paterson</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Name:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 42%">Daniel W. Paterson</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">President and Chief Executive Officer</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">RTW MASTER FUND, LTD.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    <FONT STYLE="font-size: 10pt">Darshan Patel</FONT></Font></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties have caused
this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">RTW INNOVATION MASTER FUND, LTD.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/ <FONT STYLE="font-size: 10pt">Darshan Patel</FONT></Font></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Darshan Patel</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> <FONT STYLE="font-size: 10pt">Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>, the parties hereto
have executed this Agreement as of the day and year first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>INVESTOR:</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B>RTW BIOTECH OPPORTUNITIES OPERATING
    LTD.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-size: 10pt">/s/
    Roderick Wong, M.D.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Roderick Wong,
    MD</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Managing Partner</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ATLAS PRIVATE HOLDINGS (CAYMAN) LTD.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Scott Schroeder</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Scott Schroeder</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Director</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ALYESKA MASTER FUND, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Jason Bragg</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Jason Bragg</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">CFO, Alyeska Investment Group, LP</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">NCP RFM LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BLACKWELL PARTNERS LLC - SERIES A, solely with respect to the portion of its assets for which Nantahala Capital Management, LLC acts as its Investment Manager</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Nantahala Capital Management, LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Wilmot Harkey</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Manager</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED PRIVATE INVESTMENTS IX, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Capital GP IX LLC</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Advisors LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its Managing Member</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">ORBIMED GENESIS MASTER FUND, L.P.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Genesis GP LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its General Partner</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: OrbiMed Advisors LLC,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its Managing Member</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Carl Gordon</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Member</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">CVI INVESTMENTS,&nbsp;INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">By: Heights Capital Management,&nbsp;Inc.,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Martin Kobinger</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Martin Kobinger</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">President</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY ASSET MASTER, LTD</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY TAX EFFICIENT, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">EMPERY TAX EFFICIENT III, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><B>By:</B> Empery Asset Management, LP, its authorized agent</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Brett S. Director</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">General Counsel of Empery Asset Management, LP, its authorized agent</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">STONEPINE CAPITAL, LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Jon M. Plexico</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Jon M. Plexico</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Managing Member of the General Partner</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BIOTECHNOLOGY VALUE FUND II, L.P.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%"> /s/ Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"> Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Chief Executive Officer BVF II GP LLC, itself General Partner of Biotechnology Value Fund II, L.P.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">BIOTECHNOLOGY VALUE TRADING FUND OS LP</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Mark Lampert</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; vertical-align: top">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">President BVF Inc., General Partner of BVF Partners L.P., itself sole member of BVF Partners OS Ltd., itself GP of Biotechnology Value
Trading Fund OS LP</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>IN
WITNESS WHEREOF,</B></FONT> the parties have caused this Registration Rights Agreement to be duly executed as of date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">OCTAGON INVESTMENTS MASTER FUND LP</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 45%">/s/ Ting Jia</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Ting Jia</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Managing Member</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders, which as used herein includes donees, pledgees,
transferees or other successors-in-interest selling shares of common stock or interests in shares of common stock received after the date
of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell,
transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange,
market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing
market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale,
or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may use any one or more of the following methods
when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>distributions to members, partners, stockholders or other equityholders of the selling stockholders;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block
as principal to facilitate the transaction;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>an exchange distribution in accordance with the rules&nbsp;of the applicable exchange;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>privately negotiated transactions;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>short sales and settlement of short sales entered into after the effective date of the registration statement of which this prospectus
is a part;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>a combination of any such methods of sale; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&bull;</FONT></TD><TD>any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders may, from time to time, pledge or grant a
security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured
obligations, the pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus,
or under an amendment to this prospectus under Rule&nbsp;424(b)(3)&nbsp;or other applicable provision of the Securities Act, amending
the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this
prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees,
pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the sale of our common stock or interests therein,
the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage
in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of
our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers
that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers
or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may
resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The aggregate proceeds to the selling stockholders from the sale of
the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling
stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed
purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. Upon any exercise
of the pre-funded warrants by payment of cash, however, we will receive the exercise price of the pre-funded warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders also may resell all or a portion of the shares
in open market transactions in reliance upon Rule&nbsp;144 under the Securities Act, provided that they meet the criteria and conform
to the requirements of that rule, or another available exemption from the registration requirements under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The selling stockholders and any underwriters, broker-dealers or agents
that participate in the sale of the common stock or interests therein may be &ldquo;underwriters&rdquo; within the meaning of Section&nbsp;2(a)(11)
of the Securities Act (it being understood that the selling stockholders shall not be deemed to be underwriters solely as a result of
their participation in this offering). Any discounts, commissions, concessions or profit they earn on any resale of the shares may be
underwriting discounts and commissions under the Securities Act. Selling stockholders who are &ldquo;underwriters&rdquo; within the meaning
of Section&nbsp;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent required, the shares of our common stock to be sold,
the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agent, dealer or underwriter,
and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement
or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to comply with the securities laws of some states, if applicable,
the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states
the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification
requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have advised the selling stockholders that the anti-manipulation
rules&nbsp;of Regulation M under the Exchange Act may apply to sales of shares in the market and to the activities of the selling stockholders
and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended
from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities
Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against
certain liabilities, including liabilities arising under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed to indemnify the selling stockholders against liabilities,
including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have agreed with the selling stockholders to use commercially reasonable
efforts to cause the registration statement of which this prospectus constitutes a part to become effective and to remain continuously
effective until the earlier of: (i)&nbsp;the date on which the selling stockholders shall have resold or otherwise disposed of all the
shares covered by this prospectus and (ii)&nbsp;the date on which the shares covered by this prospectus no longer constitute &ldquo;Registrable
Securities&rdquo; as such term is defined in the Registration Rights Agreement, such that they may be resold by the selling stockholders
without registration and without regard to any volume or manner-of-sale limitations and without current public information pursuant to
Rule&nbsp;144 under the Securities Act or any other rule&nbsp;of similar effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit&nbsp;B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investor Questionnaire</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby provides the following
information to the Company and represents and warrants that such information is accurate:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>QUESTIONNAIRE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"><B>1.</B></TD><TD><B>Name.</B></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Full Legal Name of Investor</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Full Legal Name of Registered Holder (if not the same as (a)&nbsp;above) through which Registrable Securities
are held:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone
or with others has power to vote or dispose of the securities covered by this Questionnaire):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt; text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>2. Address for Notices to Investor:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone:<U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">E-Mail:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; width: 45%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contact Person:<U></U></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>3. Broker-Dealer Status:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Are you a broker-dealer?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">If &ldquo;yes&rdquo; to Section&nbsp;3(a), did you receive your Registrable Securities as compensation
for investment banking services to the Company?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Note:</TD><TD STYLE="text-align: justify">If &ldquo;no&rdquo; to Section&nbsp;3(b), the Commission&rsquo;s staff has indicated that you should be
identified as an underwriter in the Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Are you an affiliate of a broker-dealer?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities
in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable Securities?</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yes
</FONT><FONT STYLE="font-family: Wingdings; font-size: 10pt">&#168;</FONT>&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;<FONT STYLE="font-size: 10pt">No
<FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">Note:</TD><TD STYLE="text-align: justify">If &ldquo;no&rdquo; to Section&nbsp;3(d), the Commission&rsquo;s staff has indicated that you should be
identified as an underwriter in the Registration Statement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>4. Beneficial Ownership of Securities
of the Company Owned by the Investor.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Except as set forth below in this
Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Type and Amount of other securities beneficially owned by the Investor:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in"><B>5. Relationships with the Company:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><I>Except as set forth below, neither
the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or
affiliates) during the past three years.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font: 10pt Times New Roman, Times, Serif">State any exceptions here:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned agrees to
promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify
the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By signing below, the undersigned
consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and the inclusion of such information
in the Registration Statement and the related prospectus and any amendments or supplements thereto. The undersigned understands that such
information will be relied upon by the Company in connection with the preparation or amendment of the Registration Statement and the related
prospectus and any amendments or supplements thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF the undersigned,
by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized
agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%">&nbsp;</TD><TD STYLE="width: 10%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: left">Beneficial Owner:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 35%; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title:</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>PLEASE EMAIL A .PDF COPY OF THE COMPLETED AND
EXECUTED QUESTIONNAIRE TO: dcalkins@verastem.com</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>tm2513177d1_ex10-3.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>THIS WARRANT AND THE SHARES OF COMMON STOCK
ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE &ldquo;SECURITIES&rdquo;) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE &ldquo;SECURITIES ACT&rdquo;), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED
FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES
ACT, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144 UNDER THE SECURITIES ACT, (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL
REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT, OR (IV) THE SECURITIES
ARE TRANSFERRED WITHOUT CONSIDERATION TO AN AFFILIATE OF SUCH HOLDER OR A CUSTODIAL NOMINEE (WHICH FOR THE AVOIDANCE OF DOUBT SHALL REQUIRE
NEITHER CONSENT NOR THE DELIVERY OF AN OPINION).</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center"><B>FORM OF PRE-FUNDED
WARRANT TO PURCHASE COMMON STOCK </B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Number
of Shares: [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT>] (subject to adjustment)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.85in; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
No. [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT>]</TD><TD STYLE="width: 20%; text-align: left">&nbsp;</TD><TD STYLE="text-align: right; width: 40%">Original Issue Date: [<FONT STYLE="font-family: Symbol">&middot;</FONT>],
2025</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Verastem,
Inc., a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), hereby certifies that, for good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, [</FONT><FONT STYLE="font-family: Symbol">&middot;</FONT>] or its registered assigns
(the &ldquo;<B>Holder</B>&rdquo;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of [<FONT STYLE="font-family: Symbol">&middot;</FONT>]
shares of common stock, $0.0001 par value per share (the &ldquo;<B>Common Stock</B>&rdquo;), of the Company (each such share, a &ldquo;<B>Warrant
Share</B>&rdquo; and all such shares, the &ldquo;<B>Warrant Shares</B>&rdquo;) at an exercise price per share equal to $0.0001 (the &ldquo;<B>Exercise
Price</B>&rdquo;), in each case as adjusted from time to time as provided in <U>Section 9</U> hereof, upon surrender of this Pre-Funded
Warrant to Purchase Common Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof,
the &ldquo;<B>Warrant</B>&rdquo;) at any time and from time to time on or after the date hereof (the &ldquo;<B>Original Issue Date</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Definitions</U></FONT></B>. For purposes of this Warrant, the
following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo;
</FONT>means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Attribution
Parties</B>&rdquo; means, </FONT>collectively, the following Persons and entities: (i) any direct or indirect Affiliates of the Holder,
(ii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any Attribution Parties and (iii) any
other Persons whose beneficial ownership of the Company&rsquo;s Common Stock would or could be aggregated with the Holder&rsquo;s and/or
any other Attribution Parties for purposes of Section 13(d) or Section 16 of the Exchange Act. For clarity, the purpose of the foregoing
is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Closing
Sale Price</B>&rdquo; means, for any security as of any date, the last trade price for such security on the Principal Trading Market for
such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours
basis and does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City </FONT>time,
as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the over-the-counter
market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot
be calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date
shall be the fair market value as mutually determined by the Company and the Holder. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Commission</B>&rdquo;
</FONT>means the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Exchange
Act</B>&rdquo; means the U.S. Securities Exchange Act of 1934, as amended, and all of the rules and regulations </FONT>promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Group</B>&rdquo;
shall have the </FONT>meaning ascribed to it in Section 13(d) of the Exchange Act, and all related rules, regulations and jurisprudence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&ldquo;<B>Person</B>&rdquo;
means an individual, partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association,
joint venture or any other entity or organization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Principal
Trading Market</B>&rdquo; </FONT>means the national securities exchange or other trading market on which the Common Stock is primarily
listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Capital Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Securities
Act</B>&rdquo; means the U.S. </FONT>Securities Act of 1933, as amended, and all of the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Standard
Settlement Period</B>&rdquo; </FONT>means the standard settlement period, expressed in a number of Trading Days, for the Principal Trading
Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original
Issue Date was &ldquo;T+1.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Trading
Day</B>&rdquo; </FONT>means any weekday on which the Principal Trading Market is normally open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;<B>Transfer
Agent</B>&rdquo; means </FONT>Computershare Trust Company, N.A., the Company&rsquo;s transfer agent and registrar for the Common Stock,
and any successor appointed in such capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Issuance of Securities; Registration of Warrants</U></FONT></B>.
The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<B>Warrant
Register</B>&rdquo;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to
which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this
Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes,
absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Registration of Transfers</U></FONT></B>. Subject to compliance
with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion
of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer taxes (if any). Upon
any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant,
a &ldquo;<B>New Warrant</B>&rdquo;) evidencing the portion of this Warrant so transferred shall be issued to the transferee, and a New
Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance
of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of the rights and obligations in
respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare,
issue and deliver at the Company&rsquo;s own expense any New Warrant under this <U>Section 3</U>. Until due presentment for registration
of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be
affected by any notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Exercise of Warrants</U></FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including
<U>Section 11</U>) at any time and from time to time on or after the Original Issue Date, and such rights shall not expire until exercised
in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Holder may exercise this Warrant by delivering to the Company (i) an exercise notice, in the form attached as <U>Schedule 1</U>
hereto (the &ldquo;<B>Exercise Notice</B>&rdquo;), completed and duly signed, and (ii) payment of the Exercise Price for the number of
Warrant Shares as to which this Warrant is being exercised (which may take the form of a &ldquo;cashless exercise&rdquo; if so indicated
in the Exercise Notice pursuant to <U>Section 10</U> below), and the date on which the last of such items is delivered to the Company
(as determined in accordance with the notice provisions hereof) is an <B>&ldquo;Exercise Date</B>.&rdquo; The Holder shall not be required
to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have the
same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number
of Warrant Shares, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this section,
following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Delivery of Warrant Shares</U></FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Upon exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the
Standard Settlement Period following the Exercise Date), upon the request of the Holder, cause the Transfer Agent to credit such aggregate
number of shares of Common Stock specified by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise
(the &ldquo;<B>Exercise Shares</B>&rdquo;) to (i) the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust
Company (&ldquo;<B>DTC</B>&rdquo;) through its Deposit Withdrawal At Custodian system or (ii) in book-entry form via a direct registration
system (&ldquo;<B>DRS</B>&rdquo;) maintained by or on behalf of the Transfer Agent, in each case, so long as either (A) there is an effective
registration statement permitting the issuance of the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B) the
Exercise Shares are eligible for resale by the Holder without volume or manner-of-sale restrictions pursuant to Rule 144 promulgated under
the Securities Act (assuming cashless exercise of this Warrant). If the conditions set forth in clauses (A) and (B) above are not met,
then the Company shall cause the Transfer Agent to either (i) record the Exercise Shares in the name of the Holder or its designee on
the certificates reflecting the Exercise Shares with an appropriate legend regarding restriction on transferability, which shall be issued
and dispatched by overnight courier to the address as specified in the Exercise Notice, and on the Company&rsquo;s share register or (ii)
issue such Exercise Shares in the name of the Holder or its designee in restricted book-entry form in the Company&rsquo;s share register.
The Holder, or any Person so designated by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of
such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&rsquo;s DTC account,
the date of the book entry positions or the date of delivery of the certificates evidencing such Exercise Shares, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to deliver to the Holder
or its designee Exercise Shares in the manner required pursuant to <U>Section 5(a)</U> within the Standard Settlement Period following
the Exercise Date (other than a failure caused by incorrect or incomplete information provided by the Holder to the Company) and the Holder
or the Holder&rsquo;s broker on its behalf purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<B>Buy-In</B>&rdquo;)
but did not receive within the Standard Settlement Period, then the Company shall, within two (2) Trading Days after the Holder&rsquo;s
request and in the Holder&rsquo;s sole discretion, promptly honor its obligation to deliver to the Holder or its designee the Exercise
Shares pursuant to <U>Section 5(a)</U> and pay cash to the Holder in an amount equal to the excess (if any) of the Holder&rsquo;s total
purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In, less the product of
(A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common Stock on the Exercise
Date. The Holder shall provide the Company written notice promptly after the occurrence of a Buy-In, indicating the amounts payable to
the Holder in respect of the Buy-In together with applicable confirmations and other evidence reasonably requested by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>To the extent permitted by law and subject to <U>Section 5(b)</U>, the Company&rsquo;s obligations to issue and deliver Warrant
Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section 11</U> below) are absolute
and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any
provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment,
limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation
or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise limit such
obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section 5(b)</U>, nothing herein
shall limit the Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation,
a decree of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver Exercise Shares;
provided, however, that the Holder shall not be entitled to both (i) require the Company to reinstate the portion of the Warrant and equivalent
number of Warrant Shares for which such exercise was not timely honored and (ii) receive the number of shares of Common Stock that would
have been issued if the Company had timely complied with its delivery requirements under <U>Section 5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Charges, Taxes and Expenses</U></FONT></B><U>.</U> Issuance
and delivery of Exercise Shares shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other
incidental tax or expense (excluding any applicable stamp duties) in respect of the issuance of such shares, all of which taxes and expenses
shall be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in respect
of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate
thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant
or receiving Warrant Shares upon exercise hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Replacement of Warrant</U></FONT></B>. If this Warrant is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof,
or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company
of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by
the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant
to the Company as a condition precedent to the Company&rsquo;s obligation to issue the New Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Reservation of Warrant Shares</U></FONT></B>. The Company covenants
that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued
and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as
herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free
from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and
restrictions of <U>Section 9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and
the payment of the applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid
and non-assessable. The Company will take all such action as may be reasonably necessary to assure that such shares of Common Stock may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange
or automated quotation system upon which the Common Stock may be listed. The Company further covenants that it will not, without the prior
written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Certain Adjustments</U></FONT></B>. The Exercise Price and number
of Warrant Shares issuable upon exercise of this Warrant (the &ldquo;<B>Number of Warrant Shares</B>&rdquo;) are subject to adjustment
from time to time as set forth in this <U>Section 9</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding, (i) pays a stock dividend on
its Common Stock or otherwise makes a distribution on any class of capital stock that is payable in shares of Common Stock, (ii) subdivides
its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines its outstanding shares of Common
Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification of shares of capital stock any additional shares
of Common Stock of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator of
which shall be the number of shares of Common Stock outstanding immediately after such event and the denominator of which shall be the
number of shares of Common Stock outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph
shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution,
provided, however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the
Number of Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of
Warrant Shares shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant
to clause (ii), (iii) or (iv) of this paragraph shall become effective immediately after the effective date of such subdivision, combination
or issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Pro Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or other
pro rata distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital
or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options, evidence of indebtedness
or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction, but, for the avoidance of doubt, excluding any distribution of shares of Common Stock subject to <U>Section 9(a)</U>, any
distribution of Purchase Rights (as defined below) subject to <U>Section 9(c)</U> and any Fundamental Transaction (as defined below) subject
to <U>Section 9(d))</U> (a &ldquo;<B>Distribution</B>&rdquo;) then, in each such case, upon any exercise of this Warrant that occurs after
the record date fixed for determination of stockholders entitled to receive such distribution, the Holder shall be entitled to participate
in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this
Warrant, including without limitation, the Maximum Percentage (as defined below)) immediately before the date on which a record is taken
for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined
for the participation in such Distribution, provided, that to the extent that the Holder&rsquo;s right to participate in any such Distribution
would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to
participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such shares of Common Stock as a
result of such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties
exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared
or made on such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had
been no such limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Purchase Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible
Securities or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders of any class
of Common Stock (the &ldquo;<B>Purchase Rights</B>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable to
such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of shares of
Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this
Warrant, including without limitation, the Maximum Percentage) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined
for the grant, issuance or sale of such Purchase Rights (provided, that to the extent that the Holder&rsquo;s right to participate in
any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such
Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and at the Holder&rsquo;s election, in its
sole discretion, either (1) such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time
or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which
time or times the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or
on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation or (2) the
Company shall offer the Holder the right upon exercise of such Purchase Right to acquire a security (e.g. a pre-funded warrant) that would
not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage but will otherwise to the extent possible
have economic and other rights, preferences and privileges substantially consistent and on par with the securities or other property issuable
upon exercise of the originally offered Purchase Rights). As used in this <U>Section 9(c)</U>, (i) &ldquo;Options&rdquo; means any rights,
warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities and (ii) &ldquo;Convertible Securities&rdquo;
mean any stock or securities (other than Options) directly or indirectly convertible into or exercisable or exchangeable for shares of
Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i) the Company effects any merger or consolidation
of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of the Company
immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving
entity immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially all
of its assets in one or a series of related transactions, (iii) pursuant to any tender offer or exchange offer (whether by the Company
or another Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the
Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the Company consummates a stock purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person whereby such other Person acquires more than 50% of the voting power of the capital stock of the Company (except for
any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same
proportions, the voting power of such Person immediately after the transaction) or (v) the Company effects any reclassification of the
Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other
securities, cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section 9(a)</U>
above) (in any such case, a &ldquo;<B>Fundamental Transaction</B>&rdquo;), then following such Fundamental Transaction the Holder shall
have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been
entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (including any Distributions or Purchase
Rights then held in abeyance pursuant to <U>Sections 9(b)</U> or <U>9(c)</U> above) without regard to any limitations on exercise contained
herein (the &ldquo;<B>Alternate Consideration</B>&rdquo;). The Company shall not effect any Fundamental Transaction in which the Company
is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the Alternate Consideration
is solely in the form of cash and the Company provides for the simultaneous &ldquo;cashless exercise&rdquo; of this Warrant pursuant to
<U>Section 10</U> below or (ii) prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity
or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate
Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the other obligations under
this Warrant. The provisions of this paragraph (d) shall similarly apply to subsequent transactions analogous to a Fundamental Transaction
type.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Number of Warrant Shares pursuant to <U>Section 9</U>,
the Exercise Price shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable
hereunder for the increased or decreased Number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately
prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common
Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Calculations</U>. All calculations under this <U>Section 9</U> shall be made to the nearest one-tenth of one cent or the nearest
share, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section 9</U>, the Company at its expense
will promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth
such adjustment, including, at the written request of the Holder, a statement of the adjusted Exercise Price and adjusted number or type
of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise
to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly
deliver a copy of each such certificate to the Holder and to the Transfer Agent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution
of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants
to subscribe for or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement
contemplating or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation
or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute material
non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days prior to the applicable
record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
provided, however, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action
required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters
into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section 9(d)</U>,
other than a Fundamental Transaction under clause (iii) of <U>Section 9(d),</U> then, except if such notice and the contents thereof shall
be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of such Fundamental Transaction
at least thirty (30) days prior to the date such Fundamental Transaction is consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Payment of Exercise Price</U></FONT></B>. Notwithstanding anything
contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &ldquo;cashless
exercise&rdquo;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected
pursuant to Section 3(a)(9) of the Securities Act, determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">X = Y (A-B)/A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&ldquo;X&rdquo; equals the number of Warrant
Shares to be issued to the Holder;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;Y&rdquo;
equals the total number of Warrant Shares with respect to which this Warrant is then being exercised;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;A&rdquo;
equals the Closing Sale Price of the shares of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;B&rdquo;
equals the Exercise Price then in effect for the applicable Warrant Shares at the time of such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued
in a &ldquo;cashless exercise&rdquo; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant
Shares shall be deemed to have commenced, on the Original Issue Date (provided that the Commission continues to take the position that
such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant
Shares is, for any reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through a cashless
exercise, as set forth in this <U>Section </U></FONT><U>10</U>. If the Warrant Shares are issued in such a cashless exercise, the Company
acknowledges and agrees that, in accordance with Section 3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall
take on the registered characteristics of the Warrants being exercised and may be tacked on to the holding period of the Warrants being
exercised. Except as set forth in <U>Section 5(b)</U> (buy-in remedy) and <U>Section 12</U> (No Fractional Shares), in no event will the
exercise of this Warrant be settled in cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Limitations on Exercise</U></FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>Notwithstanding
anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder
of this Warrant shall not have the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab
initio and treated as if the exercise had not been made, to the extent that immediately prior to or following such exercise, the
Holder, together with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section
13(d) of the Exchange Act and the rules promulgated thereunder, in excess of 9.99% (the &ldquo;<B>Maximum Percentage</B>&rdquo;) of
the Common Stock that would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for
determining whether the Maximum Percentage is or will be exceeded, the aggregate number of shares of Common Stock held and/or
beneficially owned by the Holder together with the Attribution Parties, shall include the number of shares of Common Stock held
and/or beneficially owned by the Holder together with the Attribution Parties plus the number of shares of Common Stock issuable
upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number of shares
of Common Stock which would be issuable upon (i) exercise of the remaining, unexercised Warrant held and/or beneficially owned by
the Holder or the Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other
securities of the Company held and/or beneficially owned by such Holder or any Attribution Party (including, without limitation, any
convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the
limitation contained herein. For purposes of this <U>Section 11(a)</U>, beneficial ownership of the Holder or the Attribution
Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with Section
13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of
outstanding shares of Common Stock, a Holder of this Warrant may rely on the number of outstanding shares of Common Stock as
reflected in (1) the Company&rsquo;s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K or other public filing with the
Securities and Exchange Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other notice
by the Company or the Company&rsquo;s transfer agent setting forth the number of shares of Common Stock outstanding (such issued and
outstanding shares, the &ldquo;<B>Reported Outstanding Share Number</B>&rdquo;). For any reason at any time, upon the written or
oral request of the Holder, the Company shall within one (1) Trading Day confirm orally and in writing or by electronic mail to the
Holder the number of shares of Common Stock then outstanding. The Holder shall disclose to the Company the number of shares of
Common Stock that it, together with the Attribution Parties holds and/or beneficially owns and has the right to acquire through the
exercise of derivative securities and any limitations on exercise or conversion analogous to the limitation contained herein
contemporaneously or immediately prior to submitting an Exercise Notice for the relevant Warrant. If the Company receives an
Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported
Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of shares of Common Stock then
outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&rsquo;s, together with the Attribution
Parties&rsquo;, beneficial ownership, as determined pursuant to this <U>Section 11(a)</U>, to exceed the Maximum Percentage, the
Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of
shares by which such purchase is reduced, the &ldquo;<B>Reduction Shares</B>&rdquo;) and (ii) as soon as reasonably practicable, the
Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number of
outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the
Company, including this Warrant, by the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share
Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of this Warrant results in the
Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage
of the number of outstanding shares of Common Stock (as determined under Section 13(d) of the Exchange Act), the number of shares so
issued by which the Holder&rsquo;s, together with the Attribution Parties&rsquo;, aggregate beneficial ownership exceeds the Maximum
Percentage (the &ldquo;<B>Excess Shares</B>&rdquo;) shall be deemed null and void and shall be cancelled ab initio, and the Holder
and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable
after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price
paid by the Holder for the Excess Shares. By written notice to the Company, a Holder of this Warrant may from time to time increase
or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; provided that any
increase in the Maximum Percentage will not be effective until the sixty-first (61<SUP>st</SUP>) day after such notice is delivered
to the Company and shall not negatively affect any partial exercise effected prior to such change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT>This <U>Section 11</U> shall not restrict the number of shares of Common Stock which a Holder or the Attribution Parties may receive
or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties
may receive in the event of a Fundamental Transaction as contemplated in <U>Section 9(c)</U> of this Warrant. For purposes of clarity,
the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be
beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section 13(d) of the Exchange Act
and the rules promulgated thereunder or Section 16 of the Exchange Act and the rules promulgated thereunder, including Rule 16a-1(a)(1).
No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of
this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and
implemented in a manner otherwise than in strict conformity with the terms of this <U>Section 11</U> to the extent necessary to correct
this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation
contained in this <U>Section 11</U> or to make changes or supplements necessary or desirable to properly give effect to such limitation.
The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>No Fractional Shares</U></FONT></B>. No fractional Warrant Shares
will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the
number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the
fair market value (based on the Closing Sale Price) for any such fractional shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Notices</U></FONT></B>. Any and all notices or other communications
or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective
on the earliest of (i) the date of transmission, if such notice or communication is delivered confirmed e-mail at the e-mail address specified
by the Company prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if
such notice or communication is delivered via confirmed e-mail at the e-mail address specified by the Company on a day that is not a Trading
Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally
recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice
is required to be given, if by hand delivery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Warrant Agent</U></FONT></B>. The Company shall initially serve
as warrant agent under this Warrant. Upon 30 days&rsquo; notice to the Holder, the Company may appoint a new warrant agent. Any entity
into which the Company or any new warrant agent may be merged or any entity resulting from any consolidation to which the Company or any
new warrant agent shall be a party or any entity to which the Company or any new warrant agent transfers substantially all of its corporate
trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor
warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the
Holder at the Holder&rsquo;s last address as shown on the Warrant Register.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</B></FONT><B><FONT STYLE="font-family: Times New Roman, Times, Serif"><U>Miscellaneous</U></FONT></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&rsquo;s capacity
as a holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company
for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such Person&rsquo;s capacity
as the Holder of this Warrant, any of the rights of a stockholder of the Company or any right to vote, give or withhold consent to any
corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger, amalgamation, conveyance
or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder
of the Warrant Shares which such Person is then entitled to receive upon the due exercise of this Warrant. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant
or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Further Assurances</U>. Except and to the extent as waived or consented to by the Holder, the Company shall not by any action,
including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets,
consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and
in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against
impairment. Without limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above
the amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise
of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before
taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the
Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from
any public regulatory body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Successors and Assigns</U>. Subject to compliance with applicable securities laws, this Warrant may be assigned by the Holder.
This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental
Transaction. This Warrant shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and
assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and
the Holder any legal or equitable right, remedy or cause of action under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Amendment and Waiver</U>. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors
and assigns. Except as otherwise provided herein, the Company may take any action herein prohibited, or omit to perform any act herein
required to be performed by it, only if the Company has obtained the written consent of the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES
OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE
AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION
HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION
DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS
AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL
OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE
SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY
ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed
to limit or affect any of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;</FONT><U>Severability</U>. If any part or provision of this Warrant is held unenforceable or in conflict with the applicable laws or
regulations of any jurisdiction, the invalid or unenforceable part or provisions shall be replaced with a provision which accomplishes,
to the extent possible, the original business purpose of such part or provision in a valid and enforceable manner, and the remainder of
this Warrant shall remain binding upon the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><B>[REMAINDER OF
PAGE INTENTIONALLY LEFT BLANK]</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be duly executed by its authorized officer as of the date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">VERASTEM, INC.</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: rgb(108,0,70) 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name: Daniel Paterson</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: President and Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM OF EXERCISE NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[To be executed by the Holder to purchase shares
of Common Stock under the Warrant]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
</FONT>The undersigned is the Holder of Warrant No. __ (the &ldquo;Warrant&rdquo;) issued by Verastem, Inc., a Delaware corporation (the
 &ldquo;Company&rdquo;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
</FONT>The undersigned hereby exercises its right to purchase _____ Warrant Shares pursuant to the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3)
</FONT>The Holder intends that payment of the Exercise Price shall be made as (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash Exercise </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cashless Exercise&rdquo; under <U>Section</U></FONT><U><FONT STYLE="font-size: 10pt">&nbsp; 10</FONT></U><FONT STYLE="font-size: 10pt"> of the Warrant </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4)
</FONT>If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $ _____ in immediately available funds to the Company
in accordance with the terms of the Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(5)
</FONT>Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the terms
of the Warrant. The Warrant Shares shall be delivered (check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">to the following DWAC Account Number: _______________________________</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in </FONT><FONT STYLE="font-size: 10pt">book-entry form via a direct registration system</FONT></TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 2.25in">by physical delivery of a certificate to:</TD>
    <TD STYLE="vertical-align: top"> ______________________________________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"> ______________________________________________________</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: top">&nbsp;</TD></TR>
  <TR>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">in restricted book-entry form in the Company&rsquo;s share register</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(6)
</FONT>By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise
evidenced hereby the Holder (i) the Holder is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities
Act of 1933, as amended and (ii) will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance
with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under <U>Section&nbsp;11(a)</U> of the
Warrant to which this notice relates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; width: 11%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 31%">&nbsp;</TD>
    <TD STYLE="width: 58%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name </FONT><FONT STYLE="font-size: 10pt">of
    Holder:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Signature must conform in all respects to name
of Holder as specified on the face of the Warrant)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 15; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>tm2513177d1_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Verastem Oncology Announces $75 million Private
Placement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BOSTON&ndash;(BUSINESS
WIRE) &ndash; </FONT>April 25, 2025&ndash; Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines
for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with certain
institutional and accredited investors for a private placement of approximately $24 million of shares of its common stock at a price of
$7.00 per share and, in lieu of common stock to certain investors, $51 million of pre-funded warrants to purchase shares of its common
stock at a price of $6.9999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.0001 per share. Verastem
expects to receive gross proceeds from the offering of approximately $75 million, before deducting placement agent fees and other offering
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The private placement was led by RTW Investments, with participation
from other new and existing investors, including BVF Partners, Nantahala Capital, Octagon Capital, OrbiMed and Stonepine Capital Management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
private placement is expected to close on or about </FONT>April 28, 2025, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds from the financing are expected to fund the potential launch
of avutometinib and defactinib in recurrent low-grade serous ovarian cancer, continued clinical research and development of product candidates
including VS-7375, and for working capital and other general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Guggenheim Securities is acting as the lead placement agent for the
private placement. RBC Capital Markets, BTIG, Mizuho and B. Riley Securities are acting as co-placement agents for the private placement
(together with Guggenheim Securities, the &ldquo;Placement Agents&rdquo;). The Company has agreed to pay customary placement fees and
reimburse certain expenses of the Placement Agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The securities to be sold in the private placement have not been registered
under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), or any state or other applicable jurisdictions&rsquo;
securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration
requirements of the Securities Act and applicable state or other jurisdictions&rsquo; securities laws. Verastem has agreed to file a registration
statement with the United States Securities and Exchange Commission (the &ldquo;SEC&rdquo;) registering the resale of the shares of common
stock issued in the private placement and the shares of common stock issuable upon the exercise of the pre-funded warrants issued in the
private placement, no later than 30 days after the closing of the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release shall not constitute an offer to sell or the solicitation
of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which
such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be
made by means of a prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Verastem Oncology</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical
company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven
cancers. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer
cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition and KRAS G12D inhibition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release includes forward-looking statements. These forward-looking
statements generally can be identified by the use of words such as &ldquo;anticipate,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;could,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;forecast,&rdquo; &ldquo;goal,&rdquo;
 &ldquo;project,&rdquo; and other words of similar meaning. These forward-looking statements address various matters including the expected
closing of the private placement and the expected use of proceeds from the private placement. Each forward-looking statement contained
in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed
or implied by such statement. Applicable risks and uncertainties include, among others, the risk that the conditions to closing of the
private placement are not satisfied; that the development and commercialization of our product candidates may take longer or cost more
than planned, including as a result of conducting additional studies or our decisions regarding execution of such commercialization; that
raising additional capital may cause dilution to our stockholders; that our product candidates may not receive regulatory approval, become
commercially successful products, or result in new treatment options being offered to patients; and the risks identified under the heading
 &ldquo;Risk Factors&rdquo; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and filed with the SEC, as well
as the other information we file with the SEC. We caution investors not to place considerable reliance on the forward-looking statements
contained in this presentation. You are encouraged to read our filings with the SEC for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date hereof, and we undertake no obligation to update or revise
any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>For Investor and Media Inquiries:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Julissa Viana</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Vice President, Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations and Patient Advocacy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investors@verastem.com or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">media@verastem.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Source</B></FONT>:
Verastem Oncology</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>vstm-20250425.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWaiLCbOdzZR+aYkxtmBzbWk6PycnuEasLSro8UzWQR0P -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:vstm="http://verastem.com/20250425" elementFormDefault="qualified" targetNamespace="http://verastem.com/20250425">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://verastem.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20250425_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="vstm-20250425_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>vstm-20250425_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>vstm-20250425_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.0b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://verastem.com/role/Cover" xlink:href="vstm-20250425.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://verastem.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Apr. 25, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Apr. 25,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Verastem,
Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001526119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-3269467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">117 Kendrick Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Needham<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02494<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">292-4200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VSTM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( *9+F5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( *9+F5J%N^*2[P   "L"   1
M9&]C4')O<',O8V]R92YX;6S-DE%+PS 0Q[^*Y+V]-G6"H<N+8T\*@@/%MY#<
MMF"3AN2DW;<WK5N'Z ?P,7?__.YW<*T.0O<1GV,?,)+%=#.ZSB>APYH=B8(
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ;
M 4/2='@//GL?)=-[*CG_5U/\!%!+ P04    " "F2YE:EXJ[',     3 @
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MY68R#/; @L4?>M>9_+2'V#-B#Q]6C>1FEJE@A1REW^CUK7H\@RX/J!5Z0B?
M:ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C5146L*:B]1!DZ)'!=09#K+&))@G6
M0VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_
M,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04    " "F2YE:)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ IDN96F60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( *9+F5J%N^*2[P   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ IDN96JK$(A8S 0  (@(   \
M     ( !=!   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( *9+F5HD'INB
MK0   /@!   :              "  =01  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( *9+F5IED'F2&0$  ,\#   3
M  "  ;D2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(   ,4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm2513177d1_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://verastem.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="tm2513177d1_8k.htm">tm2513177d1_8k.htm</File>
    <File>vstm-20250425.xsd</File>
    <File>vstm-20250425_lab.xml</File>
    <File>vstm-20250425_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "tm2513177d1_8k.htm": {
   "nsprefix": "vstm",
   "nsuri": "http://verastem.com/20250425",
   "dts": {
    "inline": {
     "local": [
      "tm2513177d1_8k.htm"
     ]
    },
    "schema": {
     "local": [
      "vstm-20250425.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "vstm-20250425_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vstm-20250425_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://verastem.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-04-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2513177d1_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-04-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "tm2513177d1_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CountryRegion",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Extension",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12gTitle",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://verastem.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001104659-25-039098-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-039098-xbrl.zip
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M'LK5]L-]]X_J\6FK=0,_$'Q2**SX<FWW ??X$-_;0[BWU:>IMZ*7UGA[I_%
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MTAZR%VBPP!+[/#DFQR;#/'7@T7<M.O&&1!F%Q6VKS$QB.QKFOSUJ\5(V>/?
M3;I,?"L+2E')=Y!'0K:9J6?2:!0K:?V;DDS.@MSRQ$4S)8U( B4NKN]6--/:
MRK13VXA=!Y9$4X@_)<PZBJA3IE(-M)5&F%/@=C#L_,) )JSEHHA%YP_V,Q+$
M66>=XKERGMCF<<G89%2)%1UP(@B+--.*";/JHWS[O 4+]8B V8R#O$SE<@4A
MKU5:DM%7TAG]O"Q]X$=TPED1[VJB/*H##Q"6D5T?>G(]'I2+!=\M"^%19,?G
M+BR$WX@:D),Q_%KXY#B\NA_E--AK7V4F/T3?&R<M%W=,^_TT7-^!9"E+U(J0
M-%&NY BT) *CY*$H7S"Z9$38.0$,I@.8F",(O]0OZF$*0%1 'L8.'@KB/ :,
M*6452\YX':1/HUY-^40TP*0_=2W8:.HS'3N:TA\.U6GZ(ZPYA9\I\C,-*T"C
M^<6!OL,,H##\T%4V!U;?4:TY4#WG,;Z#6;>)P,0LJ:%@_QL*W?/H5N5-FM@D
M@]TR "3XKRRF-D7Y3#8/A7T_B9+O?#.I;-^)7@M$]GJ%]I\BZ6"?XD*(DP[I
M<Y9NUMN(F5K/9$\BBQS8LJ@KRJ2H6#G19;96U?U M 4%ELCB&B9WM,)[G;!>
M+;: Y7.I$WGIC> 79TI>Y:P905X$[R"LL"F+0)$R!-IWZ& U'LDK&XKQ%0$J
M3Y%EM4HL;^]%VR8ZN@"^0SX5S[;%&YY$._]PB!4'T$T_(U_3";RP%8K,6J'"
MKF[,??KJ$Y@L@!H[##R8A?EDB%W"/)N.<F:C*9DQ%AH8B6,49]R1[";&*U3D
MP0;FPV"T?QX'P0 SPYLU9+H41U-Q[ZN D^-\;@=BM\1339::/VS=PAUPXBN&
M:8G9 *^X).]A%0V)3,Z3C8RH%@LB366=!;U8QYN*MMH1R+3L-8B!:'%&P?9"
M".[#:5E>$;4C0 Y/]H-2]CVJBFY<QY7Y7RJ(+NJ^O#<)N C$^C!*1 A&B^G0
MF>''KY'$]Z5ZN47^PI.WCL="%6/:"NZU9=LH#RD!JY3Q6D<9F_3 1X<A^$U1
M1+0!' ,6>)MJK<+=X;KLFWMI>0<]$66,89 J"@Y"Y\7=OK'(5<1F[;2+Y"M%
MBDJ_,#H3(SH\>=L6LAP#U(A4/M;N>1I:ML L5IK*O Z*E^Z+Y"\G$ W*X(P%
MGMH7Q 'R&9QUA$?$$N#*'A\#T!B(JI:09=FO+'/7V5JCJ-PMA7<530D.G/H$
MGUC\5@"I1[B6%YW"@GAC*OB'R[KMQ"_G]!TE< WY%1?B0&_L8D[X(^X%7 ,6
MHDZ@9 ,Z_(HG?GG3YX+]YA/6R>'U-^EU0CRD.2-:5.*'2*(F4G/V8814K#=Q
MU=]'D=6!;"B&$6>$FD#L81$!WJ=S>T@69BO":+N!T?9)=.RZ&W,,N#2*O-]&
M_=Z%,+W]!5O9D"R_>0LO8UEX[5#X)2,OO7XI BOK2J75_/.,[Z<%(DL*"M1>
M.<7G;IC:S&U22VZ-VM_?]!:/9WG[[&NBEE(L<5%4\T@EXNO1_6%UIU*K[.T9
ME0<Z 4M7*0[\8<1P>&%- 3:)9?F#,)6WR7UAHEWNY%]')35)K"S2O!_0EQZ-
MS6[5R:.WS&L!W.M-'>,-79F9$<>6N:FHU_M.1'!UXT2OOCG1J^G=K$GS-X9\
MC?:L]TKSVIO3O+8AFK\QY"<+:XBO19U&XZUU&::*-T&=MX?\)E4PX+4'D+B4
MG#GS-0MX1Y7GQ#)S"4NHN\I7HFQ6>.K+G)DUO@+NE0%N8ZL9[^ !](-;I(K>
MN&/55\6WWVUAR&P8,D*6_6MG-C9=D6\?;S\10W[1<L;WOL!&-G:1W:IN^AKK
MI.^T>D'08C;_)8^2M</SQUC#"2R<GH9-"OR(C4R$BC*/B&AXZPL_V> ,\7[^
MY"D!'@[MEBO8[+^S+;]Z."Q"=@L7R190?MQ 'AS 0\:..XVR3^'L8;*0A<<I
M5VAEQ00B@ H1<*\GNG^QX0U,8'&#3=^O2-R52?EL6UOM/VUM&VYK>W6RO^![
M:J)K8+5F]^STJG5W?]OI;KZ\]IJ5M.PETD<(X\=E5KP,,Y\X2""OW#,"2R:H
M#9'+\T0.3_31,D"J:/1'[:'1@6KUHFH9)NSD /2> RSV\^G4P!\X'I@G8U,)
MK!70_KMO3G^!&YKE)\!,:'<_Y*H;3F-\Z=RVNG>=2W#,KMIS>9J7NM"I?,Y.
M>7E")[S2>Z51];WDL)>[]QO#VS%ZJ@<I%S;+)=S@FA^G!\N<SN6YL4TR36GA
MO9;Q4:P$[J4-UH1\+8*1Q>(N)LI^(4F6%?=DQD(;)//_\@V YXH!&2_#<=^O
M/3!I;^X;*SWAY+VF8_\F1O -3S_L'I)K40T]$-^Y]TZ\QK<YFA!;I4L!;+P-
M_8!,C,DA.3OFOSR4]S\^\(MY1=D<P>"OT?/)R>-]^6+\V/H\N"]]OAY/OI^4
MJX^:Y]TY3U_9V=.WCJ9U'S]>^9=#O5LZJUF?_JJS^G'KYS%M-/8^L\^F6__J
M/M'.^&(\^NLOX^9KU;R^IYWOIW3_4W]ZKGHGEV?^_M<+_7NUTFB4]EJ/K8OC
M_O>G2^O8.76T&_JH7_[X>/?T_8=_\OGQ_O3ZWK0&P4"[_;)?.K.?JB>5@6_T
M]_[ZHIU;ZE70KXQ*/SKVM]VN2[4O7VCUUNZ>:I\?+SZ/>N/3\]O+D],]S_M8
M^O/+YR\G3V?.CSWS_N[:. V.U=)>6?VT__3SU&>?W9JWVVN<_EER_KMKZQ\$
M1DJ:8TSQY\ ?6LW_ 5!+ P04    " "F2YE:-FO\XH&=  "0)00 %@   '1M
M,C4Q,S$W-V0Q7V5X,3 M,2YH=&WLO5MSVT;6-GJO*OT'[-E?34E5L&+YE#C.
M3A4MRXF^U[']2O),S25(-B7$),#@()GSZ_<Z=??J!D#1L>2#K+F86"0(-+I7
MKUZ'9SWKE]]/_WCUZ_;6+[\?CE[ ?Q/\WR^G1Z>O#G_]Y0?^+WS[@WS]R_,W
M+_Z3G)S^Y]7A__>/65DT/R?[]Y=-<IHO3)V\-I?)<;G(BI0_2),34^6S?\ /
MX:=O[>\:\Z&YE\WSL^+GI,K/SIMGR2*KSG+X\_X_?OWE^:^''\[S<=[ K??V
M?_GA.0SD;72+31^M[@R7WG^6Z&?_V=9-/EO]X]=_%N-Z^>R&GD)O"*_U\LWK
M4WRY7X[@_<RD;?*RV-[ZEZEJ^,<O/QS]RF_*EUW74&[XW2:F:$Q%:W9R>/#N
M^.CTZ/ D>?ON^.#WT<EA,OKM^/#PC\/7I]>ZB#?\3B(5\F%>3 W>]/[>X[SX
MQZ^GYWF=]+_M]E;PNLE.@]?^<S[]JRV?P4]&9Y4Q"[@9?OO/BC[>3>"2:=:8
M:9+523E+1LLJG_/K/7B<)@_NX_^/5TE6P!6+LCA+0&"RNC&+E*\Z*B9[:9(E
M+\P\N\PJDTS*:EE6&4L7C,&H(1R4BV56K/0 4KJUR2;G^'B\'$:8-SE,WCRO
M<6!ED?SRSFY)?NCHEQ_>_9ID30,_@RN:,J%W=6^8[. -\=;JX4?%A:F;LE)/
MW]["AS?EF8$'5VD2CM;^H-;CW;L58D3*0#_NWBQ;Y//5SU<]D*ZM\_\:'A_M
MO'__?GA\.#I1ZB/=WL*IE.6F%<:_W80F*"B&E1"(%'X_-?/\ IX!?T9KF1=)
M!5]FQ<0D[1*D@83D@UDL4<:2654NDAIN5;'45.8,Y,8*8#:;E=449 1D^,1,
M\$.>]4<[V>[.@UW^0R3OQ-]E-&FN;V&^GY6>FCJOX*ZP(VLSG_/.5 NO=KO]
M3/]FV5:3\ZPVO*CJQBG<#J0CF\]9FHJR2?XL\Z*9PU<H%#P,. L6-5U0M^,_
M8;GM "9E,<UQ\>ND;DC=Y44D9VFR,Q)QJ,\S'%"DO$[HTT!YBMS((/]9U?AQ
MO;TU*1>@*^%1Y>1]FBRS*KG(YJU)_L_]O?OW[^\G2U,E])#X&0?\PQ/\84=+
M_@"3M?-<QKBLS+U96Z!H@]JMLJ()9Y#?87L+AJAOBA,#,P JEN8RY]T$>V3A
MU2FH0@.W@@,AUKO/2>]&8_ZW/%Z--]%J-;G,FW->'Y["6,_Z;:=?F6YRMP4W
MVH(@WG BX[%;F+*M86%QSFF:ZVQNK)SR]#MU;!>.UP.DE#2?K/YE#MN75;31
M"AJ.^F.E89-CM"[U-MK>^B01.T 12U&.ZQ;N@3)]>9Y/SO5&X\%E^$B2^:J\
MR*>PR4W59'1:Z!.@X@'2Y_42=<+:V; ?[\#8IF:6%WAVF'EYN9O@;JMZ#@HV
MCI;+>3[)QC#;I&'TD02647UG-W1$^?6;?V]OG:(\OWQS?*@E&E<+9+J&514Q
MDS5;M$V;R=*CM,$#*@.JL(9_TX7P@:C#7-9V4EZ8@M0C"AW?&,7$3%,M4VP*
M!B?3VD.'I0^$9%;.03KJG^_65ZWOL^0?O^[O_?/__>G!PZ?/;N(_UD]]]^L+
MW*1\MJ/JV ,WJ$[:NO^(9TV$"T:&)ID+<%*"-CG/+DSTM>@+T'K)PF0%?'1+
M5EGYA+-9#J9U8P*G"-\6-Q*>(59IHK8&S?O65'59I/3ODDYW_@2F+H/YG8(E
M-X']D8"I @^U?S7G5=F>@8=7&/QF48+EDZ/GOC#3/*MR?"?<EE4YAW_!DLD?
M<S/=WAKSW6K1OV);R14\R+J%;<L#N1UZ=KW7OKT%)A[K0Y9+4%0-GK P%7+<
MPL3G33:_)<>.F@Z8"K1Y41\?&[;EM[>>K_"(U08HB3#-!'\7F>HI:FXXGRN#
MVAPGS<QF(*NW;;H.P"3*9V"7-&0$'A4J.M/=\C1#=E:3=;_MF\Y,+<WW,;O/
M30&'3Y.\G6?A;(*^ZK^J1T;!;I^7*[ EQG+=$J]+E/D)\Q>$+A[N//1QB\/C
MHY,1SSF<8JR2[2U!=]I[5AG<8 +3 4,C^^C,VD]Y,9FW4U BK/#+MDGF^2)G
M<XH5/:G7P5N(_<UJ".TE#-0L,_39<W XYP9.5O *+K()BPY_E<VS:D5:/"]:
M_F*&P8"\SL9P)#4KM.P:.$ H!B3O <.%23$@6&C7+9:FJ&68X[)H:[XUO!"&
M$"_L(,CM+2E85-/2\"31Y_?&6=VYUWE9+U%YYO_E<>5%W=);I0F>5Q,P0-5'
M\WQF]-_UY+R$=ZO/\R5-5=.2<0)ODR_&X-7(O,.6 R.4#5$,3FGW!G_5Y_;@
MQ.-_9@E,!7GRN1R?>#R68Q!>VKGP8SH>\S$Z;SBM5B)H1.B**2GA($$<KXN?
M\!7OW7_XT/[_<^]>\C(W\^G/R=OLS#R#Z_]J#:P+W#:Y=T_R2[^\./J7?2;?
MZ5Y3+N&2!TN7"KHW+INF7/R</,'/QAA$K-QGS^<9R-0^/+PNY_D4!O VO!^-
M3+_H+S_ ,WL>/ZY,!E)H8$U@C$L:LQ[2DYX1X3 _]I%J8G[ F>')^!I7\^]I
MXC*KIK@Q7I#)&<;L]>DVMA=.[8714?85R_G?FYFV!A53U\F+;-4S)Q2TS5:)
M^3 QRX;^/,F:MIJBZJ2_P.JV_\8+62N!NLF2F4'W? X:_@S^_QQW0N;B/>_
M)P-5=(*V1&TU%WX/JI#O,<Z*]W!H;&^!\FSRIN7PK/R<?H=+@U/SG[)Z3RF#
MK(4#J@(O<XIWK&!OYQ6K3[#Q$J?:S\#EKPK4LQ@KH).3=.*\K,UM6]\#>"F8
MQ<V] W"9 VOB ::XP6^^G?,"8A\YMW>3@VF&:8_'S_MV[V0/;'WPS0O8/,=@
MT!4M*L<I[<;]IS\]T<;^[9N8WOS+=^QP!\FC0U"X%]G<A-D>?9:HJ'=D5&*
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M%>_PS?*(C[ZO/.*CNSSB%SP^>@&*O0Y^%^/HVQA8_-7:!@5?\<;\^W.'.HD
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MY>2=M$NVO64S]6Q#6<D2(DTBMX4I02 VTMH*J^VT5VPZL0A7=M)/TRF#[,.
MZ< OVM[&TN@2/8 M:[$H=,J:D>%8RI90T.&K$.,C=CI1Q%.K]9"$.- QM1CP
MR!0BZ^OK[VT#V*[QJE49XJNE6AV5)0^SK^Q8QT)Y*R^16%%08;!TN(V4.HAU
M@-(/'OC@'LG_-M:Z9;$Z9P01DJ;:VNZ$$H\,,Z"+D46@B*NUOX%"RB]D%_QT
MLW8!=:1XR:+X#"PTRZ:F&UU]^YQ)U]W1 T_3&Z] /-66 **2I*<%[RD$+?AR
M/- X+HC%:J92U4">*&5(?^9->,ZP?1&8=/L/8>?N/_(T\G#C_<=.A8O>UG:!
M Z$AS)QZ>7@%U)RO+?W+Z[X8^6^,?4 &)\?<D!SMC?8>XFU\*Y"3>P]!'SM+
ME<YB?$,WA\&[[A"KQ<P1+C-W-.IVH8/([-D4:"P<O45^QUP[1= 6V-81\EW
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M87B:U>]1T":$Y8UU8>KK=TFP@E8!F(1-%B3,'/5 G4(7;V]QYBP3?&3\2VU
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M$ZU5/$E47Y3:^M7).=I$W5+G'+FUN\UN\DHZI?:JW^@AP^HXZ2EV].COB4P
M/95V@ JA@F^B@WZI9#F9_7.6X64=G;PCY*@N8^)[J,ZSI;Q_ON#P(I(B228V
M#8>2TEC.4/M4J$&(W9.V+]W ]^> WT6]53&[.E>P(W+-G(Y,X3Y"AH1J0"BI
MY,X5/P=\'RZ(5118TC583.@=G>>GB'&MST2EL#!7;>E\XS*3*W'*.3&P63.$
M,O-,02Y"L,R69$V,5Q:;C9L1,POXI HV:F2Q*,(N?1*EJM^- G"'==N%8M65
MNN(:GL&_IVEIJ#;.83&$(H=5>S&!PPV)U!G(D8(:F9[Q;QG5B[AU^K5DBE)&
MLY>83923H!_83NFHH+M$K_VESC/EAJ"\")\>'V^I32Q,9+-.YAG2P>%$I$&F
MHI.2<$46*B<Q-CJAH;EC530>]$Q&1\%Y[APT>Y!$(I,P?5^O,>N\.[#5>S73
M5WS$;!BD__$["]+_>!>D_Y8MF&LBM!J.<:*!"<9SCX?NP$257(0J;!8BUG83
M9MZ@XB/07=8!K!-%6F4Y\WI+/#7]5<9YR>TM>0YSS3#4&.$*A'_E>*:@!0.J
M+0(A!;HNP"*BCPVO?/B!FB2S>(R85\/[):KIG"(.[%1\QUVBOUZU^(7D]IK8
MC8;D=I@'HA-C8D3 3=,S]%4G!Z[XY7E98T&;":N V19030+I>,[N)*HC4=?$
M)3(D49KH[[B'N\<G?OKDC'VB@70-96'0% ]JT54:I2?BEJ--JK4@>AT"GV%4
M*U>QJ[:.R*:#>.=!"ELI+7WT:*3"^!W"K(HU?- OTC[9]C^B>UH5R\_+;++)
MH%TY\.S']_=W,ID"'D+ X34$_PK'2;Q1ST+7(CZ7I._,38P[(![;WAI@'G,9
M#_(D?(6)Y;:N<B.8K9#1UR4PP+@GRH"LENRQ=4UL/0;9[I=2\(E]@LEYB/44
MS8H[B3N\8)$<S]J*O/]U@ISLV/Y/.>6K)]F27;U98B[ LLZ8W!Z?LX#7E%N
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MQ2%E10&>_<0W7!##+E"C.]%&'J#$ZO(;&REME4N/N36.4MGR FH'<>%3RMU
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M'=)OY[@GN.8#O,1EE>*O\4<6ZK>CHB_A%;9R8R?TL,.+IO8BZR"%7QO[=40
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M^D299\8,L^>JW4K-T?%6=G)\JWVB(1(FF/@](*+\.K#K_]BQ\^:=NJH($E-
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MI#EX*9M"ZDJ,FP"]:NB8EM-B>@_:,MF3"<D3HQ@D4S'-DF>8OC I<'O#7";
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M600<KJ6GE(RZ$;K-,'-0M99G[]*8,\W)C49-+- ;-RH_0F9GHT2'WM!BMLE
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MNB[)Z.P#*/!9*+.FZJUP^,;B3F\2ANSOP=#1AXZ5G7A"0<Q&Z5#H10&04HH
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MQ)TJ+\(&4T8\F;9G?CNSFKB1T6?VCFQ/X-.%'(R7<S9/)<B,9#TFCZ$0*YY
M# Q,6,H'28VJ6S6 <:6?S-#L1W)%T7C95R&8"ILU([+]#.?"EC*X=[.0MW1_
M3R<S38"G%F<FQI')0J6HD&=E_KJI+!X^H%13R+13QO@Q&)#2D1]E$-S#J,.0
M2N_FY(;6OU9YQ\U4)4IZK?041?A]G0&T$3!0(G!&]*-I[(W%DI"KP0E/2W@.
M'\B0F*^AO\>KI^XBA%:*F"Z)$K.L[WW*9E*?%;*RH(H]E*SHAH(K0=G6AG3R
M.9N:(J]$4^C+K&HI^A$O2Q%F-"BRFIH8UP6]U0LD&V?02<%]1>Z:<:)X<4TI
MB#>3YL 1NLK"Z@XN%M,G7$U^\,!0(\P_9Q<0F#0!M 0ZV^@J++Y!Z;;M[%KD
MQMWV*[F& ,F*.@CJ (D ^YDX^N>4[TI\L79K4B/A3CKB066.T37GFWUWJ,\5
M:!'I3V9*8C-UPDBOK21ZD7HDS01^RW$XI'[5P%4!WA3.7O7G99'!4^DHDY>0
MU&1=[B"Y6N4 R?-$[<0#4B*<R5<RXY>IQF"?D.^-P_$5_%?(E2PD1EU?.6M]
MCUVUVE.K>S#1-"$# S086)=V:]6:O%WI;H:.]H,(<_*892&C)N%BU.3Z$P.)
M;BF-0Q8BFI(FF/>:IU)&4IXQA0NX$1E4BA5PF/C+:@K9K,9E_#T44)7N9V34
M&1T8S>A-C?K 6E[CK,)HG]FC9>)7<N4O FJ63*9*4!F8TID)B])BN<=F?;8L
M/,[^RR^'SP]NGL*?=:/Y^9XZK25C,-QKP]]V7$:KD7.."019N.2:53M<OFEX
M/'5)#^"+1^8!?.$\@%MM):RHB:"V$KHZ&KB_UZ-T=''A5<(8XRWOS%#*(%TP
ME^80Q1DD[I1TMBTI:PM<L+DD$C?'K+ +[S]"V!>&E\-ZJK:YRP4G0M=;^6)6
MK(XKL+\%,Q6V,QN6SWN-D;50-P5M3FGW(#D-U+!,;X $_NJ9RB(G7AF_CHO=
M;,U33N0+C,"_,KMKO;3Z.T.B4<_-Y_IL%'"LR^<Z@51(?S9\:%N \:S _+$2
M^OD:L6X$$$9.I(&0%E 9A6UL98%"S6A(_:B=821#'@- 8JI,7<#\Z:0R6S@G
MDH4]S\/,H(0C_C/;-B&+J6Q<WC-]NERG:BXW&0FAW8]A%$'2L0Q^@GO-"+_'
M,S/LJ1AM9%B[OBBYSGXRZ,F'D+"KR\S :$RG21[2)>-TY-R._09QGM:<GKGM
ME2C\C@DF<#$@^$GD%_AZN=CZ_MCOJ\7NULH04C>IH8RB+B/:7&^NHY7'M7%4
M'"P6158'5^%"9#4*UYFMH])Q-W-8Q<?@9E#;0[@U.GE6D0!1-V?% X)N0G)F
M$?EZ^4#!JF)S!%H0F>P*X]+71NTU<?MA5CM,88XK3PH\12 XJ%3?*?E[%0Z0
M*0LZ?0;E!K&E3%KJ@F#)LP8;@P^EK5?4($9KZT^0MYQ<2_('.#MX?X!'9'I%
M_XN[><,?K(M792H1RSP0BD'-J&"#,X$EK%QQ2ED]FDD.B\&$E*=+!U+'WYX<
M@8<Z%"MJAF%6<:F:0GTP2ELNJ=-D%2(<BF^I9J/![/0!D2>K1U'*BF)N5"(;
M6X"3T(=T-JF541H%)@+5;E?DC]"-7;!QL_DJ@P 2"Q11\QID)-0)QFH3;=!(
MOK7+A[U1,,#\F1#C(9/AR*BV+.<I&<UHU$=RRF7#-L5*W/YU>'FH<O,[E]V/
M/:]%M%POCHZ.?"\\O#X4NNC;MT/P",.SH'5=W;KM[T'>(%>A,ONA^ACWQ_!4
M>PP:%633%V0H6AJ 5".J2;J9%)#67X4Y8Z@Y2%0;$)](8\L+Y<$Z'2A7E;$R
MX"])AU--B_94/]M=\<H57U''#H/T1]Q/,+W5E7[KM:#'UEAEMGO]^@((VLHY
MMH%1+X>97X.;<#B5*H1K(23MI7PB-MA"DKEKXKU2(54CH\W,[;!#K@8C@$8A
ME N.LYP36BB3<*HXD?052D['<4 1FOJZ;-F,+/>HJB@RZZ;%@ S36_R$H$^Z
M)*UD6XF#=5:U]LIQ^>%=0]+489)Z <L'@QB )?50HX]17\2!2E(43^/_!S6N
M>EC1&M-RS"O_5V)&-2.JR!MKH:=)#&$!F8V@ZN61!BB>::52#DX1'BH#/N1_
M$B<DR$%$CX/_I!ES'*JJ\FK.;@'* ALT6955N4T:0=LI\Y;C-%>'P^"**-O2
MAK> 3-V*)]JS'-%%5;,R9)!-[]3-NX+R27(PC"CZ ;M2LRG&0Y"1;5B!KB6_
M@<F%44/:4:Z[Y>VC8G]YI!##,_D;AO8H8%->&T:CI&."_$8<N!):\65>/%@!
M-TA34(' ^C-XSNE3:(V 4H<8I(RQ2L5O'#&3^PM&B .VG3><=AX%'/[/Q<W(
M1RSJY!/4:C 64C,H^='9\:0W:G'?,,:%FAN/+PPA0QXB1-%H@')7U1@C@][,
M&J#!BV*.\([#Z9F)&F$L<!R3S59*-I+EQ,O^'@L7?5KD,M2$)GY&9Z E8):B
MF:F+Z?AL=@YD$TRV8:\A1J/S7U PR).:QN5,F*V+/2\9M'CYR((6+UW08JO-
MX171N1H-'[%$(8@--XC*'JXWTXS@KBQ^,_ E2^Y%6;[EV@C#PI#Z7H Z@_#0
M,F+JV8_*Z4YHLLUUE)KA#"23X.Y-Z.*UTZQ-^J8%>=8J.:C!(O&ASNR*6%Q+
M7#M"^P*+5+?D-9,Q-+LG*9P@"KPP]*[&U2KA'VE^+3);=(]>B4_8/!A/BRFZ
M@(B&E:P!,Q:A.LZ,34M36F=EKV&)NGA$ADUP'8"]9V2[N(Z?<T[?B@@2#4K$
M;"PS9_?W3L+D6DB@G@%VR8?P0=9TWJ;1D)&+-TRG5TS(IO9:1XIDP2D$NG20
M3T<EE'F<5\6B$%/@EAJ&5&;&@12NLT6PID?]+*9!FPA]:PX.F4CBE'3?_<^%
MV2CW7!&_=677$:RY/@E'!1ADR=?#__W]I^Z[E4_T80S75X_,<'WE#->-B>&C
M5:?)_W[\KMO;W_O2[?<ZEY?>ET^=B\[9A]]_.G['8K4L$]F&Q$B&\HE52\58
M" *!-XC'60C=NJ(,U.)5>JL<.FL4;?W6\4G':W=.3LY;[]]W>Q__]>3H"?Y\
M>=YJRY_G72"^>X,TCH-)+GXM_^^M,&N'Q0U\[NB_GN 9^[U_,?<YMY!J/PAB
MN:ETD)_(L]E_/^>;>CK]]\:'VV<P^MZ_GKQ\4EZOJS0>+K%H3]ZUST[% _[^
M#1\L_KEHS!26&;WQQ$:-?>GE_]RY:%WV.Z<^J\->^[!YL]GFG=B"L=][O,>S
MW^9-_X6:_F)K@03_<J_[*?_)>Q\D0F5Z7PZ%GB\PCWK]RZ5$Z\\@65>Q=.J)
M+U?]P)_% ]$.6M'S7KT0#WR(15_5&5W-4_J0VO.#:_KDW;F 5ICL@;9'^R8*
M1UZ'TA"$Z7%&52O6TOZ$]@*:#DTT#9=$'C]O!F\L8W8[2_]N2]\VZL$4]VHL
M\;DF^/Y>DVSP^EDUP2Z_4SK6 *HZ&4E^ICMU\3V-PL7O[O8^=R[[9Q>_F:^O
MTPG;/,GJNW=MAA?]+]XIV/X7WH>_>N]][Z3__K"1$][IW6S,Y.0'39OW^^?[
M(W;LXK<B^%CPRE7A#FT*WSTF@5!H'.^#+(>2;+"7XX<\;RL^8PPM-K#L=XUD
M5U=8(HTF+#$7U->O[FJ!"?[[ @RS98RU%;UTCK6[#*#YQ0&:=0":N?@#T(;#
M.@[K.*SCL,Z/89UNKW?VN=7OGO4<['&3<[#'P9XE88_7#*-\1Y=X^W#/9DRU
M!\0XOSJ,LSF,TSQPL[_7N&2JU8.;;<(R/R[9</\5DE&9=,XDW*+)B3T$&'/<
M/>MWVI^\L_/SLXO^7[UNO]NY%#]U+@2VZ7VDH1"F<?O\B"?G<,T*<,U%"L2N
MXH5?4BA"/SU\6%?!S@9URNM,PSA]OT-+W2"4<PJ=P*" $ABJDW C49Z-F+Y+
MHIO7;[TSY$;,?X,'<SG]UM7%[#)2<H4L#<)>S0@BK3N_^,<C$ ; >N@:A.\Q
M2IM2/_'=Z]_JG[0NO?.+[N=6O^-].CN!HWGI';1;?Y^V>D\9$S5M>DW:FC76
M.X#-7:T:6:N)[T'9R.5 /%3\>Y.EP""X/>4+"VHY5F<H;NWJ+"K+6-WRZ'C
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M"^_RT)O30&1'T<.FIFU:EG$X*NZS5_:;A=6X*9@A(^?M=)KD80PVT(^*I-U
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M3H%":2Y(<$D, B<4&ET>QNYD<&Y&))8.;Y_A>"@SVG\<X#GJ02.4';@IIX.
M9;65C/U>KJ8JSYE\M<@J:N+/TM>.'$BK2GFG.=[+'=F7ZV!\R]-T7WV<]7NP
MKFJB?!:%QTK2BK6ZRS/#>9Z!\@54H_(R!.( OA47I:AZ9)& O@,;FM,8'W:.
M=H ?6?5D%]@RT.F#WQX]&@2N9J&O65XEJN##QX]@^"J1BX$:AJ*Q!ZAQX-P*
MN#<)\*ZBFDQ44<"GJ)]4P$BW7+*F!8$9Z)"P-Z5E930$[2:>T,4FC0<8N'D
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MVH#$*?Q)6>+C2.F2#_H"X(-E4"5#HTN5J/4N"+KOEBX*$]Q&N,^(TA-/:\P
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M*#D&:"F,(H16805]2M4,Q2TYP8<LK/^ ^XO],L61.DHG5Z?=N.]Y\."7X%_
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M'K[3=>_[>SN;MYK;?!*W8.Z7GN_+Q=.VY3\TRU^M&K"6O-[K?BI^TG "'W=
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M#7SB,.P+-"^X]N9CIHTF>G(,+:MF=J>_":</6F^< JL+QGGV2>6H +J<&3A
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MWU7VS'WWCSE]1-Q(AIZI,)74.#$R>'L>;H7;6P\>;)N+[9]'L!67\!)\DEX
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MF+@N69,SPO $AMQ]\:(5]#0>#(B_ #X<(]C>=4>PM%Y_\ $6UCT,CHX'AP/
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M)&,EJ,1N)1W"'T8/&U4"C9:EDE%88@.DV$KD-4&X".:$*>#MB[,<T&&5 JH
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M($%!/^]\3D;QS+A=8<99G";G<;%F4YRMF"LW>'"85V28DC"+&IG9W#!T)KB
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M<7]X/.R/N_AD<+0/;P]&FQL?N\-A%R'V#J=YVP]^/?H P_?W@K>?Z$69 +[
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M[V#0+0#R 2P!MD#C#/NC8YA$@\7"%UF>@,2:;'-C[ZAW@L^,.B&!O@'>'[L
MW!'_W/UUV.^/@L,CFJ<+ZQF."74.\5P&8WA*P#\$-#CJ]?NXP)!^[QUT!^]A
M!5UX _[/HQSWAZ.C0T#53YL;<+#_L';@'R?/ 1A#!_BEV,.[T?,&L(,/@QZA
M-2UX-&)LP6N"<,'5R ]PFQ#:^(9<&+6B]JWCK7O?'1S@/[LPZ/$GA?[!AT$7
M+\Y@!!<9QH/7@ Z,!_L#^("OP.4!!,++._CUW3C8ZQ_ RH>?@BTZ[OZ'P5[_
MD!>N?NK@8FE!O+T 0,VXNC?$]<.2^_O["&+$8@ _;)PV.!C;ITM'Q/MBX,#1
M$#4ATC$8(XK_>G3$!&1TLK\_Z T0S>J@I"=X'G/KX?,[! <B>G=P:#!:DZR]
M/N MD9.#P?N!1K"/W4]X-I^"(0$$]XI'H2>3Q^"R'L+9 PC@W3$3/B [-T$8
M01)<#LU%0.K"S1D QL#O@)J?'A(/OHZQ[=D#,[8]>S2VW4]DO3V!\?2N&H._
MBRGSH52Z= QR/7^C]%.,()BK4G190JB%2F88S'*RB=G:!466UG02MY"(#B>B
M@B/D&"0_I"DJ4D\F?GA>A>^@J?P(NT]+<K;NZZ**PE!+=76 ]93_DBOTKK(8
M$ZVGL>4'PU"O%).P=5:S9=-%0RZYW<4MI1+!<5K;$15*.C1Y4;F8L#U3;856
M['$1+X'4@X;+]F1K%U(X8LHVY_(LQD $-]QBF9=EHE(Y809I2J0CG%6A@5R2
MQNJ@HOQT7C9EIEFKYJQU4TB*RS?/I-!;@WV5']!V8>T+7JIBE^0(O'?7:H*1
M<U\Z.4>+Y 6PJ]42RS1%9=S$D2G\][^&?1!P64':W]PX[O[:)WWV$.5GU 6"
M@_[^.'A[T#W\YW]S;.\?NN3[ ;?K"&'/'Y@0]OQ/(83](6C,__N6H>R@GX'J
M>HBJVD=6!KVN8F@Q)U?1S.5;;'2?K5*J S!=5<KP7NHX#'0[S.?)E,.E1)2A
M-%).#D%:/.4*YQBC=!]"^<?=MP>@B/8/#HY!00>-^.]/GCZASZ/C;D]];KMG
M<D6G>9I&RQ*^5O]Z!1QT5IWA<T__\H10\?5XV#H.%<R?1JG: >/[$X7"X[V6
M-\UVQGO6P[TC7/WAWY\\>_)%./[DS8?^L#L:]]^'P!)Z.S0\_#&\-QNYSAZL
M$>_5VJ]]"-]J QI9?T1<;=S,C:^GC/@<!GR[?MD\FL?@BM/)UN[3G\.GX=^>
M=@RC8[G^1K.^^-M?_O#C_QIT_8I1F#GO1:"MIL"C*XHD>&A &&.6!(@H18R5
MYD0+[YTE\1P+9@#KPEB+(^94'FQ^((;PYI;X,OWY_+I]?)_=60_E&R[A6E+N
MBV\CVUY'Q+O'4N4?@#)W(E-:BN.H]ZZ_=P)2T^YE6N$MS7>G1BAK4_M'P_?H
MENC_JS_L#49]<9C\67;X7^-<6AMKP;TE7ZNMP9;IQ"T*P7]_7W!Y\N8@FJG6
M([_"'%3'[^4MCG\W!ZGO^BV;1G<[L$958S:6]ND<(Y;X":-*!3S,=X+_^1^G
M:KS\I O%FQ+W'^(B*JMX 2I$-MW!^N1[<1I=4-ZLE0"U1;'_:CC=M4AU >IQ
MBBWIEAR60YJI,M!GW/;1A*+-XKD5HF-UJ30QG8LXRLC*7^O2=5=AD,X9?E]H
M\JP=31#$$U,4L"13@$X*U@3E?_ _/SG$KX[["/D:Y)^[D-=E"BO*0J:\J66T
M7E@QC&X"C;'J4V/%J RVIF<Q]O'*XL[MT;UK -K86&R;BF]S^5(5$RTLEUAB
MM/&EKE#( "Q%-1S!9<J(KRB!<*E7U#I@.W9\!()$KD>8]3]V?_I9NYJN/_D-
M9KLI+O:P,*;&+GMI#8K3[7/2[P)_OA9=[A0[;A,9%*<&G* .9 HOA&>+H&@J
M*MOU6TX:UE&_<?!!;_"J-[P&TW>.G#?A*XT*W/UD-B\,LQDX;4_1&Q!+G\TH
M< A!6(^V5C5UR]4"#^;_"O,'\<I.+X[.HR0EK^Y\1;PL=ST0#?U.O9SR/UA@
M^(X.]D=SL,=^M7NO>&Q3QJT4R_1:&7G"W.6M:O71^?5...;&&\NJ4ZN*JMZ)
MV'+OF<Q-V<DM\(\&C\4=\Q)!*U-W=N]CMQ=T 8.P; %WKGO)1*3]OV:2_W6P
MO*Y'YZJ7;VL]W^'98IL56<JE''R2YY^W@?9A CYF?6$-Y2B8)=@U C/PD[(2
M4T&Y1GO"]W?<WY^\J.=Z)G.!GK\\6Y?XF"Z@S(FZ=J6;*F_Q]#7"[:I[W7K=
M[_K@[^J%[V?1]_9H'DGP#4FP:@^&-EF/T"9.6KDN',BE#0LIL'J%/O4H>+<)
MWC\9P?LM1TG9=+-=_K8MK$6\A/.CPC5HZ98"O+["Q+9 +*+5U+'8U#Z*J8+A
MU%AN+8E>M7E05D:<4-GD0:"G.GDDWI\#/N6%TO6I0^Y<2?Y#'9<<[#G-NXSO
M:*3K4FQN8,,O:AGZ_#G5XU&9Z[K+M-7UL]Y[SFV;=F7C.Z^9KZ.G8/L;4%3$
M7L&XY_0Z,ZMVVY7QZE_8J^]@6CHVE==IZMR6S;>*R"RJN[CN&6U%VUG%DZ0R
M91%CUX?;[R7SK:WD]U+UNI0FUV6Y,[@0V^4RPEB(++\H(B,T[>[^Y39)R1[>
MH9>7BG!>.,7$#:<PT5B[5\1WJ3BPGZ^.G_IB,-TF:##:Z7I:!F8)X-J8P'T-
M-)LA^%V BR+Q'N+&*2KN86Z=8^&^T=YOW<[^1\3*?)-)MD;P,:JP2M4"&T1(
MU\U RAM*N *)>AD@+]E.K4JDNGF49#7-(].\7D2(SI\!3->*1/SQ57#$11]?
M!@?8/>+>!"9^HP3@EB/YX>W1WB>\C#^\&[\_>//_ 5!+ P04    " "F2YE:
M-=)Y<G$+  !8)P  %@   '1M,C4Q,S$W-V0Q7V5X.3DM,2YH=&W-6EEOVSH6
M?C?@_\ I@J(%;&?I;3M-,L'867HS;1;$OBGZ2$FTS$8255*TX_[Z^QU2DN4E
M;6<0#-R'-I'(LR_?.>KQGZ.KSR?MUO&?Y_TS_,OHS_'H<O3Y_.1XU_^+M[OE
MZ^/!S=E7-AQ]_7S^KQ=CE16';'\O+]A(IL*P:S%C=RKE6<<_Z+"AT'+\ A=Q
M];:Z5XC'HLL3&6>'3,MX4ARQE.M8XM>]%R?'@Y/SQXD,9,$^?.CM'^\.(,CM
M"HG&^9=98/*C]2._*UV#.8[N';&F>*'("J&=4/="<U.(E-UDH4I4/&?]+%,V
M"T%ZY_U;ELHDD2ICMUI.>2':K=N$AR(%@<TJ_(_R/;O"4.[BYGK4I-(=<V@S
M/_P5'7?6R!_"LWUQ,K@9CFZN7V81-Y.C5X._AI?7Y\-AN_7E\N[\-2N?L^-=
M8GC2S[5,V,';#CO8.WA;O5PW\ZMK;B+^_9#=#T=7KSN,LT"J?,)U"OO:0H8\
M8:%*<Y[-Z=]4%H6(6*$8CZ8\"V46LPP:I"*2^$68=FNL-,MY(>$;PV:RF+"[
M_G#WJG_[B1Y/9GS>C>!%D;$0!(2&QH6*^)SQTN,@/^$%0XA.N&$N1O!,9L24
M&1%:+4'=L-SJ$"<$X[$6+A8\.] LN,S:+9F90A900F70@F<1XV$(6K)P]*;"
M%$H;1@)SEOO(8GD56$R-&<]SK1YEBA?)G.T<_%$'(EX:6 EBX"<)3<DX> Z2
MX0.#^(YB*/"ZW=IYW]O;8[G0_@Z)TH$ +)'"TOVENU"SU& A8X?MO-UO\LZU
MZ(YM%D&1&=>:DZUQL3;))MG:K0W"L9UWO0_XXZ1;I]ICHXE@XE'H4()L?4OP
M<++A.!R0)$Q\M[#WSAZ4WMM?J-VKPZ_=$H^Y"+W,6H0"X<!BK0R<JE4H1 2O
M:)4B$(C;& F!.%OWQZ(P=%@@X$?!((P-"SJ^<"2/Z>^Q@$$H"!2HZIJLER4S
MPO2VN8R0&]9#=(8$26#^8,[N1E_8I8L7>@,Z+A=RKI'#DO*1 L 9U>M/64O6
M$(_2.'LU@DUF86(C>CBXOV"WH)&Y/+V&B_F$)YR=\EP6/.FPF[#@,6)R\4 '
M\@HB$>UAH3*1HRQ4K]D5S^ -DG"KK?U\11M^:[?6'2=1V%P*^&(:)@K91:F-
M4A0H6ZR4\7_Z,MYAQ@;?<(ON4&X8^-6,>5B492&T\"!TF3N*Y,!09:AW>+W=
MX7V[EO9CF97]A2IFTUA4<MR17!6PI418)1R-8])N48F86IA (*1EX((P$LY
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M#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ>P-9*>0HU_N'Y)+%@Q"I='X
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M;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A0#-]0U.G_J&9#H5F&C0TT_=
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MH_[9"]5**&"43"]D#FWLG8'&WMDSQUZ4C,]G"HEM,3?<'E&W$\YFQ+^2+%@
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M,S$W-V0Q7V5X,3 M,2YH=&U02P$"% ,4    " "F2YE:G ALU0U>  ![WP(
M%@              @ ' O0  =&TR-3$S,3<W9#%?97@Q,"TR+FAT;5!+ 0(4
M Q0    ( *9+F5JRSM4PPT4  +]Z 0 6              "  0$< 0!T;3(U
M,3,Q-S=D,5]E>#$P+3,N:'1M4$L! A0#%     @ IDN96C72>7)Q"P  6"<
M !8              ( !^&$! '1M,C4Q,S$W-V0Q7V5X.3DM,2YH=&U02P$"
M% ,4    " "F2YE:."F!D2@#  #B"P  $0              @ &=;0$ =G-T
M;2TR,#(U,#0R-2YX<V102P$"% ,4    " "F2YE:)"[-C/P*  !_A@  %0
M            @ 'T< $ =G-T;2TR,#(U,#0R-5]L86(N>&UL4$L! A0#%
M  @ IDN96G\V1N%7!P  U%<  !4              ( !(WP! '9S=&TM,C R
C-3 T,C5?<')E+GAM;%!+!08     "  ( !4"  "M@P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>tm2513177d1_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="vstm-20250425.xsd" xlink:type="simple"/>
    <context id="AsOf2025-04-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001526119</identifier>
        </entity>
        <period>
            <startDate>2025-04-25</startDate>
            <endDate>2025-04-25</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-04-25" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-04-25" id="Fact000004">0001526119</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-04-25" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-04-25" id="Fact000010">2025-04-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-04-25" id="Fact000011">Verastem, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-04-25" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-04-25" id="Fact000013">001-35403</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-04-25" id="Fact000014">27-3269467</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-04-25" id="Fact000015">117 Kendrick Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-04-25" id="Fact000016">Suite 500</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-04-25" id="Fact000017">Needham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-04-25" id="Fact000018">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-04-25" id="Fact000019">02494</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-04-25" id="Fact000020">781</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-04-25" id="Fact000021">292-4200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-04-25" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-04-25" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-04-25" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-04-25" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-04-25" id="Fact000026">Common stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-04-25" id="Fact000027">VSTM</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-04-25" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-04-25" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
